Transcriptional Regulation of Stem Cell Self-Renewal. by He, Shenghui
TRANSCRIPTIONAL REGULATION OF 















A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Cellular and Molecular Biology) 










Professor Sean J. Morrison, Chair 
Professor Andrzej A. Dlugosz 
Professor Deborah L. Gumucio 






















© Shenghui He 
 





I wish to most sincerely thank my mentor Sean Morrison, for his intellectual and 
financial support throughout my graduate training. His passion for the hunt for new 
knowledge and his dedication to rigorously answering every scientific question in the 
finest detail will be a great source of inspiration throughout my scientific career. 
I wish to thank Anna Molofsky and Ricardo Pardal for training me to study 
central and peripheral nervous system neural stem cells. They initiated the project on the 
function of Bmi-1 in regulating neural stem cell self-renewal and contributed to the 
majority of the work described in Chapter 2 of this dissertation. 
I wish to thank Mark Kiel for his support and friendship. He has taught me all the 
skills to study mouse hematopoietic stem cells (HSCs), and has been the driving force 
leading the project testing immortal strand segregation and label retention in HSCs 
(described in Chapter 5). 
I wish to thank Daisuke Nakada, Jack Mosher, Melih Acar, Jeff Megee, Injune 
Kim and Lei Ding for their technical assistance and intellectual contribution to my work 
at various stages of my training. I also wish to thank all former and current members of 
the Morrison lab for their support and friendship, which made the pursuit of my degree an 
enjoyable experience. 
I wish to thank my program director Jessica Schwartz and administrator Cathy 
Mitchell for their support during my entire graduate training, and for ensuring that I 
would graduate on time. 
ii 
I wish to thank the members of my thesis committee, Andrzej Dlugosz, Deborah 
Gumucio and Thomas Glaser for their support and guidance during the pursuit of my 
degree.  
I wish to thank the Rackham School of Graduate Studies for providing the 
financial support for my first year of graduate training, and for providing travel grants 
allowing me the opportunity for scientific travel to Vancouver and Toronto. 
Lastly, I wish to thank my parents and my wife Jing Xu, without whose support 
none of the work described here would be possible. 
The work described in this dissertation was supported by grants from the Howard 






The work described in this thesis comprises most of the work I have performed in 
the Morrison laboratory since January, 2004. 
Most of the contents described in Chapter 1 (Introduction) were published in 
Annual Reviews of Cell and Developmental Biology. 2009;25:377-406. Daisuke Nakada 
and I contributed equally to this work. 
Chapter 2 describes the identification of Ink4a and Arf as the two major 
downstream target genes mediating the depletion of central and peripheral nervous 
system (CNS and PNS) stem cells in the absence of Bmi-1. Anna Molofsky and Ricardo 
Pardal initiated this project. Anna collected all the data for the CNS neural stem cells, 
Ricardo and I collected all the data from the PNS as well as the growth and survival data 
of Bmi-1, Ink4a, Arf compound mice. This work was published in Genes and 
Development. 2005, 19:1432-7; and a modified version of this chapter was included in 
Anna Molofsky’s thesis as chapter three. 
Chapter 3 describes the effects of Bmi-1 overexpression on CNS stem cell self-
renewal and neural development, and was originally published in Developmental Biology. 
2009, 328:257-72. I conducted most of the experiments described in this chapter. 
Toshihide Iwashita generated the original Nestin-Bmi-1-IRES-GFP transgenic mice. 
Anna Molofsky performed southern blotting on the transgenic mouse founders and 
iv 
generated the MSCV-Bmi-1 retrovirus vector. Johanna Buchtaller analyzed Bmi-1 
expression in human brain tumor samples with help from Dafydd Thomas. 
Chapter 4 demonstrates that Sox17 overexpression in adult hematopoietic stem 
and/or progenitor cells is sufficient to confer certain fetal characteristics including 
enhanced self-renewal potential and fetal specific gene expression. This work has not yet 
been published. I conducted all the experiments and collected all the data described in 
this chapter. Injune Kim generated the Sox17GFP knock-in mice that were used in this 
study. Megan Lim helped with the pathological evaluation of the Sox17 overexpression 
induced leukemia. 
Chapter 5 demonstrates that adult mouse bone marrow hematopoietic stem cells 
(HSCs) do not asymmetrically segregate their chromosomes during cell division, and 
BrdU label retention cannot be used as a reliable marker for identifying HSCs. Mark Kiel 
initiated this project and collected most of the data. I participated in the design and 
interpretation of all the experiments testing immortal strand segregation of HSCs, and 
collected the chromosome segregation data from in vitro cultured HSCs. This work was 
originally published in Nature. 2007, 449:238-42, and a modified version of this chapter 
was included in Mark Kiel’s thesis as chapter 5. 
In additional work which will not be included in this dissertation, I have 
performed experiments to optimize the purification of fetal and adult mouse enteric 
neural crest stem cells, and compared the gene expression profiles of these cells with help 
from Melih Acar. I have also studied the in vivo differentiation of adult mouse enteric 
neural crest stem cells under both physiological and pathological condition in 
collaboration with Nancy Joseph and Elsa Quintana. 
v 
TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS ............................................................................................. ii 
PREFACE......................................................................................................................... iv 
LIST OF FIGURES ......................................................................................................... xi 
ABSTRACT..................................................................................................................... xv 
CHAPTER 1 MECHANISM OF STEM CELL SELF-RENEWAL ............................1 
SUMMARY................................................................................................................1 
INTRODUCTION ......................................................................................................2 
THE REGULATION OF PLURIPOTENT STEM CELL SELF-RENEWAL..........5 
Maintenance of ES cell pluripotency................................................................5 
Cell Cycle Regulation in ES Cells....................................................................9 
CELL INTRINSIC REGULATION OF TISSUE STEM CELL SELF-
RENEWAL...............................................................................................................10 
Cell cycle regulation of tissue specific stem cells ..........................................10 
Ink4-CDK4/6-Rb pathway.....................................................................10 
p19Arf-p53-p21Cip1 pathway...................................................................12 
Developmental regulation of Rb and p53 pathway in tissue stem 
cells .......................................................................................................13 
Stem cell self-renewal versus progenitor proliferation.........................15 
Maintaining stem cell self-renewal by suppressing lineage commitment ......16 
Asymmetric stem cell division .......................................................................19 
MAINTAINING GENOMIC INTEGRITY IN STEM CELLS...............................20 
Reactive Oxygen Species ...............................................................................21 
Telomere maintenance....................................................................................22 
vi 
DNA Damage Response .................................................................................23 
CELL EXTRINSIC REGULATION OF STEM CELL SELF-RENEWAL............24 
Niche signals regulate stem cell maintenance ................................................25 
Niche signals maintain mammalian stem cell quiescence..............................28 
Long-range and systemic signals regulate stem cell function ........................29 
STEM CELL AND THEIR SELF-RENEWAL MECHANISMS CHANGE 
OVER TIME.............................................................................................................30 
Developmental changes of stem cell self-renewal..........................................30 
Stem cell self-renewal, aging and cancer .......................................................32 
Tumor suppressors regulate stem cell self-renewal and aging .......................35 
Cancer cells hijack normal self-renewal mechanisms ....................................36 
BIBLIOGRAPHY.....................................................................................................47 
CHAPTER 2 BMI-1 PROMOTES NEURAL STEM CELL SELF-
RENEWAL AND NEURAL DEVELOPMENT BUT NOT GROWTH AND 




RESULTS AND DISCUSSION...............................................................................68 
Ink4a, Arf, or Ink4a-Arf deficiency partially rescue Bmi-1-/- neural stem 
cell frequency..................................................................................................69 
Ink4a, Arf, or Ink4a-Arf deficiency partially rescue neural development 
in Bmi-1-/- mice ...............................................................................................71 
Arf, or Ink4a-Arf deficiency partially rescue cerebellum development in 
Bmi-1-/- mice ...................................................................................................72 
Ink4a, Arf, or Ink4a-Arf deficiency do not rescue the growth or survival 
of Bmi-1-/- mice ...............................................................................................73 
vii 
MATERIALS AND METHODS..............................................................................75 
ACKNOWLEDGEMENTS......................................................................................81 
BIBLIOGRAPHY.....................................................................................................94 
CHAPTER 3 BMI-1 OVEREXPRESSION IN NEURAL 
STEM/PROGENITOR CELLS INCREASES PROLIFERATION AND 
NEUROGENESIS IN CULTURE BUT HAS LITTLE EFFECT ON THESE 




Bmi-1 expression is elevated in a subset of human CNS tumors .................101 
Generation of Nestin-Bmi-1-GFP transgenic mice.......................................102 
Characterization of transgene expression in vivo .........................................103 
The transgene increases Bmi-1 expression in neural stem cells...................105 
Transgenic neural stem cells show increased self-renewal and 
neurogenesis in culture .................................................................................107 
Bmi-1 overexpression has little effect on neural stem/progenitor cell 
proliferation in vivo.......................................................................................109 
Bmi-1 overexpression has little effect on fetal or adult neurogenesis in 
vivo................................................................................................................110 
Bmi-1 overexpression has little effect on glial differentiation in vivo..........112 
Bmi-1 overexpression does not further enhance the self-renewal or 
neurogenic potential of cultured Ink4a-Arf-/- neural stem cells. ...................113 
A subset of Bmi-1 transgenic mice developed hydrocephalus but not 
CNS tumors ..................................................................................................115 
viii 
DISCUSSION.........................................................................................................118 
MATERIALS AND METHODS............................................................................121 
ACKNOWLEDGEMENTS....................................................................................132 
BIBLIOGRAPHY...................................................................................................148 
CHAPTER 4 SOX17 IS SUFFICIENT TO CONFER SELF-RENEWAL 
POTENTIAL AND FETAL CHARACTERISTICS TO ADULT 




Sox17 expression levels decline with fetal development and 
differentiation ...............................................................................................155 
Overexpression of Sox17 in adult bone marrow cells enhances their 
long-term reconstituting potential, and biases lineage differentiation..........157 
Sox17 overexpression confers fetal characteristics to adult HSPCs.............162 
Overexpression of Sox17 in purified short-term adult hematopoietic 
progenitors is sufficient to confer long-term self-renewal potential ............164 
Sox17 overexpression upregulates genes associated with stem cell and 
fetal characteristics. ......................................................................................166 
Long-term Sox17 overexpression leads to development of non-
lymphoid leukemia .......................................................................................169 
DISCUSSION.........................................................................................................171 
MATERIALS AND METHODS............................................................................174 
ACKNOWLEDGEMENTS....................................................................................184 
AUTHOR CONTRIBUTIONS ..............................................................................184 
BIBLIOGRAPHY...................................................................................................208 
CHAPTER 5 HEMATOPOIETIC STEM CELLS DO NOT 






RESULTS AND DISCUSSION.............................................................................216 
MATERIALS AND METHORDS.........................................................................223 
ACKNOWLEDGEMENTS....................................................................................233 
AUTHOR CONTRIBUTION STATEMENT........................................................234 
BIBIOGRAPHY .....................................................................................................244 
CHAPTER 6 CONCLUSIONS.....................................................................................246 
BMI-1 MAINTAINS STEM CELL SELF-RENEWAL BY SUPPRESSING 
INK4A/ARF .............................................................................................................247 
SOX17 CONFERS FETAL LIVER HSC IDENTITY ...........................................257 
IMMORTAL STRAND SEGREGATION IS NOT A UNIVERSAL 







Figure 1.1: The regulation of pluripotency. ...................................................................... 39 
Figure 1.2: Differences in cell-cycle regulation among stem cells at different stages of 
life. .................................................................................................................................... 40 
Figure 1.3: Mechanisms suppressing stem cell differentiation......................................... 42 
Figure 1.4: Niche regulation of stem cell self-renewal..................................................... 43 
Figure 1.5: Distinct factors regulate hematopoietic stem cell (HSC) and neural stem cell 
(NSC) self-renewal at different ages................................................................................. 45 
Figure 1.6: Stem cell self-renewal, stem cell aging and cancer cell proliferation are 
regulated by common networks of proto-oncogenes and tumor suppressors. .................. 46 
Figure 2.1: p19Arf is upregulated in the absence of Bmi-1, and deletion of Arf or Ink4a-Arf 
significantly increased the self-renewal of neural stem cells from the SVZ and gut of 
Bmi-1-/- mice. .................................................................................................................... 83 
Figure 2.2: Bmi-1 deficiency significantly reduced the diameter of neurospheres, but this 
effect was partially rescued by Ink4a, Arf, or Ink4a-Arf deficiency................................. 84 
Figure 2.3: Bmi-1 deficiency significantly reduced the percentage of cells within primary 
neurospheres capable of forming secondary neurospheres, but Ink4a, Arf, or Ink4a-Arf 
deficiency significantly increased this percentage............................................................ 85 
Figure 2.4: Deletion of Ink4a, Arf, or Ink4a-Arf significantly increased neural stem cell 
frequency in Bmi-1-/- mice. ............................................................................................... 86 
Figure 2.5: Ink4a deficiency partially rescued the frequency of uncultured NCSCs in the 
adult gut. ........................................................................................................................... 87 
Figure 2.6: Deletion of Ink4a, Arf, or Ink4a-Arf partially rescued SVZ proliferation and 
gut neurogenesis in 3 to 9 week old Bmi-1-/- mice in vivo. ............................................... 88 
Figure 2.7: Deletion of Arf or Ink4a-Arf, but not Ink4a alone, partially rescues cerebellum 
development in Bmi-1-/- mice............................................................................................ 89 
Figure 2.8: p16ink4a is expressed in the cerebellum of adult Bmi-1-/- mice........................ 90 
xi 
Figure 2.9: Ink4a, Arf, or Ink4a-Arf deficiency did not rescue the overall growth or 
survival of Bmi-1-/- mice. .................................................................................................. 91 
Figure 2.10: The brain masses of adult Bmi-1-/- mice were significantly reduced relative 
to littermate controls regardless of Ink4a and/or Arf deletion. ......................................... 92 
Figure 2.11: cip1 expression increases in the absence of Bmi-1 and decreases in the 
absence of Arf in CNS and PNS neurospheres ................................................................. 93 
Figure 3.1: Bmi-1 expression was elevated in human brain tumors............................... 133 
Figure 3.2: Transgene expression in Nestin-Bmi-1-GFP transgenic mice. .................... 134 
Figure 3.3: Southern blot analysis of transgene copy number and insertion site in 
transgenic founders. ........................................................................................................ 136 
Figure 3.4: Characterization of transgene expression in lines that gave germline 
transmission. ................................................................................................................... 137 
Figure 3.5: Bmi-1 transgenic mice were born at expected Mendelian frequency and 
showed no substantial growth defects............................................................................. 138 
Figure 3.6: Bmi-1 expression was elevated in transgenic neural stem/progenitor cells. 139 
Figure 3.7: Bmi-1 overexpression increased the self-renewal and neuronal differentiation 
of neural stem/progenitor cells in culture. ...................................................................... 140 
Figure 3.8: Most neurospheres grown under our culture conditions were clonal........... 141 
Figure 3.9: Bmi-1 overexpression had little effect on fetal or adult neural stem/progenitor 
cell proliferation in vivo. ................................................................................................. 142 
Figure 3.10: Bmi-1 overexpression had little effect on fetal or adult neurogenesis. ...... 143 
Figure 3.11: Bmi-1 overexpression had little effect on gliogenesis in vivo.................... 144 
Figure 3.12: Bmi-1 overexpression increased proliferation, self-renewal, and 
neurogenesis by wild-type but not Ink4a-Arf deficient neural stem/progenitor cells in 
culture. ............................................................................................................................ 145 
Figure 3.13: A minority of Bmi-1 transgenic mice developed idiopathic hydrocephalus 
but showed no sign of brain tumors................................................................................ 147 
Figure 4.1: Sox17 expression in hematopoietic stem and progenitor cells decreased with 
fetal development and lineage commitment. .................................................................. 185 
Figure 4.2: Level of Sox17 overexpression from retroviral infection............................. 186 
Figure 4.3: Sox17 overexpression enhanced the long-term reconstitution potential of adult 
bone marrow cells and biased their lymphoid versus myeloid lineage output in peripheral 
blood. .............................................................................................................................. 187 
xii 
Figure 4.4: Representative flow cytometry plots of primary recipient peripheral blood 
reconstitution at 16 weeks after transplantation.............................................................. 189 
Figure 4.5: Sox17 overexpression leads to thrombocytopenia and increased peripheral 
blood reticulocyte count.................................................................................................. 190 
Figure 4.6: Sox17 overexpression biased hematopoiesis in bone marrow and spleen.... 191 
Figure 4.7: Sox17 overexpression led to changes in bone marrow myeloid and 
megakaryocyte phenotypes that resembled their fetal liver counterparts. ...................... 192 
Figure 4.8: Sox17 transgene expression led to a similar phenotype as observed in 
recipients of Sox17 virus infected bone marrow cells. ................................................... 193 
Figure 4.9: Sox17 overexpression led to expansion of hematopoietic progenitor cells and 
fetal HSC specific marker expression............................................................................. 195 
Figure 4.10: Sox17-overexpressing LSK48+41- cells from primary recipients were 
capable of long-term erythroid and/or myeloid reconstitution. ...................................... 196 
Figure 4.11: Sorting strategy for isolation of adult hematopoietic stem and progenitor 
cells for virus infection and viral infection efficiency. ................................................... 197 
Figure 4.12: Adult bone marrow LSK48+41- cells possessed only short-term multilineage 
reconstituting potential.................................................................................................... 198 
Figure 4.13: Overexpression of Sox17 in transiently-reconstituting adult hematopoietic 
progenitors conferred long-term reconstituting potential. .............................................. 199 
Figure 4.14: Sox17 overexpression did not enhance the long-term reconstituting potential 
of adult GMPs or Pre-MegE progenitors. ....................................................................... 201 
Figure 4.15: Sox17 overexpression in purified adult bone marrow HSCs, MPPs and 
LSK48+41- cells resulted in a similar bone marrow reconstitution pattern after 
transplantation................................................................................................................. 202 
Figure 4.16: Sox17 overexpression increased the expression of genes associated with 
stem cell and fetal characteristics. .................................................................................. 203 
Figure 4.17: Sox17 overexpression in LSK48+41- cells upregulated HSC specific genes 
and downregulated genes associated with lineage commitment/differentiation............. 205 
Figure 4.18: Long-term Sox17 overexpression induces nonlymphoid leukemias. ......... 206 
Figure 5.1: Contrasting predictions regarding stem cell labeling based on the immortal 
strand model versus random chromosome segregation. ................................................. 235 
Figure 5.2: 6.0% of HSCs stochastically enter cell cycle each day................................ 236 
Figure 5.3: Administration of CldU and IdU does not affect HSC proliferation or cell 
death and BrdU incorporation during DNA repair is negligible..................................... 237 
xiii 
xiv 
Figure 5.4: Few HSCs retain BrdU and the vast majority of BrdU-retaining bone marrow 
cells are not HSCs........................................................................................................... 238 
Figure 5.5: Few HSCs retain BrdU, and the vast majority of BrdU label-retaining bone 
marrow cells are not HSCs even when BrdU incorporation is measured by flow-
cytometry. ....................................................................................................................... 239 
Figure 5.6: HSCs identified as c-kit+Flk-2-lineage-Sca-1+ cells also cannot be reliably 
identified based on BrdU label-retention........................................................................ 240 
Figure 5.7: HSCs segregate chromosomes randomly in vivo and in vitro. .................... 241 
Figure 5.8: CldU+ and IdU+ cells can be distinguished by antibody staining................. 242 




Self-renewal is a defining feature that distinguishes stem cells from transiently 
amplifying progenitors. Regulation of stem cell self-renewal involves precise control of 
cell cycle progression, suppression of premature differentiation, as well as maintenance 
of stem cell genomic integrity.  
The polycomb group protein Bmi-1 is essential for the postnatal self-renewal of 
mouse neural stem cells. We show that the depletion of neural stem cells in the absence 
of Bmi-1 is partially due to the derepression of two cell cycle inhibitors, p16Ink4a and 
p19Arf. Deletion of Ink4a and Arf from Bmi-1 deficient mice is sufficient to partially 
rescue the self-renewal defects of neural stem cells, indicating Bmi-1 regulates adult 
neural stem cell self-renewal mainly, but not exclusively by repressing the expression of 
Ink4a and Arf. Conversely, overexpression of Bmi-1 is sufficient to enhance the self-
renewal potential of CNS neural stem cells in vitro by suppressing culture-induced Ink4a 
and Arf expression, but has little effect on stem cell number or SVZ proliferation in vivo, 
where Ink4a and Arf are not normally expressed. Together, our data demonstrate that 
stem cell self-renewal capacity is modulated by factors affecting their cell cycle 
progression.
The Sry-related HMG box transcription factor Sox17 is specifically expressed by 
fetal, but not adult, hematopoietic stem cells (HSCs), and is essential for their 
maintenance. We demonstrate that Sox17 overexpression is sufficient to confer adult 
xv 
hematopoietic progenitors with certain fetal characteristics, and bias adult hematopoiesis 
to resemble fetal hematopoiesis. This is achieved at least partially by upregulating fetal 
HSC-specific gene expression, and suppressing differentiation-associated genes, raising 
the possibility that Sox17 may maintain fetal HSC identity by repressing differentiation 
or lineage commitment. 
The immortal strand hypothesis has been proposed as a mechanism to protect the 
genomic integrity of stem cells by asymmetrically segregating old and newly synthesized 
chromosomes during cell division. Using HSCs as a model system, we demonstrate that 
asymmetric chromosome segregation does not occur at a significant frequency in HSCs 
in vivo or in culture. Therefore “immortal strand” segregation cannot be a universal 




CHAPTER 1  
 
MECHANISM OF STEM CELL SELF-RENEWAL1
 
SUMMARY 
Self-renewal is the process by which stem cells divide to make more stem cells, 
perpetuating the stem cell pool throughout life. Self-renewal is division with maintenance 
of the undifferentiated state. This requires cell cycle control and maintenance of 
multipotency or pluripotency, depending on the stem cell. Self-renewal programs involve 
networks that balance proto-oncogenes (promoting self-renewal), gate-keeping tumor 
suppressors (limiting self-renewal) and care-taking tumor suppressors (maintaining 
genomic integrity). These cell-intrinsic mechanisms are regulated by cell-extrinsic signals 
from the niche, the microenvironment that maintains stem cells and regulates their 
function in tissues. In response to changing tissue demands stem cells undergo changes in 
cell cycle status and developmental potential over time, requiring different self-renewal 
programs at different stages of life. Reduced stem cell function and tissue regenerative 
capacity during aging are caused by changes in self-renewal programs that augment 
tumor suppression. Cancer arises from mutations that inappropriately activate self-
renewal programs. 
                                                 
1 Originally published in Annual Reviews of Cell and Developmental Biology. 2009;25:377-406 with 




Self-renewal is the process by which a stem cell divides asymmetrically or 
symmetrically to generate one or two daughter stem cells that have a developmental 
potential similar to the mother cell. The ability to self-renew is essential for stem cells to 
expand their numbers during development, for their maintenance within adult tissues, and 
to restore the stem cell pool after injury. Defects in self-renewal mechanisms can lead to 
developmental defects, premature aging phenotype, and cancer. Thus, the elucidation of 
stem cell self-renewal mechanisms offers the potential for fundamental insights into 
development, cancer, and aging. 
Studying stem cell self-renewal requires the precise identification of stem cells 
using anatomical, phenotypic, or functional criteria. Invertebrate stem cells are usually 
defined by position and marker expression, in accordance to fate mapping experiments 
that place them at the top of a cell hierarchy. For example, male germline stem cells 
(GSCs) in Drosophila are identified based on marker expression as well as based on their 
position surrounding hub cells, which constitute the niche (Fuller and Spradling, 2007). 
This makes it possible to image the self-renewing divisions of many invertebrate stem 
cell populations in the niche in vivo (Cheng et al., 2008). In contrast, mammalian stem 
cells are mainly identified based on functional assays or marker expression among 
dissociated cells because anatomical criteria are often less useful in large and complex 
mammalian tissues. It has been impossible to image the self-renewing divisions of many 
mammalian stem cells within the niche. Rather mammalian stem cell self-renewal is 
generally inferred based on changes in stem cell numbers in functional assays performed 
in vitro or in vivo. Nonetheless, important insights have been gained by imaging the 
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divisions of undifferentiated cells in the skin, nervous system, and muscle (Huttner and 
Kosodo, 2005; Kuang et al., 2007; Lechler and Fuchs, 2005). As a result of these 
technical differences among invertebrate and mammalian stem cell systems we often 
have different types of information regarding the regulation of self-renewal in these 
systems. 
Self-renewal is not the same as proliferation, although both processes depend on 
cell division. Proliferation is a more general term that incorporates all types of stem and 
progenitor cell divisions, self-renewing and otherwise. Self-renewal requires that at least 
one of the daughter cells has a developmental potential that is similar to the mother cell. 
For most mammalian stem cells, like hematopoietic stem cells and neural stem cells, this 
means that self-renewal is division with maintenance of multipotency. As a result, 
molecular mechanisms that regulate stem cell self-renewal include mechanisms that 
regulate the ability of stem cells to divide while remaining multipotent. For stem cells 
that make a single type of daughter cell, like spermatogonial stem cells, self-renewal 
involves mechanisms that regulate the ability of stem cells to divide while remaining 
undifferentiated. Some of these mechanisms might overlap with mechanisms that 
generically regulate the proliferation of many cells, though a surprising number of stem 
cell self-renewal mechanisms preferentially regulate stem cell self-renewal (Molofsky et 
al., 2003; Nishino et al., 2008).  
Self-renewal is not uniquely a property of stem cells. Some types of restricted 
progenitors and differentiated cells, such as restricted glial progenitors and lymphocytes, 
can also undergo self-renewing divisions. Indeed, self-renewal mechanisms in 
lymphocytes share at least some mechanistic similarities to stem cell self-renewal, such 
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as a common dependence on Bmi-1 (Luckey et al., 2006; van der Lugt et al., 1994a). 
Nonetheless, the extensive self-renewal potential of stem cells can generally be 
quantitatively distinguished from the limited self-renewal potential of restricted 
progenitors. The mechanistic differences that distinguish stem cell self-renewal from the 
more limited self-renewal of restricted progenitors and differentiated cells largely remain 
to be identified.  
Although stem cells have extensive self-renewal potential, this does not 
necessarily mean that these cells actually self-renew extensively under physiological 
conditions. For example, individual hematopoietic stem cells have the potential to 
undergo extensive self-renewing divisions upon serial transplantation in irradiated mice 
(Harrison and Astle, 1982); however, under physiological conditions in vivo, most 
hematopoietic stem cells are quiescent most of the time and may undergo a limited 
number of self-renewing divisions in normal adult mouse (Cheshier et al., 1999b; Foudi 
et al., 2008; Wilson et al., 2008). Neural crest stem cells likely undergo a limited number 
of self-renewing divisions in vivo before differentiating (Fraser et al., 1991; Morrison et 
al., 1999), despite having the potential for massive self-renewal upon serial subcloning in 
culture (Kruger et al., 2002). Thus stem cells may be fated in vivo to execute many fewer 
divisions than they have the potential to undergo. This may have evolved to endow stem 
cells with the potential to repair tissues after injuries that involve much higher 




THE REGULATION OF PLURIPOTENT STEM CELL SELF-RENEWAL 
Embryonic stem (ES) cells are derived from the inner cell mass of the blastocyst 
prior to implantation. They possess indefinite self-renewal potential as well as the ability 
to generate all cell types within the body (pluripotency). These characteristics distinguish 
ES cells from somatic stem cells, which have extensive, though limited, self-renewal 
potential and more limited developmental potentials. The unlimited self-renewal potential 
and pluripotency of ES cells appear to be conferred by unique transcriptional and cell 
cycle regulation (Jaenisch and Young, 2008; Niwa, 2007; Silva and Smith, 2008) (Figure 
1.1). 
Maintenance of ES cell pluripotency 
The self-renewal of pluripotent stem cells is regulated by a transcriptional 
network involving Oct4, Sox2 and Nanog (Jaenisch and Young, 2008). The POU domain 
transcription factor Oct4 is critical for the pluripotency of both the inner cell mass in vivo 
and ES cells in culture (Nichols et al., 1998; Niwa et al., 2000). Reducing Oct4 
expression in ES cells leads them to differentiate into trophectoderm, while 
overexpression leads to differentiation into primitive endoderm and mesoderm, indicating 
ES cell pluripotency depends upon an optimal level of Oct4 expression (Niwa et al., 
2000). The SRY-related HMG-box transcription factor Sox2 is also required for the 
maintenance of pluripotency in the embryo and in ES cells in culture (Avilion et al., 
2003; Masui et al., 2007). Sox2 cooperates with Oct4 to activate the expression of a 
number of genes that regulate pluripotency, including Oct4 and Nanog ((Masui et al., 
2007) and references therein). The homeodomain protein Nanog is required for the 
maintenance of pluripotency in the inner cell mass in vivo (Mitsui et al., 2003). 
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Overexpression of Nanog can bypass the requirement of leukemia inhibitory factor (LIF) 
in maintaining ES cell pluripotency, while Nanog-deficient ES cells are prone to 
spontaneous differentiation (Chambers et al., 2003; Mitsui et al., 2003). However, rather 
than being absolutely required for pluripotency, Nanog appears to stabilize the 
pluripotent state (Chambers et al., 2007). These three factors form the core of a 
transcriptional regulatory network that promotes the expression of genes that maintain 
pluripotency while repressing genes that induce differentiation (Fujikura et al., 2002; 
Niwa et al., 2005). 
Ectopic expression of Oct4 together with various combinations of other 
transcription factors including Sox2 and Nanog can reprogram differentiated mouse and 
human cells into ES-like induced pluripotent stem (iPS) cells (Okita et al., 2007; Park et 
al., 2008; Takahashi et al., 2007; Takahashi and Yamanaka, 2006; Wernig et al., 2007; 
Yu et al., 2007). This demonstrates that these factors can restore pluripotency to cells that 
are epigenetically quite different from ES cells. 
To maintain the pluripotency of ES cells, the Oct4-Sox2-Nanog network needs to 
be fine-tuned by positive and negative regulation, as slight hyper- or hypo-activation of 
some of these factors can disrupt pluripotency (Niwa et al., 2000). These three 
transcription factors interact physically with each other, and co-occupy regulatory regions 
in many target genes coordinately regulating the pluripotent state (Boyer et al., 2005; Loh 
et al., 2006; Masui et al., 2007; Wang et al., 2006). Oct4, Sox2, and Nanog also regulate 
their own expression as well as each other’s expression, forming a positive feedback 
circuit that maintains pluripotency (Figure 1.1). Since overexpression of Oct4 leads to 
6 
 
trophectodermal differentiation of ES cells, this circuit also requires negative feedback 
(reviewed by (Niwa, 2007)). 
Maintenance of ES cell pluripotency is aided by epigenetic regulators that balance 
gene repression and activation. Polycomb and Trithorax proteins modulate the expression 
of numerous developmental genes through histone modification and chromatin 
remodeling (Schuettengruber et al., 2007). Polycomb complexes trimethylate histone H3 
at lysine 27 (H3K27) and then assemble complexes that promote chromatin compaction 
on this methylation mark. Trithorax proteins oppose polycomb repression by methylating 
histone H3 at lysine 4 (H3K4), promoting transcription by recruiting nucleosome 
remodeling enzymes and histone acetylases (Ruthenburg et al., 2007). Polycomb and 
trithorax complexes segregate the pluripotent genome into stably repressed domains 
marked by H3K27 methylation as well as activated domains marked by H3K4 
methylation (Mikkelsen et al., 2007). However, polycomb and trithorax complexes also 
coincide at “bivalent domains” within genes in ES cells that bear regions containing both 
marks (Bernstein et al., 2006; Zhao et al., 2007). It appears that such domains repress the 
expression of genes involved in fate determination and differentiation, while poising such 
genes for activation upon exit from the pluripotent state (Azuara et al., 2006; Bernstein et 
al., 2006; Boyer et al., 2006; Lee et al., 2006b). Loss of certain polycomb complex 
components from ES cells leads to the inappropriate activation of some of these 
developmental regulators, rendering ES cells prone to spontaneous differentiation 
(Azuara et al., 2006; Boyer et al., 2006; Lee et al., 2006b; Marson et al., 2008). 
There are also other critical transcription factors beyond Oct4, Nanog and Sox2. 
The zinc finger DNA-binding protein Ronin is necessary and sufficient for maintaining 
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ES cell pluripotency (Dejosez et al., 2008). Overexpression of Ronin maintains ES cell 
pluripotency in the absence of LIF or Oct4 (Dejosez et al., 2008). Ronin suppresses ES 
cell differentiation by directly binding and suppressing the transcription of many 
differentiation-inducing genes, including GATA4 and GATA6. Upon induction of 
differentiation, Ronin (Dejosez et al., 2008) and Nanog (Fujita et al., 2008) are 
inactivated by Caspase-3 proteolysis to allow differentiation. The requirement for Ronin 
emphasizes the critical role that factors that block differentiation play in the promoting 
self-renewal. 
Like other stem cells, ES cell self-renewal is also under cell-extrinsic controls 
(Figure 1.1). LIF is a key factor that blocks the differentiation of mouse ES cells in 
culture (Williams et al., 1988). LIF receptor consists of a heterodimer of LIFR and gp130 
which activates the JAK/Stat3 pathway (Niwa et al., 1998). The targets of JAK/Stat3 
pathway are largely unknown but have been suggested to include c-myc, a known 
promoter of pluripotency (Cartwright et al., 2005; Takahashi and Yamanaka, 2006). 
Maintaining the pluripotency of ES cells also requires Bone Morphogenetic Proteins 
(BMPs) that signal through SMAD proteins to promote the expression of Inhibitor of 
differentiation (Id) transcriptional regulators, helix-loop-helix domain proteins that 
dimerize with and inhibit the function of other helix-loop-helix transcription factors 
(Ying et al., 2003). LIF/JAK/Stat3 and BMP/Id signaling pathways work together to 
prevent the differentiation of ES cells in culture by inhibiting the consequences of 
mitogen-activated protein kinase (MAPK) pathway signaling, which tends to promote 
differentation (Ying et al., 2008). These studies demonstrate that the inhibition of 
differentiation is a key mechanism to promote self-renewal. Regulatory networks act in a 
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concerted manner in pluripotent stem cells to do this at the level of signal transduction, 
chromatin structure, and transcriptional regulation 
Cell Cycle Regulation in ES Cells 
ES cell self-renewal is facilitated by rapid proliferation and unique cell cycle 
kinetics. Mouse ES cells have a very short G1 phase of the cell cycle, marked by little or 
no hypophosphorylated Rb (Burdon et al., 2002; Stead et al., 2002). The lack of Rb 
activity renders the cells insensitive to cyclin D/cyclin-dependent kinase (CDK) 
regulation and to the cyclin-dependent kinase inhibitor, p16Ink4a (Burdon et al., 2002; 
Savatier et al., 1996). Unlike tissue stem cells, ES cells also do not undergo p53-
dependent cell cycle arrest in response to DNA damage (Aladjem et al., 1998). ES cells 
have high levels of constitutively active CDK2-cyclin A/cyclin E, allowing rapid S phase 
entry (Stead et al., 2002). In contrast, when ES cells differentiate, G1 phase lengthens and 
the rate of cell division slows (White et al., 2005), mitogen-induced cyclin D-CDK4/6 
activity becomes required for progression through G1 phase of the cell cycle and cyclin 
E-CDK2 activity becomes cell cycle regulated (Savatier et al., 1996). As a result of these 
differences, ES cells are not subject to many of the cell cycle checkpoints that regulate 
tissue stem cells. Reprogramming of somatic cells to pluripotency confers similar cell 
cycle regulation as in mouse ES cells (Jaenisch and Young, 2008), suggesting that the 




CELL INTRINSIC REGULATION OF TISSUE STEM CELL SELF-RENEWAL 
In contrast to ES cells, tissue-specific stem cells possess extensive, but limited, 
self-renewal potential and they are multipotent rather than pluripotent. The emergence of 
tissue specific stem cells within the embryo marks the requirement for a new set of 
tissue-specific self-renewal programs that allow more elaborate cell cycle control. In 
many cases, these programs must perpetuate stem cells throughout life, responding to 
developmental changes in the regenerative requirements of tissues, while avoiding 
transformation to cancer. These programs must maintain multipotency while restricting 
developmental potential to avoid fates that are inappropriate to the tissue of origin. These 
are different problems than ES cells must confront and require self-renewal mechanisms 
that are not active in ES cells. 
Cell cycle regulation of tissue specific stem cells 
To self-renew throughout life, tissue stem cells need mechanisms that confer the 
potential for repeated periods of quiescence and cell cycle re-entry. This distinguishes 
tissue stem cells from ES cells and most other types of progenitors. To control this 
potential, tissue stem cells are subject to more complex cell cycle regulation, more 
checkpoints, and perhaps more cell extrinsic control than ES cells. Mechanisms 
regulating the transition from quiescence to G1 to S phase are necessary for long-term 
stem cell maintenance as well as homeostasis in many tissues.  
Ink4-CDK4/6-Rb pathway 
Rb family proteins are major regulators of the G1-S cell cycle transition (Figure 
1.2). Rb family proteins Rb, p107, and p130 inhibit E2F transcription factors, which 
induce genes required for DNA replication and S-phase entry (reviewed by (Giacinti and 
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Giordano, 2006)). Rb appears to be relatively inactive in ES cells, rendering them less 
dependent upon mitogens to stimulate cell cycle entry via cyclin D-CDK4/6 complex 
activation (reviewed by (Burdon et al., 2002)). However, as embryogenesis progresses, 
tissue-specific stem cells become dependent upon mitogens that activate cyclin D-
CDK4/6 so that Rb can be inactivated (reviewed by (Sherr and Roberts, 2004)). Rb 
family proteins redundantly promote quiescence. Deletion of a single Rb gene in 
hematopoietic cells only modestly affects HSC homeostasis (Daria et al., 2008; Walkley 
and Orkin, 2006; Walkley et al., 2007). However, deletion of all three Rb family genes 
leads to the proliferation and mobilization of HSCs as well as to myeloproliferative 
disease (Viatour et al., 2008). Additional studies will be required to determine whether 
HSCs are able to maintain themselves in the complete absence of Rb function. 
Cyclin D-CDK4/6 promotes cell cycle entry by phosphorylating and inactivating 
Rb proteins, and by sequestering p21Cip1/p27Kip1 cyclin-dependent kinase inhibitors, 
thereby facilitating the activation of cyclin E-CDK2 (Figure 1.2). Deletion of all three D 
cyclins is embryonic lethal (likely due to heart defect and and hematopoiesis failure) but 
not until late gestation (E14.5-E17.5) (Kozar et al., 2004). In the absence of D cyclins, 
HSCs are unable to divide normally and become depleted (Kozar et al., 2004). Similarly, 
mice lacking both CDK4 and CDK6 die with defective hematopoiesis, but not until late 
gestation (Malumbres et al., 2004). These studies demonstrates that cell cycle progression 
in the early embryo is remarkably independent of D cyclin and CDK4/6 activity, 
consistent with the relative inactivity of Rb in ES cells, but that tissue stem cells become 
G1 phase regulated by Rb, cyclins and CDKs. This reversible activation and inactivation 
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of Rb in response to cell extrinsic signals may be a fundamental difference in cell cycle 
control between ES cells and tissue stem cells.  
The activity of the cyclin D-CDK4/6 complex is regulated by the Ink4 (Inhibitor 
of cyclin dependent kinase) family proteins. The Ink4 family consists of p16Ink4a, p15Ink4b, 
p18Ink4c and p19Ink4d in mice, all of which function by binding and inactivating the cyclin 
D-CDK4/6 complex (reviewed by (Sherr and Roberts, 2004)). p16Ink4a is encoded by the 
Cdkn2a locus in mice, which encodes a second unrelated protein, p19Arf, using an 
alternative reading frame. Combined deletion of both p16Ink4a and p19Arf at the Cdkn2a 
locus in young animals has only a modest effect on hematopoietic stem cell frequency or 
self-renewal, suggesting that these proteins have little function under normal conditions 
in young mice (Stepanova and Sorrentino, 2005). However, p16Ink4a and p19Arf 
expression increase with age, and at least p16Ink4a expression reduces stem cell frequency 
and function in a variety of aging tissues (Janzen et al., 2006; Krishnamurthy et al., 2006; 
Molofsky et al., 2006). The function of p19Arf in aging tissues has not yet been tested, and 
there is some evidence that its expression may be regulated differently in mice and 
humans, because p19Arf expression may not increase with age in humans. p18Ink4c 
deficiency also increases hematopoietic stem cell frequency and enhances the 
repopulating capacity of hematopoietic stem cells in transplantation assays, though the 
function of p18 Ink4c is observed even in stem cells from young mice (Yuan et al., 2004). 
These results suggest that Ink4 family proteins negatively regulate stem cell self-renewal 
by slowing cell division, though the exact effect of these proteins on the cell cycle in 




The p19Arf-p53-p21Cip1 pathway also regulates cell division and quiescence in a 
variety of mammalian stem cells. p53 is a transcription factor that negatively regulates 
stem cell frequency under steady state conditions. p53 deficiency modestly increases 
stem cell frequency and self-renewal in adult mouse neural stem cells and HSCs (Meletis 
et al., 2006; TeKippe et al., 2002), perhaps by reducing quiescence (Liu et al., 2009b). 
p53 function is increased above steady-state levels by a variety of stresses including 
DNA damage and oncogenic stimuli and sometimes by induction of p19Arf expression. 
p19Arf is a tumor suppressor that increases p53 levels by relieving p53 from Mdm2-
mediated degradation (reviewed by (Sherr, 2001a)). Elevated p53 levels can promote 
DNA repair but can also induce cell cycle arrest and apoptosis (Sherr, 2001a). The 
function of p53 in some stem cells may be mediated partly by its ability to promote the 
transcription of the p21Cip1 CDK inhibitor (Kippin et al., 2005; Qiu et al., 2004)(Figure 
1.2). Although p53 generally functions to restrict stem cell self-renewal, it likely also 
contributes to the long-term maintenance of stem cells by maintaining the integrity of the 
genome. 
Developmental regulation of Rb and p53 pathway in tissue stem cells 
Over-activation of the Rb and p53 tumor suppressor pathways can lead to 
senescence and premature depletion of the stem cell pool, at least in HSCs and neural 
stem cells (Levi and Morrison, 2009). This is avoided in part by overlapping 
transcriptional mechanisms that repress Ink4a and Arf in normal stem cells (Figure 1.2). 
In fetal and young adult mice this is accomplished partly through the high mobility group 
transcriptional regulator, Hmga2, which regulates chromatin structure (Nishino et al., 
2008). In the absence of Hmga2, p16Ink4a and p19Arf expression modestly increase and 
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stem cell frequency and self-renewal potential modestly decline. A more powerful 
repressor of the Ink4a/Arf locus is the polycomb repressor complex. Bmi-1 is one 
component of the polycomb repressor complex 1 that appears to repress Ink4a/Arf by 
binding to trimethylated H3K27 at this locus (Bracken et al., 2007; Kotake et al., 2007). 
Bmi-1 is not necessary in vivo for Ink4a/Arf locus repression during fetal development 
but becomes critical postnatally (Jacobs et al., 1999a; Molofsky et al., 2003). Bmi-1-
deficient mice exhibit profound stem cell self-renewal defects and progressive stem cell 
depletion in multiple tissues (Lessard and Sauvageau, 2003a; Molofsky et al., 2003; Park 
et al., 2003b). Bmi-1-deficient mice generally die within a month after birth with severe 
growth retardation, hematopoietic failure, and neurological abnormalities (van der Lugt et 
al., 1994a). Deletion of p16Ink4a and/or p19Arf and/or p53 partially rescues the stem cell 
defects in Bmi-1 deficient mice (Akala et al., 2008; Bruggeman et al., 2005; Molofsky et 
al., 2005; Molofsky et al., 2003; Oguro et al., 2006). Repression of p16Ink4a/p19Arf is 
critical for appropriate regulation of the Rb and p53 pathways in stem cells and for the 
maintenance of stem cells throughout life. 
Under-activation of the Rb pathway can lead to stem cell hyperproliferation and 
cancer (Levi and Morrison, 2009). This is avoided in stem cells by the function of JunB, 
an AP-1 family transcription factor which promotes p16Ink4a expression (Passegue and 
Wagner, 2000). JunB-deficiency in the hematopoietic system leads to reduced p16Ink4a 
expression, expansion of primitive hematopoietic progenitors, and eventually to 
myeloproliferative disease (Passegue et al., 2004). Thus stem cells have both positive and 
negative transcriptional regulators of p16Ink4a and p19Arf expression that are balanced to 
promote stem cell maintenance while avoiding neoplastic proliferation. 
14 
 
Stem cell self-renewal versus progenitor proliferation 
Stem cell self-renewal is mechanistically distinct from the proliferation of many 
downstream progenitors. Bmi-1 and Hmga2 are required for multipotent neural stem cell 
self-renewal but not for the proliferation of many restricted neuronal or glial progenitors 
(Molofsky et al., 2003; Nishino et al., 2008). Nonetheless, this is not a black and white 
difference as granule precursor cells in the cerebellum and lymphocytes in the 
hematopoietic system also require Bmi-1 for their proliferation (Leung et al., 2004; van 
der Lugt et al., 1994a). The trithorax protein Mll is required for the maintenance of HSCs 
but not required for the maintenance of committed lymphoid and myeloid progenitors 
(Jude et al., 2007; McMahon et al., 2007). Sox17 is required for the maintenance of fetal 
and neonatal hematopoietic stem cells but is expressed by less than 1% of cells in the 
hematopoietic system and therefore must not be required for the function of many 
downstream hematopoietic progenitors (Kim et al., 2007). Conversely, p27Kip1 is required 
for the limited self-renewal of transit amplifying cells and the proliferation of restricted 
progenitors in the hematopoietic and nervous systems but not stem cells in these tissues 
(Cheng et al., 2000; Doetsch et al., 2002). These results demonstrate that some 
mechanisms preferentially regulate stem cell self-renewal while other mechanisms 
preferentially regulate restricted progenitor proliferation. 
The p53 and Rb pathways may be required to exit the stem cell state. When 
certain members of the p53 and Rb tumor-suppressor pathways are mutated, some types 
of progenitors can regain self-renewal capacity and behave like stem cells. For example, 
transiently self-renewing multipotent hematopoietic progenitors can regain long-term 
self-renewal potential when p53, Ink4a, and Arf are deleted (Akala et al., 2008). 
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Similarly, the deletion of Ink4a and Arf in astrocyte progenitors allows these cells to 
dedifferentiate in culture into neural stem cell like cells (Bachoo et al., 2002). 
Remarkably, deleting five out six Rb family alleles in terminally differentiated retinal 
neurons allows these cells to resume division (Ajioka et al., 2007). These observations 
suggest that Rb and p53 pathways reinforce the ability of progenitors to exit the stem cell 
state, although the mechanisms by which they do so remain unknown. 
Maintaining stem cell self-renewal by suppressing lineage commitment 
Tissue stem cell self-renewal requires maintenance of multipotency in addition to 
the ability to divide. Stem cells maintain their undifferentiated state by repressing the 
expression of genes that restrict developmental potential or specify differentiation (Figure 
1.3). In Caenorbabditis elegans, the PUF RNA-binding proteins FBF-1 and FBF-2 are 
specifically expressed in undifferentiated germ-line stem cells and maintain stem-cell 
identity by repressing the translation of two critical regulators of meiotic cell-cycle entry, 
gld-1 and gld-3 (Kimble and Crittenden, 2007). In the absence of fbf-1 and fbf-2, germ-
line stem cells enter meiosis, committing to differentiation. Similarly, in the Drosophila 
ovary, Pumilio and its binding partner Nanos are essential in germ-line stem cells to 
prevent premature differentiation by inhibiting the translation of proteins that promote 
differentiation (Wong et al., 2005)(Figure 1.3A). 
Mammalian tissue stem cells have analogous mechanisms that prevent 
differentiation, as illustrated by neural stem cells. The bZIP transcription factor ATF5 
maintains neural stem cells by suppressing both neuronal and glial differentiation 
(Angelastro et al., 2003; Angelastro et al., 2005). SoxB1 family proteins (including Sox1, 
2, 3) suppress neuronal differentiation and maintain neural stem cell identity during the 
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neurogenic phase of cortical development, avoiding premature differentiation (Avilion et 
al., 2003; Graham et al., 2003). The orphan nuclear receptor Tailless (Tlx) and the 
nuclear co-receptor N-coR suppress the differentiation of postnatal neural stem cells into 
astrocytes, thereby preventing the premature depletion of the stem cell pool (Hermanson 
et al., 2002; Shi et al., 2004). The maintenance of neural stem cell identity appears to 
depend on the function of many transcription factors avoid premature differentiation at 
various times during development (Figure 1.3B). 
Premature lineage commitment is also suppressed by epigenetic mechanisms 
(Figure 1.3C). The promoter regions of many astrocyte-specific genes, including gfap, 
are preferentially methylated in cortical neural progenitors during neurogenesis, 
rendering them refractory to gliogenic signals (Takizawa et al., 2001). Consistent with 
this, DNA methyltransferase 1 (Dnmt1)-deficient neural progenitors show precocious 
astrocytic differentiation (Fan et al., 2005). Hematopoietic stem cells deficient in Dnmt1, 
or Dnmt3a and Dnmt3b lack long-term repopulating ability (Broske et al., 2009; 
Tadokoro et al., 2007; Trowbridge et al., 2009), raising the possibility that DNA 
methylation is also required to prevent the spontaneous differentiation of HSCs. 
Chromatin structure is also regulated to avoid premature differentiation. Stem 
cells lacking Bmi-1 exhibit little self-renewal potential (Lessard and Sauvageau, 2003a; 
Molofsky et al., 2003; Park et al., 2003b) and can prematurely differentiate in at least 
certain circumstances (Pietersen et al., 2008). Polycomb complexes therefore promote 




Some stem cells may rely on a balance between the activities of lineage 
specification genes, rather than their outright repression, to maintain multipotency. No 
stem-cell specific factor that can suppress lineage determination has so far been identified 
in hematopoietic stem cells. Instead, many lineage specification genes are expressed at 
low levels in hematopoietic stem cells (Ye et al., 2003). This phenomenon has been 
described as lineage priming and has been proposed to be characteristic of the 
multipotent state (Orkin and Zon, 2008). However, it is unclear how multipotency is 
maintained in the presence of these lineage specification factors. One possibility is that 
the function of these factors is suppressed through yet to be identified mechanisms, or 
that the expression levels in hematopoietic stem cells are too low to influence fate. 
Alternatively, opposing lineage specification factors may act antagonistically and the 
balance may maintain multipotency (Figure 1.3D). Pairs of lineage specification factors 
in the hematopoietic system are known to be mutually antagonistic (Laslo et al., 2008). 
Furthermore, the multipotency and self-renewal capacity of hematopoietic stem cells are 
compromised when one component of these paired transcription factors, such as PU.1, is 
deleted (Iwasaki et al., 2005; Kim et al., 2004). Thus hematopoietic stem cell 
multipotency may be maintained by counterbalanced lineage specification genes. 
However, for this model to be true, hematopoietic stem cells would have to have 
mechanisms that avoid the differentiation of the entire stem cell pool upon exposure to an 




Asymmetric stem cell division 
Strategies by which stem cells regulate the symmetry of division (Morrison and 
Kimble, 2006) and molecular mechanisms regulating asymmetric division have been 
reviewed in detail elsewhere (Gonczy, 2008; Knoblich, 2008; Lin, 2008). Many stem cell 
populations likely undergo both symmetric and asymmetric divisions, either 
stochastically or in response to environmental cues. Symmetric divisions predominate in 
circumstances in which stem cells must expand in number, such as during development 
and after injury. Under steady-state conditions, asymmetric divisions allow stem cells to 
generate a stem cell daughter as well as a daughter fated to differentiate, maintaining the 
balance between stem cells and differentiated cells. 
Intrinsically asymmetric divisions allow stem cells to regulate self-renewal by 
asymmetrically segregating fate determinants into daughter cells (Figure 1.3E). For 
example, Drosophila neuroblasts divide asymmetrically to segregate atypical Protein 
Kinase C to daughters fated to remain as stem cells and Numb, Prospero and Brat to 
daughters fated to differentiate (Knoblich, 2008). Mutations that affect the expression or 
the asymmetric segregation of these cell fate determinants can lead to either symmetric 
self-renewing divisions that create stem cell tumors or to symmetric differentiating 
divisions that prematurely deplete the stem cell pool (Knoblich, 2008; Lee et al., 2006a). 
Mammalian stem cells employ similar mechanisms to self-renew asymmetrically in the 
central nervous system, in the basal layer of the epidermis, in skeletal muscle and in other 
tissues (Huttner and Kosodo, 2005; Kuang et al., 2007; Lechler and Fuchs, 2005). 
Alternative, asymmetric divisions need not be intrinsically asymmetric, as 
polarized divisions can lead daughter cells to acquire different fates as a result of ending 
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up in different environment. Mitotic spindle orientation can determine the positions of the 
daughter cells with respect to the stem cell niche, thereby determining daughter cell fate 
(Figure 1.3F). For example, Drosophila spermatogonial stem cells self-renew 
asymmetrically with the spindle oriented perpendicularly to the hub cells that constitute 
the niche, such that one daughter cell ends up adjacent to the niche and the other daughter 
cells is displaced from the niche (Fuller and Spradling, 2007). Spindle orientation is 
determined by centrosome orientation (Yamashita et al., 2003), where the mother 
centrosome is located apically (close to the hub), whereas the daughter centrosome is 
located basally (away from the hub)(Yamashita et al., 2007). Indeed, spermatogonial 
stem cells have a spindle orientation checkpoint in which they are unable to divide until 
one centrosome aligns apically and the other aligns basally (Cheng et al., 2008; 
Yamashita et al., 2007). It remains uncertain whether mammalian stem cell divisions are 
also regulated by the orientation and asymmetric segregation of centrosomes. 
 
MAINTAINING GENOMIC INTEGRITY IN STEM CELLS 
As the longest-lived, mitotically active cells in the body, stem cells are 
particularly sensitive to the accumulation of genetic lesions. Preserving genomic integrity 
is not only important for maintaining normal function but also prevents carcinogenesis. 
This is more important in stem cells than in other cells because stem cells pass mutations 
on to large numbers of progeny, amplifying the risk of cancer. Many mechanisms protect 
stem cells from endogenous and exogenous mutagens and enhance their capacity to repair 
the damages that has already occurred. In cases where the damage is too extensive to be 
repaired, stem cells may undergo apoptosis or senescence. 
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Reactive Oxygen Species 
Reactive oxygen species (ROS) are toxic byproducts of oxidative energy 
metabolism (Balaban et al., 2005). Although important for certain physiological 
processes such as intracellular signal transduction and combating infection, excessive 
level of ROS within cells can damage lipids, proteins, RNA and DNA, thus impairing 
cellular function. To persist throughout adult life, stem cells must minimize ROS 
damage.  
FoxO family transcription factors are tumor suppressors that protect stem cells 
and other cells from oxidative damage, reducing mutagenesis and extending cellular 
lifespan (Paik et al., 2007). In response to oxidative stress, FoxO transcription factors 
increase the expression of genes required for detoxification of ROS including superoxide 
dismutase and catalase as well as genes that promote quiescence (Tothova and Gilliland, 
2007). FoxO function is negatively regulated by PI-3kinase pathway signaling as Akt 
phosphorylates FoxOs, causing their translocation out of the nucleus. Deletion of three 
members of the FoxO family, FoxO1, 3 and 4 in mouse HSCs leads to increased levels of 
ROS, increased proliferation, and stem cell depletion (Tothova et al., 2007). These 
defects can be at least partially rescued by treating the mice with antioxidant N-acetyl-L-
cysteine (NAC). Disruption of FoxO3 alone also increases ROS levels in hematopoietic 
stem cells and leads to their depletion, though to a lesser extent than in the triple knock-
out (Miyamoto et al., 2007). Enzymes involved in ROS metabolism including superoxide 
dismutase and catalase were reduced in FoxO-deficient HSCs, providing a potential 
mechanism for ROS accumulation. 
21 
 
ATM, a kinase that is activated in response to DNA damage, is required for 
normal DNA repair and to avoid oxidative stress (Barzilai et al., 2002). Atm-deficient 
HSCs are depleted due to their accumulation of ROS, which activates p38 MAPK and 
induces p16Ink4a (Ito et al., 2004; Ito et al., 2006). Neural stem cells also require Atm to 
avoid genomic instability, abnormal proliferation, and depletion (Allen et al., 2001). 
These defects can be partially rescued by treating the mice with NAC or a p38 inhibitor. 
Although it remains unclear precisely why ROS accumulates in the absence of ATM, 
these data demonstrate a link between DNA repair, ROS levels, and stem cell 
maintenance. 
Telomere maintenance 
Mammalian telomeres are repetitive DNA sequences (thousands of TTAGGG 
repeats) along with specialized protein complexes that are located at the ends of each 
chromosome (Gilson and Geli, 2007). Telomeres are required to protect chromosomes 
from fusing to each other, from exonuclease activity, and from the loss of coding 
sequence due to the “end replication problem”. That is, based on the way in which DNA 
replication occurs, 50-150 base pairs of sequence are lost from each end of the 
chromosomes during each round of replication (Gilson and Geli, 2007). As a result, 
telomeres become progressively shorter with each round of replication in most cells that 
lack telomerase (Gilson and Geli, 2007). This telomere attrition ultimately leads to 
cellular senescence when telomeres reach a critical length, limiting the number of 
divisions that a cell can undergo in a lifetime. Cells that escape senescence exhibit 
genomic instability due to aberrant chromosome fusions (Counter et al., 1992). Some 
cells, including stem cells and many cancer cells, express telomerase, an enzyme that can 
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lengthen telomeres by adding new TTAGGG repeats (Gilson and Geli, 2007). This 
allows stem cells to escape the replication limits imposed by telomere length. Some cells 
also use alternative mechanisms for lengthening telomeres (Bryan et al., 1997). Thus, 
telomere maintenance is critical for ensuring genetic stability and for maintaining the 
proliferative capacity of cells. 
Many stem cells express telomerase, reducing the rate at which telomeres erode 
and increasing replicative capacity (Lee et al., 1998; Morrison et al., 1996a; Vaziri et al., 
1994). Deletion of the RNA or the catalytic component of the telomerase reverse 
transcriptase enzyme accelerates telomere loss (particularly in highly replicative tissues), 
leading to genomic instability and carcinogenesis (Blasco et al., 1997; Rudolph et al., 
1999). Loss of telomerase activity also reduces the self-renewal potential of 
hematopoietic stem cells upon serial transplantation (Allsopp et al., 2003), their 
functional capacity during aging (Rossi et al., 2007a) and the regenerative capacity of 
other tissues (Herrera et al., 1999; Lee et al., 1998). Adult neural stem cells lacking 
telomerase activity also have less proliferative capacity, and increased genomic 
instability in vitro and in vivo (Ferron et al., 2004). These results highlight the importance 
of telomere maintenance for maintaining the genomic integrity and self-renewal potential 
of stem cells. 
DNA Damage Response 
DNA repair mechanisms are critical for maintaining genomic integrity in all cells, 
but they are particularly important for maintaining the replicative capacity of stem cells 
(Rossi et al., 2008; Sharpless and DePinho, 2007). DNA damage occurs during normal 
DNA replication or upon exposure to ionizing irradiation, chemical mutagens, or ROS. 
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DNA damage in stem cells can lead to senescence, apoptosis, reduced self-renewal 
potential, or cancer, all of which will ultimately deplete the stem cell pool and reduce 
tissue regenerative capacity. DNA damage accumulates in stem cells during aging (Rossi 
et al., 2007a), but the rate at which it accumulates is limited by DNA mismatch repair, 
nucleotide excision repair, double-strand break repair and DNA damage checkpoints. 
Conditional deletion of the DNA damage response gene, ATR, in all tissues of adult mice 
leads to widespread stem cell depletion, defects in tissue regenerative capacity, and 
phenotypes that resemble premature aging (Ruzankina et al., 2007). A variety of other 
DNA repair/damage response factors are also required for the maintenance of normal 
hematopoiesis and hematopoietic stem cell function, including the DNA repair protein 
Brca2 (Navarro et al., 2006), the non-homologous end-joining proteins Lig4 (Nijnik et 
al., 2007) and Ku80 (Rossi et al., 2007a), the mismatch repair protein MSH2 (Reese et 
al., 2003), the nucleotide excision repair proteins XPD (Rossi et al., 2007a), Ercc1, and 
XPA (Prasher et al., 2005), and the double strand break-repair proteins Rad50 (Bender et 
al., 2002) and ATM (Ito et al., 2004). Although the roles of these pathways have mainly 
been studied in the hematopoietic system, they are likely to have similar functions in 
stem cells from other tissues.  
 
CELL EXTRINSIC REGULATION OF STEM CELL SELF-RENEWAL 
To maintain homeostasis within complex tissues, metazoans have evolved 
sophisticated mechanisms to externally control the survival, self-renewal and 
differentiation of stem cells by both local and systemic signals. 
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Most stem cells in metazoans reside within specialized microenvironments known 
as “niches” (Fuchs et al., 2004; Morrison and Spradling, 2008). These niches contain 
supporting cells that promote stem cell maintenance and regulate stem cell function. 
Niches accomplish these functions by providing an anchorage site for stem cells as well 
as by producing membrane bound and secreted signals that regulate stem cell survival, 
cell cycle status, and differentiation. In many cases, the size and availability of niches 
physically limits the number of stem cells within tissues. Displacement of cells from the 
niche fates these cells to differentiate as these cells lose access to niche signals required 
to remain undifferentiated. 
Niche signals regulate stem cell maintenance 
The primary function of the niche is to maintain undifferentiated stem cells. In the 
Drosophila germline an average of 9 spermatogonial stem cells adhere to the hub, a 
cluster of 12 somatic cells that secrete a factor called Unpaired (Fuller and Spradling, 
2007) (Figure 1.4A). Unpaired is required for the maintenance of spermatogonial stem 
cells and is concentrated in the extracellular matrix surrounding hub cells, so the stem 
cells can only be maintained immediately adjacent to the hub (Kiger et al., 2001; Tulina 
and Matunis, 2001). The stem cells divide asymmetrically such that one daughter cell 
remains adjacent to the hub and retains stem cell identity, whereas the other daughter cell 
is displaced from the niche and is fated to differentiate. Because the niche is constrained 
by the need for contact with the hub, this physically limits the number of stem cells that 
can reside within the tissue and ensures that half of the progeny of stem cells are 
displaced from the niche and fated to differentiate.  
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In the C. elegans germline, stem cells are found in the distal half of the mitotic 
region within the gonad, in contact with the distal tip cell (Kimble and Crittenden, 2007) 
(Figure 1.4B). In contrast to fly germline, there is no evidence that germline stem cells 
undergo asymmetric division in the worm germ line (Morrison and Kimble, 2006). 
Rather, the distal tip cell expresses the GLP-1/Notch ligand Lag-2, which promotes 
mitosis and suppresses differentiation (entry into meiosis) by activating GLP-1/Notch 
signaling within the germline stem cells (Kimble and Crittenden, 2007). Ablation of the 
distal tip cell or loss of GLP-1 signaling causes the germline stem cells to prematurely 
enter meiosis. In contrast, constitutive GLP-1 signaling in the stem cells blocks 
differentiation and causes uncontrolled mitosis, resulting in tumorigenesis (Berry et al., 
1997). Comparison of mechanisms employed by the fly and worm germlines suggests 
that one key element of stem cell niches is the expression of factors that maintain 
undifferentiated stem cells. 
In germline niches, stem cell progeny that are initially fated to differentiate can 
de-differentiate to re-occupy the niche in certain circumstances. If Drosophila germline 
stem cells are ablated, the daughter cell that is normally destined to differentiate can 
reoccupy the open space in the niche to maintain homeostasis (Brawley and Matunis, 
2004; Kai and Spradling, 2003). Under physiological circumstances, this appears to be a 
mechanism by which the fly spermatogonial stem cell pool is maintained during aging, as 
de-differentiated spermatogonial stem cells accumulate with age. Adult mouse 
spermatogonial cells have also been suggested to contribute to the stem cell pool through 
de-differentiation (Barroca et al., 2008; Nakagawa et al., 2007). These results suggest that 
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in addition to maintaining undifferentiated stem cells, germ line niches also have 
mechanisms that can reprogram differentiating cells to restore stem cell identity.  
The identity of mammalian stem cell niches and the mechanisms by which these 
niches regulate stem cell maintenance are not as well understood as in the fly and worm 
germ lines. Part of the problem is that we generally do not have the ability to identify and 
image stem cells or niche cells with certainty in vast mammalian tissues (Morrison and 
Spradling, 2008). In addition, not as much has been done in mammalian tissues to test 
genetically for which factors are required for stem cell maintenance, and which cells 
produce these factors. As a result, models of mammalian stem cell niche are often 
provisional as key questions remain to be answered.  
In the mammalian hematopoietic system, some of the key factors required for 
stem cell maintenance have been identified but the cells that produce these factors and 
create the niche remain uncertain (Kiel and Morrison, 2008) (Figure 1.4C). 
Hematopoietic stem cells are maintained primarily in the bone marrow during steady-
state adult hematopoiesis. Bone marrow hematopoietic stem cell niches have been 
proposed to be created by endosteal (bone-lining) cells, perivascular cells, or a 
collaboration between these cell types, but direct evidence is lacking for each of these 
possibilities (Kiel and Morrison, 2008). It remains unclear precisely which bone marrow 
cells are the physiological sources of the factors that regulate HSC maintenance. The 
chemokine CXCL12 (SDF-1) is required for the maintenance of bone marrow HSCs and 
is expressed by both perivascular and endosteal cells (Kollet et al., 2006; Sacchetti et al., 
2007; Sugiyama et al., 2006). Angiopoietin-1, a factor proposed to regulate HSC 
quiescence (Arai et al., 2004), has been suggested to be expressed by both osteoblasts at 
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the endosteum (Arai et al., 2004) and by perivascular mesenchymal progenitors 
(Sacchetti et al., 2007). So far, none of the factors that are thought to regulate HSC 
maintenance have been conditionally deleted from specific cell types to determine which 
cell is the physiologically important source. Similar results have been obtained in 
multiple other mammalian systems such as hair follicles (Blanpain and Fuchs, 2006) and 
forebrain subventricular zone (Riquelme et al., 2008) (Figure 1.4D) where some of the 
factors that regulate stem cell maintenance have been identified but the sources of such 
factors generally have not. 
Niche signals maintain mammalian stem cell quiescence 
Adult mammalian stem cell niches often promote stem cell quiescence. For 
unknown reasons, many mammalian stem cells appear to require intermittent periods of 
quiescence for their maintenance. Genetic manipulations that reduce their ability to 
remain quiescent also tend to deplete the stem cell pool (Ficara et al., 2008; Jude et al., 
2007; McMahon et al., 2007; Yilmaz et al., 2006). Nonetheless, quiescence is not a 
defining feature of stem cells as mouse gut epithelial stem cells appear to divide 
frequently (Barker et al., 2007) and many invertebrate stem cells divide at a rate 
comparable to their more differentiated progeny and show no sign of quiescence 
(Crittenden et al., 2006; Wallenfang et al., 2006).  
The maintenance of stem cell quiescence is regulated at least partly through the 
niche. The quiescence of mouse hematopoietic stem cells depends upon a series of stem 
cell-extrinsic factors in the bone marrow including Steel factor (McCarthy et al., 1977; 
Thoren et al., 2008), CXCL12 (Nie et al., 2008; Sugiyama et al., 2006), Thrombopoietin 
(Qian et al., 2007; Yoshihara et al., 2007), and Angiopoietin-1 (Arai et al., 2004; Puri and 
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Bernstein, 2003). Loss of signaling by the receptors for any of these factors leads to 
increased hematopoietic stem cells proliferation and stem cell depletion. BMP signaling 
is similarly required to maintain the quiescence of mouse hair follicle stem cells (Horsley 
et al., 2008; Kobielak et al., 2007). In the absence of BMP signaling these stem cells 
over-proliferate and form tumors (Kobielak et al., 2007). Therefore, mammalian stem cell 
maintenance depends on niche signals that promote quiescence. 
Long-range and systemic signals regulate stem cell function  
In addition to being regulated by local niche signals, stem cell self-renewal can 
also be modulated by long-range signals, such as circulating hormones, cytokines and/or 
neural activity. One mechanism by which a long-range signal can regulate stem cells is 
by directly activating receptors on the stem cells. The rate of cell division in Drosophila 
ovary stem cells is regulated by Drosophila insulin-like peptides (DILPs) secreted by 
cells in the brain (Drummond-Barbosa and Spradling, 2001; LaFever and Drummond-
Barbosa, 2005). This provides a mechanism by which the rate of egg production can be 
regulated by the nutritional status of the fly. Systemic signals can also modulate stem cell 
activity through niche-mediated (indirect) mechanisms. For unknown reasons, HSCs are 
regularly mobilized from the bone marrow through the circulation (Wright et al., 2001) 
according to circadian rhythms (Mendez-Ferrer et al., 2008). This is accomplished by 
adrenergic signals that come from the innervation of cells in the HSC (Mendez-Ferrer et 
al., 2008). These signals are thought to reduce CXCL12 expression within the niche, 
allowing the stem cells to go into cycle and to be released from the bone marrow. The 
observation that many long-range signals can modulate CXCL12 expression level in the 
bone marrow raises the possibility that this maybe a common mechanism by which 
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hematopoietic stem cell activation and mobilization are tied to physiological variables 
such as stress level and circadian time (Spiegel et al., 2008). Unlike local niche signals, 
systemic signals do not generally appear to be specifically required for stem cell 
maintenance (with the possible exception of Thrombopoietin, which may regulate 
hematopoietic stem cells after being secreted by the liver). Rather system signals appear 
to dynamically modulate stem cell activity according to physiological demands. 
STEM CELL AND THEIR SELF-RENEWAL MECHANISMS CHANGE OVER 
TIME 
Developmental changes of stem cell self-renewal 
Many stem cells undergo cell-intrinsic changes in their developmental potential 
over time. For example, Drosophila neuroblasts and mammalian cortical and retinal 
neural stem cells undergo temporal restrictions in the types of neurons they can make 
during development (Desai and McConnell, 2000; Livesey and Cepko, 2001; Pearson and 
Doe, 2003; Shen et al., 2006). Neural crest stem cells from the fetal and postnatal gut 
undergo similar restrictions in neuronal subtype potential, even while remaining self-
renewing and multipotent (Kruger et al., 2002). Even HSCs change their developmental 
potential throughout life. Fetal hematopoietic stem cells have the potential to make 
certain subtypes of B and T lymphocytes that adult stem cells cannot generate (even 
when transplanted into the fetal environment) (Hayakawa et al., 1985; Ikuta et al., 1990; 
Kantor et al., 1992). During aging, hematopoietic stem cells undergo intrinsic changes 
that bias them toward the myelopoiesis and away from lymphopoiesis (Rossi et al., 
2005). Thus, multipotent stem cells persist throughout life in the nervous and 
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hematopoietic systems, but they undergo restrictions in the cell type they can produce. 
Therefore self-renewing divisions perpetuate undifferentiated multipotent stem cells 
throughout life but do not necessarily generate daughter cells that are identical to the 
mother cell. 
To meet the changing demands of tissue growth and regeneration during 
development and aging, many tissue stem cells undergo dynamic changes in their cell 
cycle status. For instance, fetal liver hematopoietic stem cells appear to undergo daily 
symmetric self-renewing divisions to expand the stem cell pool (Morrison et al., 1995). In 
contrast, adult hematopoietic stem cells are quiescent most of the time (Cheshier et al., 
1999b). Most adult mouse hematopoietic stem cells asynchronously go into cycle once 
every 12 days, but a more slowly dividing subset of HSCs divides only once every 55 
days or so (Foudi et al., 2008; Kiel et al., 2007; Wilson et al., 2008). The rate at which 
adult hematopoietic stem cells divide further changes during aging (de Haan et al., 1997; 
Morrison et al., 1996b). These changes in stem-cell cell cycle status and developmental 
potential require developmental changes in self-renewal programs. 
Although multiple transcriptional regulators are required by both fetal and adult 
hematopoietic stem cells, there are also mechanistic differences in the self-renewal of 
these stem cells (Levi and Morrison, 2009) (Figure 1.5). Fetal HSC maintenance depends 
on AML1 and Sox17, but these transcription factors are not required for the maintenance 
of adult HSCs (Ichikawa et al., 2004; Kim et al., 2007; Okuda et al., 1996b). Conversely, 
adult hematopoietic stem cell maintenance depends on several transcriptional regulators 
that are dispensable for the maintenance of fetal hematopoietic stem cells, including Bmi-
1 (Park et al., 2003b), Gfi-1 (Hock et al., 2004a) and Tel/Etv6 (Hock et al., 2004b). These 
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changes in the transcriptional regulation of self-renewal between fetal and adult HSCs at 
least partially reflect changes in cell cycle regulation. Sox17 is turned off as neonatal 
stem cells make the transition to a more slowly dividing adult phenotype (Kim et al., 
2007), and Gfi-1 is required in adult hematopoietic stem cells to maintain quiescence 
(Hock et al., 2004a) (Figure 1.5). 
Neural stem cells exhibit similar changes in the transcriptional regulation of self-
renewal between the fetal and adult stages (Figure 1.5). Fetal and young adult neural stem 
cells depend on Hmga2 for self-renewal (Nishino et al., 2008). Hmga2 negatively 
regulates the expression of p16Ink4a and p19Arf in these cells, increasing stem cell 
frequency and self-renewal potential. However, Hmga2 expression is extinguished in old 
adult neural stem cells (Nishino et al., 2008). Bmi-1 also promotes neural stem cell self-
renewal by repressing the expression of p16Ink4a and p19Arf (Bruggeman et al., 2005; 
Molofsky et al., 2005; Molofsky et al., 2003); however, Bmi-1 is not required in vivo 
during fetal development to repress p16Ink4a and p19Arf, rather it is required throughout 
adulthood. These studies demonstrate that stem cells employ overlapping transcriptional 
regulators to repress p16Ink4a/p19Arf expression throughout life. 
Stem cell self-renewal, aging and cancer 
Stem cells from diverse tissues exhibit changes in their self-renewal capability 
during aging. The frequency, self-renewal potential, mitotic activity, and rate of 
neurogenesis of neural stem/progenitor cells in the forebrain subventricular zone decline 
with age (Maslov et al., 2004; Molofsky et al., 2006). In the hematopoietic system, stem 
cells also change their frequency and cell cycle status with age, but in a strain-dependent 
manner: stem cell frequency increases with age in long-lived strains and decreases with 
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age in short-lived mouse strains (de Haan et al., 1997; de Haan and Van Zant, 1999; 
Morrison et al., 1996b). Aging HSCs also exhibit increased myelopoiesis and decreased 
lymphopoiesis (Rossi et al., 2005) as well as decreased capacity to home to the bone 
marrow upon intravenous injection (Liang et al., 2005; Morrison et al., 1996b). These 
data indicate that stem cells properties change with age, though the nature of the changes 
varies depending on tissue and genetic background. 
Age-related changes in stem cell properties are determined by both cell-intrinsic 
and cell-extrinsic changes. Cell-intrinsic changes in the transcriptional regulation of self-
renewal involve changes in p16Ink4a expression. p16Ink4a is not expressed by most types of 
stem cells in fetal and young adult animals (partly due to Hmga2 and Bmi-1 mediated 
repression), but its expression is upregulated with age in multiple tissues (Krishnamurthy 
et al., 2004) including in HSCs (Janzen et al., 2006) and neural stem cells (Molofsky et 
al., 2006) (Figure 1.5). Deletion of p16Ink4a from these tissues partially rescues the age-
related decline in stem cell frequency and self-renewal potential (Janzen et al., 2006; 
Krishnamurthy et al., 2006; Molofsky et al., 2006). The increased p16Ink4a expression in 
aging stem cells is at least partially attributable to the decline in Hmga2 expression, 
which is caused by increased let-7 microRNA expression during aging (Nishino et al., 
2008) (Figure 1.5). This demonstrates that by having overlapping transcriptional 
regulators, stem cells achieve fine-gain control over the expression of tumor suppressors 
that limit self-renewal potential. By maintaining Bmi-1-mediated repression and 
eliminating Hmga2-mediated repression during aging, stem cells can modestly increase 
p16Ink4a expression to achieve tumor suppression while maintaining a reduced level of 
stem cell function (Figure 1.6A).  
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Cell extrinsic changes that regulate changes in stem cell function during aging 
have best been studied in muscle, where Notch ligand expression declines with age, 
reducing Notch activation in satellite cells and muscle regenerative capacity (Conboy et 
al., 2003). Parabiosis of old mice to young mice and exposure of old satellite cells to 
young serum increases Notch ligand expression, muscle satellite cell proliferation, and 
muscle regenerative capacity, thereby demonstrating that local cues are regulated by 
circulating systemic factors (Conboy et al., 2005). It appears that such circulating factors 
include Wnts as canonical Wnt pathway activation increases with age in muscle satellite 
cells and inhibitors of this pathway can restore myogensis and suppress fibrogenesis by 
satellite cells (Brack et al., 2007). The premature aging of Klotho mutant mice have also 
been associated with increased Wnt signaling, and serum Klotho levels decline with age 
(Liu et al., 2007). These systemic changes in the environment of aging tissues may cause 
the cell intrinsic changes in tumor suppressor expression that have been observed in 
aging stem cells as increased Wnt and TGFß in the aging environment appear to 
counteract the effects of Notch ligands on muscle satellite cells, promoting the expression 
of CDK inhibitors including p16Ink4a. 
It is not clear whether there is any relationship between stem cell aging and 
lifespan. On one hand, the changes in stem cell function that occur during aging appear to 
reduce tissue regenerative capacity and the accumulation of genetic damage in stem cells 
likely contributes to increased cancer incidence during aging (Rossi et al., 2008; 
Sharpless and DePinho, 2007). On the other hand, the effects of aging on fully 
differentiated cells are likely a major and independent contributor to age-related 
morbidity, cancer incidence, and degenerative disease. It remains unclear whether the 
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changes that occur in stem cells during aging are a major or minor contributor to age-
related morbidity and lifespan. Notably, the transgenic overexpression of 
p15Ink4d/p16Ink4a/p19Arf and p53 increases mouse lifespan (Matheu et al., 2007) even 
though loss of p16Ink4a rescues stem cell function in multiple tissues during aging (Janzen 
et al., 2006; Krishnamurthy et al., 2006; Molofsky et al., 2006). These observations raise 
the possibility that tumor suppressors may have anti-aging effects in some cells, and that 
lifespan may reflect a convoluted mixture of pro-aging and anti-aging effects by tumor 
suppressors on stem cells and differentiated cells. 
Tumor suppressors regulate stem cell self-renewal and aging 
Tumor-suppressor genes can be largely divided into care-taking tumor 
suppressors and gate-keeping tumor suppressors (Campisi, 2005; Kinzler and Vogelstein, 
1997). Gate-keeping tumor suppressors, like p53, p16Ink4a, and p19Arf serve as fail-safe 
mechanisms to prevent uncontrolled cell proliferation. As indicated above, these genes 
tend to negatively regulate self-renewal by slowing cell division, or by inducing 
senescence or apoptosis when activated by DNA damage, stress, or oncogenic stimuli. In 
contrast, care-taking tumor suppressors, like the DNA damage response proteins ATM 
and ATR, maintain cellular integrity and therefore promote the maintenance of stem 
cells. As discussed above, ROS detoxification, telomere maintenance, and DNA repair by 
care-taking tumor suppressors are all required to maintain genomic integrity in stem cells. 
A loss of care-taking tumor suppressor function resembles premature aging phenotype 
marked by stem cell depletion and reduced tissue regenerative capacity (Lombard et al., 
2005) (Figure 1.6C). This functional distinction of tumor suppressors is not clear-cut and 
some genes, such as p53 and Pten have both care-taking and gate-keeping functions. 
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Care-taking tumor suppressors are unable to completely prevent the accumulation 
of damage in stem cells during aging. To compensate for this, cellular stress or damage 
activates gate-keeping tumor suppressor mechanisms to ensure that stem cells are not 
transformed into cancer cells. For example, critical levels of telomere attrition lead to p53 
activation, inducing cell death or cell senescence (Chin et al., 1999). p53 deficiency 
reduces the cell death and senescence observed in response to telomere dysfunction but 
also accelerates cancer development in these cells. Together, these results illustrate how 
DNA damage activates gate-keeping tumor suppressors that reduce normal stem cell 
function as a consequence of their efforts to prevent cancer (Figure 1.6C). Although these 
mechanisms operate in many cells, they are particularly important in stem cells to prevent 
the propagation of DNA damage throughout tissues and to avoid stem cell 
transformation, which might occur more easily than the transformation of their post-
mitotic progeny. 
Cancer cells hijack normal self-renewal mechanisms 
Cancer cells proliferate out of control by inappropriately activating normal self-
renewal pathways either through mutations that constitutively activate oncogenes or 
through mutations that inactivate tumor suppressors (Pardal et al., 2005) (Figure 1.6D). 
Like normal stem cells, cancer cells rely on mechanisms that promote proliferation and 
suppress differentiation. In many cases, self-renewal regulators have surprisingly similar 
functions in cancer cells and in normal stem cells. For example, the proto-oncogene Bmi-
1 is required to maintain the proliferative potential of leukemic stem cells (Lessard and 
Sauvageau, 2003a) and brain tumor cells (Bruggeman et al., 2007) just as it is required to 
maintain the self-renewal potential of normal hematopoietic and neural stem cells 
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(without being generically required for the proliferation of all cells) (Molofsky et al., 
2003; Park et al., 2003b). Hedgehog signaling is not only required for normal neural stem 
cell maintenance, but also for brain tumor cell proliferation (Balordi and Fishell; Balordi 
and Fishell, 2007; Ruiz i Altaba et al., 2002). These are only a few of many examples. 
Therefore, by identifying the mechanisms that regulate normal stem cell self-renewal we 
can also gain insights into the regulation of cancer cell proliferation; however it is 
difficult to target these mechanisms in the context of cancer without also impairing 
normal stem cell function and tissue regenerative capacity. This contributes to the 
toxicity of cancer therapy. 
It is possible, however, to identify mechanistic differences between stem cell self-
renewal and cancer cell proliferation, even cancer stem cell proliferation. The PI-3kinase 
pathway is essential for the regulation of normal stem cell self-renewal and is frequently 
hyper-activated by mutations in cancer (Yuan and Cantley, 2008). Pten, a tumor 
suppressor that attenuates signaling through this pathway, is one of the most frequently 
deleted loci in cancer. In some tissues, the consequences of Pten function appear to be 
very similar in cancer cells and normal stem cells. For example, Pten is frequently 
deleted in brain tumors and Pten also negatively regulates the self-renewal of normal 
neural stem cells (Groszer et al., 2006; Groszer et al., 2001). However, the situation in the 
hematopoietic system is more complicated. Widespread deletion of Pten in the 
hematopoietic system does lead to leukemogenesis, as expected (Yilmaz et al., 2006); 
however, deletion in hematopoietic stem cells leads to the depletion of these cells, rather 
than their expansion (Yilmaz et al., 2006; Zhang et al., 2006). In the absence of Pten, 




days, transiently expanding the stem cell pool. However, within weeks, the stem cells 
become depleted through mechanisms that are just being elucidated now, but which 
depend upon hyper-activation of mTor. Treatment of these mice with the mTor inhibitor 
rapamycin not only reduces leukemogenesis but also rescues normal stem cell function, 
(Yilmaz et al., 2006), providing proof-of-principle that it is possible to identify 
chemotherapies that are more effective against cancer while exhibiting less toxicity to 
normal stem cells. 
Since normal stem cells employ different self-renewal programs at different ages, 
one prediction is that cancers will require different mutations at different ages to hijack 
these self-renewal programs. This remains to be tested but offers a potential explanation 
for the differences that are observed in mutation spectrum between the childhood and 
adult versions of certain cancers (Gilliland et al., 2004). 
 
 
Figure 1.1: The regulation of pluripotency.  
ES cell self-renewal is maintained by the Oct4-Sox2-Nanog transcriptional regulatory 
network, which forms a positive feedback loop that negatively regulates the expression of 
differentiationpromoting genes. Polycomb family (PcG) proteins aid in this process by 
suppressing the expression of genes associated with differentiation. Leukemia inhibitory 
factor (LIF) and bone morphogenetic protein (BMP) signaling suppress differentiation by 
inhibiting MAPK pathway signaling, which is activated by autocrine fibroblast growth 
factor (FGF) signaling. Thus ES cells self-renew by inhibiting differentiation (Ying et al. 
2008). Self-renewal is possible in culture conditions that lack differentiation inducing 
stimuli, but ES cells spontaneously differentiate when they achieve high densities in 




Figure 1.2: Differences in cell-cycle regulation among stem cells at different stages 
of life. 
A) ES cells have constitutive cyclin E-CDK2 activity which hyperphosphorylates and 
inactivates Rb. This leads to a short G1 phase of the cell cycle, with rapid G1-S 
transition, and little dependence upon mitogenic signals or D cyclins for S phase entry. B) 
In fetal stem cells, mitogens promote a relatively rapid G1-S transition through 
cooperative action of cyclin D-CDK4/6 and cyclin E-CDK2 to inactivate Rb family 
proteins. p16Ink4a and p19Arf expression are inhibited by Hmga2-dependent chromatin 
regulation. C) Many young adult stem cells are quiescent most of the time. In the absence 
of mitogenic signals, cyclin-CDKs and the G1-S transition are suppressed by cell-cycle 
inhibitors, including Ink4 and Cip/Kip family proteins. As a result, Rb is 
hypophosphorylated and inhibits E2F, promoting quiescence in G0-phase of the cell 
cycle. Mitogen stimulation mobilizes these cells into cycle by activating cyclin D 
expression. D) In old adult stem cells, let-7 microRNA expression increases, reducing 
Hmga2 levels and increasing p16Ink4a and p19Arf levels (Nishino et al., 2008). This 
reduces the sensitivity of stem cells to mitogenic signals by inhibiting cyclin-CDK 
complexes. As a result, stem cells either cannot enter the cell cycle, or cell division 
slows. Red ovals indicate proto-oncogene products and blue ovals indicate tumor 
suppressors. P denotes phosphorylation, R denotes the cell cycle restriction point. Ovals 
with more intense color indicate gene products that are functionally important in these 










Figure 1.3: Mechanisms suppressing stem cell differentiation. 
A) In some systems, such as the C. elegans germline, differentiation is blocked by RNA-
binding proteins that post-transcriptionally block the function of differentiation-inducing 
gene product. B) Expression of lineage specification genes can be repressed by stem cell-
specific transcription factors (orange oval). C) Epigenetic modifications can also 
contribute to the repression of these genes by recruiting chromatin modifiers and 
transcriptional repressors. D) A balance among lineage specification genes that promote 
alternative fates may suppress differentiation by mutual inhibition (Shin et al., 2008). E) 
Intrinsically asymmetric divisions can ensure that one daughter remains a stem cell by 
asymmetrically segregating factors that promote stem-cell identity (Lee et al., 2006a) or 
that inhibit differentiation (Seydoux et al., 1996) to one daughter (orange). F) 
Asymmetric divisions can also suppress differentiation by ensuring that one daughter cell 
remains within the niche (yellow), and exposed to factors that promote stem-cell 
maintenance (orange), while the other daughter cell is displaced from the niche (green) 
similar to Drosophila spermatogonial stem cells (Fuller and Spradling, 2007).
 
Figure 1.4: Niche regulation of stem cell self-renewal 
A) In Drosophila testis, germ-line stem cells (GSCs) are anchored to the hub cells (niche) 
through DE-cadherin and β-catenin/armadillo (Arm) mediated adherens junctions. Hub 
cells also secrete Upaired and Gbb/Dpp to activate JAK-STAT and BMP signaling in the 
GSCs which suppress GSC differentiation by repressing Bam expression. The mother 
centrosome in GSCs (red circle) is tethered to the adherens junction by the Adenomatous 
Polyposis Coli (APC2) complex, while the daughter centrosome (yellow circle) migrates 
to the other pole of the cell. This determines spindle orientation and the polarity of 
division, such that stem cells divide asymmetrically to generate one daughter that remains 
a stem cell within the niche and another daughter that is displaced from the niche and 
fated to differentiate. B) In the C.elegans germ line, the distal tip cell (DTC) expresses 
the Notch ligand LAG-2, which binds to and activates GLP-1 on GSCs to induce Notch 
signaling. GLP-1/Notch activation induces the expression of the RNA-binding protein 
FBF-1 and FBF-2 which suppress GSC differentiation by repressing the translation of the 
meiosis-inducing transcripts, gld-1 and gld-3. C) Models for the HSC niche. Endosteal 
and perivascular cells have been implicated in the regulation of HSC maintenance, 
though the cell type(s) that produce the factors that maintain HSCs remain uncertain, and 
diverse models remain compatible with existing evidence: a, Spatially distinct but 
redundant endosteal and perivascular niches may maintain HSCs through similar 
mechanisms. b, Spatially and functionally distinct endosteal and perivascular niches may 
maintain HSCs through different mechanisms. c, Endosteal and perivascular cells may 
work together to form a common niche influenced by both cell types. d, As yet identified 
cells may create niches or “zones” of HSC maintenance. These models are not mutually 
exclusive and are not the only models consistent with existing evidence. D, The 
subventricular zone niche. Neural stem cells (type B-cells) generate transiently 
amplifying (type C) cells, which then form (type A) neuroblasts. Neural stem cell 
maintenance is regulated by factors produced by ependymal cells (E) as well as 
perivascular cells. Neural stem cells contact the ventricle through a short apical process 









Figure 1.5: Distinct factors regulate hematopoietic stem cell (HSC) and neural stem 
cell (NSC) self-renewal at different ages. 
Schematic representation of stage-specific regulators of HSC and NSC self-renewal. The 
functional importance of each factor at each developmental stage is depicted by the color 
shading of bar graph (red indicates a positive regulator of self-renewal; blue indicates a 






Figure 1.6: Stem cell self-renewal, stem cell aging and cancer cell proliferation are 
regulated by common networks of proto-oncogenes and tumor suppressors. 
A,B) Stem cell self-renewal is maintained by a balance between proto-oncogenes and 
gate-keeping tumor suppressors. Proto-oncogenes promote stem cell self-renewal and 
cancer cell proliferation, while gate-keeping tumor suppressors negatively regulate self-
renewal and promote stem cell aging. C) As organisms age, DNA damage accumulates 
and telomeres erode, activating gate-keeping tumor suppressors and leading to reduced 
stem cell function and tissue regenerative capacity. D) DNA damage can also activate 
oncogenes and inactivate gate-keeping tumor suppressors, disrupting the balance in their 
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CHAPTER 2  
 
BMI-1 PROMOTES NEURAL STEM CELL SELF-RENEWAL AND NEURAL 
DEVELOPMENT BUT NOT GROWTH AND SURVIVAL BY SUPPRESSING 
THE P16INK4A AND P19ARF SENESCENCE PATHWAYS1 
 
SUMMARY 
Bmi-1 is required for the postnatal maintenance of stem cells in multiple tissues 
including the central (CNS) and peripheral (PNS) nervous systems. Deletion of Ink4a or 
Arf from Bmi-1-/- mice partially rescued stem cell self-renewal, and stem cell frequency in 
the CNS and PNS as well as forebrain proliferation and gut neurogenesis. Arf deficiency, 
but not Ink4a deficiency, partially rescued cerebellum development, demonstrating 
regional differences in the sensitivity of progenitors to p16Ink4a and p19Arf. Deletion of 
both Ink4a and Arf did not affect the growth or survival of Bmi-1-/- mice or completely 
rescue neural development. Bmi-1 thus prevents the premature senescence of neural stem 
cells by repressing Ink4a and Arf but additional pathways must also function downstream 
of Bmi-1. 
                                                 
1 Originally published in Genes and Development. 2005;19:1432-7 with authors listed as Molofsky, A.V., 




Stem cells must persist throughout adult life in numerous tissues in order to 
replace the mature cells that are lost to turnover, injury, or disease. The mechanism by 
which stem cells persist throughout life involves self-renewal - stem cell divisions that 
generate one or two daughter stem cells (Molofsky et al., 2004; Morrison et al., 1997a). 
Stem cells self-renew postnatally in numerous tissues, including the CNS (Maslov et al., 
2004), PNS (Kruger et al., 2002), and hematopoietic system (Harrison, 1979; Morrison et 
al., 1996b).  
The polycomb family transcriptional repressor Bmi-1 is required for the self-
renewal and postnatal maintenance of hematopoietic stem cells (Lessard and Sauvageau, 
2003b; Park et al., 2003a), and neural stem cells from the CNS and PNS (Molofsky et al., 
2003). In each tissue Bmi-1-/- stem cells form in normal numbers and appear to 
differentiate normally, but exhibit a postnatal self-renewal defect that leads to their 
depletion by early adulthood. Bmi-1 tends to be turned off as cells differentiate (Lessard 
et al., 1998) and is not required for the proliferation of all cells (Molofsky et al., 2003). 
Bmi-1 functions as part of a protein complex that maintains gene silencing by regulating 
chromatin structure (Valk-Lingbeek et al., 2004). Except for a mild skeletal 
transformation, Bmi-1-/- mice are normal in size and appearance at birth (van der Lugt et 
al., 1994b). However, they exhibit progressive postnatal growth retardation and die by 
early adulthood with signs of hematopoietic failure (hypocellular bone marrow) and 
neurological abnormalities (seizures and ataxia) (van der Lugt et al., 1994b).  
Bmi-1-/- mice develop several specific neural abnormalities. The rate of 
proliferation in the forebrain subventricular zone (SVZ; where CNS stem cells undergo 
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neurogenesis) is reduced by postnatal day 30 (P30) when stem cell depletion becomes 
severe (Molofsky et al., 2003). The cerebellum also fails to develop normally, partly 
because Bmi-1 is required for the proliferation of granule precursor cells (Leung et al., 
2004). Finally, adult Bmi-1-/- mice exhibit fewer neurons in the myenteric plexus of the 
gut as the neural crest stem cells (NCSCs) in this region of the postnatal PNS become 
depleted (Molofsky et al., 2003). These defects indicate that the pathways regulated by 
Bmi-1 have important consequences for neural development.  
Bmi-1 represses transcription at the Ink4a-Arf locus (Jacobs et al., 1999b; Jacobs 
et al., 1999c) which encodes two inhibitors of cell proliferation (Sherr, 2001b). Ink4a 
encodes p16Ink4a, a cyclin-dependent kinase inhibitor that promotes Rb activation. Arf 
encodes p19Arf, which promotes p53 activation. p16Ink4a and p19Arf are induced in 
cultured primary cells and can cause these cells to senesce (reviewed in (Lowe and Sherr, 
2003)). Bmi-1 overexpression can prevent senescence and extend the replicative lifespan 
of primary cells by reducing p16Ink4a and p19Arf expression (Dimri et al., 2002; Itahana et 
al., 2003; Jacobs et al., 1999b). Deletion of Ink4a-Arf from Bmi-1-/- mice rescues the 
ability of mouse embryonic fibroblasts to proliferate in culture and at least partially 
rescues defects in cerebellum development (Jacobs et al., 1999b). p16Ink4a expression is 
elevated in Bmi-1-/- neural stem cells and deletion of Ink4a from Bmi-1-/- mice partially 
rescues neural stem cell self-renewal in culture (Molofsky et al., 2003).  
To test whether Ink4a deletion rescues stem cell frequency or neural development 
in Bmi-1-/- mice, and whether p19Arf also mediates part of the effect of Bmi-1 on stem cell 
function or neural development we have generated compound mutant mice that lack Bmi-
1 (van der Lugt et al., 1994b) and/or Ink4a (Sharpless et al., 2001), Arf (Kamijo et al., 
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1997), or Ink4a-Arf (Serrano et al., 1996). Our results indicate that the repression of 
Ink4a and Arf each represent major mechanisms by which Bmi-1 promotes neural stem 
cell self-renewal and neural development. The postnatal maintenance of neural stem cells 
depends upon the repression of senescence pathways that otherwise cause the premature 
depletion of stem cells. 
 
RESULTS AND DISCUSSION 
Like p16Ink4a (Molofsky et al., 2003), p19Arf expression increased in the absence 
of Bmi-1. p19Arf was not detected in the wild-type SVZ or cerebellum, but was detected 
in these tissues in the absence of Bmi-1 (Figure 2.1A). p19Arf was upregulated in Bmi-1-/- 
CNS neurospheres cultured from the SVZ (Figure 2.1B) and Bmi-1-/- PNS neurospheres 
cultured from the adult gut wall (data not shown), though p19Arf was also detected at 
lower levels in wild-type neurospheres. The detection of both p16Ink4a (Molofsky et al., 
2003) and p19Arf in cultured neurospheres despite not detecting these proteins in vivo 
suggests that Ink4a and Arf are induced in wild-type cells in culture, though not to the 
extent as in Bmi-1-/- cells. This is consistent with our failure to detect Ink4a or Arf by 
PCR in uncultured wild-type NCSCs isolated by flow-cytometry (Molofsky et al., 2003). 
Arf deficiency significantly increased self-renewal within both Bmi-1+/+ and Bmi-
1-/- neurospheres from the CNS and PNS (Figure 2.1C, D). The ability of Arf deficiency 
to increase the self-renewal of Bmi-1+/+ neural stem cells in culture presumably reflects 
the fact that primary neurospheres were subcloned after 10 days in culture, well after 
p19Arf was induced in these cells. Since only about half as much self-renewal was 
observed within Bmi-1-/-Arf -/- neurospheres as compared to Bmi-1+/+Arf -/- neurospheres 
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in the CNS and PNS, Arf deficiency appeared to only partially rescue the self-renewal of 
Bmi-1-/- neurospheres. Consistent with this, Arf deficiency also significantly increased the 
size of neurospheres (Figure 2.2B), and the percentage of cells within Bmi-1-/- 
neurospheres that could form secondary neurospheres (Figure 2.3B). 
Deletion of Ink4a and Arf (Ink4a-Arf -/-) significantly increased self-renewal 
within Bmi-1+/+ and Bmi-1-/- neurospheres from the CNS and PNS (Figure 2.1E,F). The 
rates of self-renewal suggested that Ink4a-Arf deficiency rescued most but not all of the 
Bmi-1-/- CNS self-renewal defect and about half of the PNS self-renewal defect (compare 
Bmi-1-/-Ink4a-Arf -/- versus Bmi-1+/+Ink4a-Arf -/-, Figure 2.1E,F). More self-renewal was 
observed in Figure 2.1F than in Figure 2.1D because the neurospheres were cultured 
longer before subcloning. Ink4a-Arf deficiency also significantly increased the size of 
neurospheres (Figure 2.2C,D), and the percentage of cells within Bmi-1-/- neurospheres 
that could form secondary neurospheres (Figure 2.3C). 
Ink4a, Arf, or Ink4a-Arf deficiency partially rescue Bmi-1-/- neural stem cell 
frequency 
To test whether Ink4a deficiency could also rescue stem cell frequency in vivo, we 
cultured dissociated forebrain SVZ cells from 4 to 8 week old mice to determine the 
frequency of freshly dissociated cells that could form multipotent neurospheres. Cells 
were plated at clonal density, cultured for 10 days, then replated to adherent cultures for 3 
to 5 days and stained for neurons, astrocytes, and oligodendrocytes. As observed 
previously, a significantly lower percentage of cells from the Bmi-1-/- SVZ formed 
multipotent neurospheres (Figure 2.4). Ink4a deficiency significantly increased the 
percentage of Bmi-1-/- but not Bmi-1+/+ SVZ cells that formed multipotent neurospheres 
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(Figure 2.4A). This is consistent with p16Ink4a expression in Bmi-1-/- but not in Bmi-1+/+ 
SVZ cells in vivo (Molofsky et al., 2003). The magnitude of the increase suggested that 
Ink4a deficiency partially rescued stem cell frequency in the Bmi-1-/- SVZ. 
We also cultured dissociated cells from the outer gut wall where NCSCs persist 
throughout adult life (Kruger et al., 2002). Cells were plated at clonal density, cultured 
for 10 days, then replated to adherent cultures for 5 days and stained for neurons, glia, 
and myofibroblasts. Ink4a deficiency significantly increased the percentage of Bmi-1-/- 
but not Bmi-1+/+ cells that formed multipotent neurospheres (Figure 2.4B). The 
magnitude of the increase again suggested that Ink4a deficiency partially rescued stem 
cell frequency in the Bmi-1-/- gut. 
To confirm the partial rescue in neural stem cell frequency in vivo, we exploited 
our ability to prospectively identify uncultured NCSCs by flow-cytometry based on their 
expression of high levels of the p75 neurotrophin receptor (p75+ cells) (Bixby et al., 
2002; Kruger et al., 2002). In these experiments, 30 to 50% of p75+ cells of all genotypes 
formed NCSC colonies in culture (data not shown), a 30 to 300-fold enrichment for 
NCSCs relative to unfractionated cells (0.1 to 1.4% of unfractionated gut cells, depending 
on genotype, formed stem cell colonies in culture; Figure 2.4). The frequency of p75+ 
cells was significantly reduced in the absence of Bmi-1 (Figure 2.5A,B). Ink4a deficiency 
had no effect on the frequency of p75+ cells from Bmi-1+/+ mice, but did significantly 
increase the frequency of p75+ cells in Bmi-1-/- mice (Figure 2.5C-E). The magnitude of 
the increase again suggested a partial rescue of Bmi-1-/- stem cell depletion. This analysis 
of prospectively identified, uncultured NCSCs was thus consistent with results from the 
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functional assays in culture in indicating that Bmi-1 promotes the postnatal maintenance 
of neural stem cells partly by repressing Ink4a. 
Arf deficiency (Figure 2.4C, D) and Ink4a-Arf deficiency (Figure 2.4E,F) also 
partly rescued the depletion of CNS and PNS stem cells in Bmi-1-/- mice, significantly 
increasing the percentage of freshly dissociated SVZ cells and outer gut wall cells from 
Bmi-1-/- but not Bmi-1+/+ mice that formed multipotent neurospheres in culture. The 
percentages of SVZ and gut cells from Bmi-1-/-Ink4a-Arf -/- and Bmi-1+/+Ink4a-Arf -/- mice 
that formed multipotent neurospheres suggest that Ink4a-Arf deficiency rescued most of 
the CNS stem cell maintenance defect and about half of the Bmi-1-/- PNS stem cell 
maintenance defect. These results demonstrate that increased expression of p16Ink4a and 
p19Arf in the absence of Bmi-1 are responsible for much but not all of the neural stem cell 
self-renewal and maintenance defects observed in Bmi-1-/- mice. 
Ink4a, Arf, or Ink4a-Arf deficiency partially rescue neural development in Bmi-1-/- 
mice 
In the absence of Bmi-1 there was a significant decline in the rate of proliferation 
(the percentage of cells that incorporated a pulse of BrdU) in the adult SVZ, where 
neurogenesis occurs in the forebrain (Figure 2.6A). Ink4a deficiency had no effect on 
proliferation in the Bmi-1+/+ forebrain (data not shown) but significantly increased 
proliferation in the Bmi-1-/- forebrain, suggesting a partial rescue of this phenotype 
(Figure 2.6A). The number of myenteric plexus neurons per cross-section of the adult 
small intestine was significantly reduced in the absence of Bmi-1 (Figure 2.6B). Ink4a 
deficiency significantly increased the number of neurons per section through the Bmi-1-/- 
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intestine (Figure 2.6B). Thus Ink4a deficiency partially rescued 
proliferation/neurogenesis in the forebrain and enteric nervous system of Bmi-1-/- mice. 
Arf deficiency (Figure 2.6C) or Ink4a-Arf deficiency (Figure 2.6E) also 
significantly increased proliferation in the Bmi-1-/- but not Bmi-1+/+ SVZ, suggesting 
partial rescue of this defect. Arf deficiency appeared to increase the number of neurons 
per section through the Bmi-1-/- small intestine, though the effect was not statistically 
significant (Figure 2.6D). Ink4a-Arf deficiency significantly increased the number of 
neurons per section through the Bmi-1-/- but not Bmi-1+/+ small intestine (Figure 2.6F) to 
a degree consistent with a complete rescue. That some phenotypes (e.g. gut neurogenesis) 
appeared to be completely rescued by deleting Ink4a and Arf, while other phenotypes 
(e.g. SVZ proliferation) were only partially rescued indicates that the importance of other 
pathways downstream of Bmi-1 differs between regions of the nervous system. 
Arf, or Ink4a-Arf deficiency partially rescue cerebellum development in Bmi-1-/- 
mice 
Bmi-1-/- mice exhibit morphologically smaller cerebellums, including significantly 
thinner granular and molecular cell layers, and reduced cell density in the molecular layer 
(Figure 2.7A-C) (Leung et al., 2004; van der Lugt et al., 1994b). Ink4a-Arf deficiency 
partially rescues cerebellum development in Bmi-1-/- mice (Jacobs et al., 1999b), though 
the relative importance of Ink4a and Arf in cerebellum development was not tested. 
Consistent with this prior report, we found that Ink4a-Arf deficiency had no effect on 
cerebellum development in Bmi-1+/+ mice (data not shown), but did increase the overall 
cerebellum size in Bmi-1-/- mice, including significantly increasing the thickness of the 
granular and molecular layers, as well as cell density in the molecular layer (Figure 
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2.7C). Nonetheless, all of these parameters remained significantly less than observed in 
wild-type littermates, indicating a partial rescue of cerebellum growth (Figure 2.7C). 
Ink4a deficiency had no effect on cerebellum development in Bmi-1-/- mice 
(Figure 2.7A), despite the increased expression of p16Ink4a in the Bmi-1-/- cerebellum 
(Figure 2.8). This suggests that progenitors from some regions of the nervous system can 
be insensitive to p16Ink4a expression. Arf deficiency had no effect on cerebellum 
development in Bmi-1+/+ mice (data not shown) but increased the overall cerebellum size 
in Bmi-1-/- mice, in addition to significantly increasing the thickness of the granular and 
molecular layers, and cell density in the molecular layer (Figure 2.7B) to a similar degree 
as observed from Ink4a-Arf deficiency (compare to Figure 2.7C). The observation that 
Arf deficiency had a greater effect than Ink4a deficiency on cerebellum development in 
Bmi-1-/- mice indicates that the relative importance of p16Ink4a and p19Arf differs between 
progenitor populations and regions of the nervous system. 
Ink4a, Arf, or Ink4a-Arf deficiency do not rescue the growth or survival of Bmi-1-/- 
mice 
Although Ink4a deficiency, Arf deficiency, or Ink4a-Arf deficiency each partially 
rescued aspects of neural stem cell function and neural development in Bmi-1-/- mice, 
they did not affect the overall growth of Bmi-1-/- mice, which were significantly smaller 
than wild-type littermates (Figure 2.9). Ink4a deficiency or Arf deficiency also did not 
significantly affect brain mass in Bmi-1-/- mice (Figure 2.10A,B). Ink4a-Arf deficiency on 
the other hand did significantly increase brain mass in adult Bmi-1-/- mice, though only 
slightly (Figure 2.10C). The ability of Ink4a deficiency, Arf deficiency, and Ink4a-Arf 
deficiency to substantially rescue neural stem cell function while having little or no effect 
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on brain growth in Bmi-1-/- mice indicates that the effects of Bmi-1 on neural stem cells 
can be uncoupled from effects on tissue growth. 
Ink4a deficiency, Arf deficiency, or Ink4a-Arf deficiency also did not rescue the 
survival of Bmi-1-/- mice, which usually died by postnatal day 30 (Figure 2.9), despite 
being born in nearly expected numbers (data not shown). Ink4a-Arf deletion did not 
prevent Bmi-1-/- mice from exhibiting ataxia (data not shown). Abnormalities in other 
tissues, such as the hematopoietic system, are also not completely rescued by Ink4a-Arf 
deletion and may exhibit less of a rescue than observed in the nervous system (see 
companion paper from van Lohuizen and colleagues). It is likely that Bmi-1-/- mice have 
uncharacterized defects in the maintenance of other tissues that could also affect viability. 
Thus the early death of these mice is likely to derive from complex combinations of 
defects in multiple tissues. 
It is difficult to precisely estimate the fraction of each phenotype rescued by Ink4a 
or Arf deletion; however, the extent to which Ink4a-Arf deficiency rescued SVZ 
proliferation (Figure 2.6E) did not appear to be greater than observed from deletion of 
Ink4a (Figure 2.6A) or Arf alone (Figure 2.6C). Similarly, the extent to which Ink4a-Arf 
deficiency rescued neural stem cell frequency (Figure 2.4E, F) appeared to be less than 
the sum of the effects of Ink4a deficiency (Figure 2.4A, B) and Arf deficiency (Figure 
2.4C, D). This suggests that there is cross regulation between the p16Ink4a and p19Arf 
pathways. A number of mechanisms by which the p16Ink4a and p19Arf pathways influence 
each other have already been identified (Lowe and Sherr, 2003). For example, since 
p21cip1, like p16Ink4a, promotes Rb activation, changes in p21cip1 expression affect the 
levels of p16Ink4a that are required to inhibit proliferation (Lowe and Sherr, 2003). 
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Consistent with this, we found that cip1 RNA levels were reduced by Arf deficiency and 
increased by Bmi-1 deficiency (as would be predicted based on the presumed changes in 
p19Arf and p53 activity in these cells; Figure 2.11). These changes in cip1 levels offer one 
possible source of cross regulation that could account for the less-than-additive effects of 
Ink4a and Arf deletion, particularly given that p21cip1 regulates neural stem cell self-
renewal (Kippin et al., 2005; Qiu et al., 2004). 
Ink4a and Arf repression represent important mechanisms by which Bmi-1 
promotes postnatal stem cell self-renewal, stem cell maintenance, and development in the 
nervous system. Since induction of p16Ink4a and p19Arf have been associated with cellular 
senescence (Lowe and Sherr, 2003), neural stem cells appear to undergo premature 
senescence in the absence of Bmi-1 and become depleted by adulthood. This suggests 
that the repression of these senescence pathways is a fundamental requirement for the 
maintenance of neural stem cells throughout life. 
 
MATERIALS AND METHODS 
The Bmi-1+/-, Arf +/-, and Ink4a-Arf +/- mice were backcrossed at least 8 times onto 
a C57BL background. Initial experiments employed Ink4a+/- mice on an FvB 
background, but all results were subsequently confirmed using Ink4a+/- mice backcrossed 
5 times onto a C57BL background. All mice were genotyped by PCR using primers 
described in Suppl. Methods. 
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Isolation of CNS and PNS progenitors 
Adult SVZ was obtained by coronally sectioning brains in ice-cold Opti-MEM 
medium (Gibco). The lateral walls of the lateral ventricles were removed, minced, then 
dissociated for 20 min at 37˚C in 0.025% trypsin/0.5mM EDTA (Calbiochem, San Diego, 
CA) plus 0.001% DNase1 (Roche, Indianapolis, IN). Cells were quenched with staining 
medium (L15 medium containing 1 mg/ml BSA (Sigma A-3912, St. Louis, MO), 10 mM 
HEPES (pH 7.4), and 1% penicillin/streptomycin (BioWhittaker, Walkersville, MD)) 
containing 0.014% soybean trypsin inhibitor (Sigma) and 0.001% DNAse1. After 
centrifuging, the cells were resuspended in staining medium, triturated, filtered through 
nylon screen (45 m, Sefar Amer　 ica, Kansas City, MO), counted by hemocytometer, 
and plated. 
For PNS progenitor isolation, adult mouse guts were dissected into ice cold PBS. 
Outer muscle/plexus layers were peeled free from the underlying epithelium as described 
(Kruger et al., 2002); then minced, and dissociated for 45 min in 0.025% trypsin/EDTA 
(Gibco 25300-054, Grand Island, NY) plus 1 mg/ml type 4 collagenase (Worthington) in 
Ca, Mg-free HBSS at 37°C with agitation every 5 minutes. The dissociated cells were 
then quenched in staining medium, resuspended and filtered as described above. 
Dissociated gut cells were sometimes stained with an antibody against p75 (Ab 1554; 
Chemicon International) as described previously (Bixby et al., 2002). The analysis and 
sorting of p75+ cells was performed by a FACS VantageSE flow-cytometer (Becton-
Dickinson).  
Cell culture and self-renewal assay 
Cells were plated at clonal density (2000 cells per well of a 6-well plate; 1.3 
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cells/ul of culture medium) on ultra-low binding plates (Corning) to grow neurospheres. 
Culture medium was based on a 5:3 mixture of DMEM-low glucose: neurobasal medium 
(Gibco) supplemented with 20 ng/ml human bFGF (R&D Systems, Minneapolis, MN), 
1% N2 supplement (Gibco), 2% B27 supplement (Gibco), 50 M 2　 -mercaptoethanol, 
and 1% pen/strep (Biowhittaker). CNS cultures also contained 20 ng/ml EGF (R&D 
Systems) and 10% chick embryo extract (prepared as described (Stemple and Anderson, 
1992)). PNS cultures contained 15% chick embryo extract, 35 mg/ml (110 nM) retinoic 
acid (Sigma), and 20 ng/ml IGF1 (R&D Systems). All cultures were maintained at 37˚C 
in 6% CO2/balance air. 
To measure self-renewal, individual CNS neurospheres were dissociated by 
trituration then replated at clonal density in non-adherent cultures. Secondary 
neurospheres were counted 5-10 days later to determine the number of secondary 
neurospheres formed per primary neurosphere. Individual PNS neurospheres were 
replated for 48 h into adherent plates to allow the spheres to spread out over the culture 
dish. The adherent colonies were then treated with trypsin and collagenase (4 parts 0.05% 
trypsin-EDTA plus 1 part 10mg/ml collagenase IV) for 5 min at 37°C followed by 
trituration. 5,000 dissociated cells were replated per well of a 6 well plate and secondary 
neurospheres were counted 10 days later. 
Anti-BrdU antibody staining 
For detection of BrdU in the CNS tissue sections, DNA was first denatured in 2M 
HCl for 30 min at room temperature and neutralized with 0.1M Sodium Borate. Sections 
were pre-blocked for 1 hr at room temperature in goat serum solution (GSS) (PBS 
containing 5% goat serum, 1% BSA, and 0.3% Triton X-100 (Sigma)). Primary rat anti-
77 
 
BrdU (1:200, Accurate Chemical, Westbury, NY) diluted in GSS was incubated 
overnight at 4˚C, followed by FITC-conjugated anti-rat Fc fragment (Jackson Labs) for 
3-4 hrs at room temperature. Slides were counter stained in 2.5µg/ml DAPI for 10 min at 
RT, then mounted using ProLong antifade solution (Molecular Probes, Eugene, OR). 
Numbers of BrdU labeled cells were divided by total DAPI-positive nuclei. 
Western blots and quantitative RT-PCR 
Cells or tissues were resuspended in ice-cold cell lysis buffer (Cell Signaling 
Technology) with protease inhibitor cocktail (complete mini tablet, Roche), and 
incubated for 15-30 minutes on ice. Tissues were briefly homogenized, then all samples 
were sonicated for 1 minute at 20-30% power in a microson ultrasonic cell disruptor, 
spun down for 5 minutes at 16,000g and the supernatant quantified colorimetrically 
(BioRad protein assay). 50-100 ug of protein per lane were separated in 12% denaturing 
SDS-PAGE gels and transferred overnight at 4°C to PVDF membranes (Bio-Rad). The 
membranes were blocked in Tris buffered saline with 0.1% tween-20 and 5% milk, 
incubated with primary and secondary antibodies, and washed following standard 
procedures. Horseradish peroxidase conjugated secondary antibodies were detected by 
chemiluminescence (ECL Plus; Amersham-Pharmacia). Primary antibodies were mouse 
monoclonal anti-ß-actin (Ab-1; Oncogene), rabbit polyclonal anti-p19ARF (ab80, Abcam), 
mouse monoclonal anti p21cip1 (Pharmigen) and rabbit polyclonal anti-p16Ink4a (M-156; 
Santa Cruz Biotechnology). 
Quantitative RT-PCR was performed as described previously (Molofsky et al., 
2003). Primers used to amplify Ink4a were 5’CGAACTCTTTCGGTCGTACCC-3’ 
(sense) and 5’-CGAATCTGCACCGTAGTTGAGC-3’ (antisense). These primers 
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amplified an 89 nucleotide product that spanned an intron and that was identical to Ink4a 
upon sequencing. Primers for cip1 (cdkn1a) were 5-
GCAGACCAGCCTGACAGATTTC-3 (sense) and 5-
TCCTGACCCACAGCAGAAGAGG-3 (antisense). These primers spanned an intron and 
yielded a single 109 nucleotide product that was identical to cip1 upon sequencing. 
Immunocytochemistry of cultured cells 
CNS neurospheres were tested for multipotency by replating one neurosphere per 
well into 48-well plates and then culturing adherently for 3 to 5 days prior to triple 
staining for markers of oligodendrocytes (O4), neurons (TuJ1), and astrocytes (GFAP). 
Plates were incubated first in anti-O4 antibody, and then in donkey anti-mouse IgM 
secondary antibody conjugated to horse radish peroxidase (Jackson Immunoresearch) 
followed by nickel diaminobenzidine staining (Shah et al., 1996). The cultures were then 
fixed in acid ethanol (5% glacial acetic acid in 100% ethanol) for 20 min at –20°C. After 
blocking in PBS containing 4% horse serum, 0.4% BSA, 0.05% sodium azide, and 0.1% 
Igepal (Sigma), the cultures were stained with anti-Tuj1 (1:500, Covance, Princeton, NJ) 
and anti-GFAP (1:200, Sigma G-3893) primary antibodies followed by FITC-conjugated 
goat anti mouse IgG1, and PE-conjugated goat anti mouse IgG2a antibodies (Southern 
Biotech, Birmingham, AL). PNS neurospheres were replated into adherent cultures in 
which the plates had been coated with poly-D-lysine and human fibronectin as described 
previously (Bixby et al., 2002). The neurospheres were allowed to differentiate for 7 to 
10 days and then fixed in acid ethanol for 20 min at –20°C, washed, blocked, and triply 
labeled for Peripherin (Chemicon International AB1530), GFAP (Sigma G-3893), and 
SMA (Sigma A　 -2547) as described previously (Shah et al., 1996). Cells were stained 
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for 10 min at room temperature with 10 g/ml DAPI (Sigma D　 -8417) to visualize 
nuclei. 
Immunohistochemistry of tissue sections 
To quantify SVZ proliferation, mice were injected with 50 mg/kg of 
bromodeoxyuridine (BrdU) (Sigma), and sacrificed one or two hours after BrdU 
injection, depending on the experiment. Brains were fixed in 4% paraformaldehyde 
overnight, then cryoprotected in 15% sucrose, embedded in 7.5% gelatin/15% sucrose, 
and flash frozen. 12 µm sections were cut on a Leica cryostat. See supplementary 
material for BrdU immunohistochemistry. 
For cerebellum histology, 30 um sagital sections were obtained, post-fixed in 10% 
neutral buffered formalin and stained with hematoxylin and eosin.  
To study gut neurogenesis, segments of intestine were fixed in 4% 
paraformaldehyde overnight, then cryoprotected in 30% sucrose, embedded in OCT 
(Tissue-Tek) and frozen. 12 µm sections were labeled with the neuronal marker HuC/D, 
by subjecting the sections to antigen retrieval as recommended by the antibody 
manufacturer, then pre-blocked for 1 hr at room temperature in modified GSS (PBS 
containing 5% goat serum, and 0.5% Triton X-100). Primary mouse anti-HuC/D 
(Molecular Probes, Inc., Eugene, OR) diluted in modified GSS was incubated for 1h at 
room temperature, followed by Alexa Fluor 555-conjugated goat anti-mouse IgG2b 
(Molecular Probes, Inc., Eugene, OR) for 30 min at room temperature. Slides were 
counter stained in 2.5µg/ml DAPI for 10 min at room temperature, then mounted using 
ProLong antifade solution (Molecular Probes, Eugene, OR). Only HuC/D+ neurons in the 
myenteric plexus were counted. 
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Primers used for mouse genotyping 
Ink4a genotyping was performed by PCR as described (Sharpless et al., 2001). 
Bmi-1 genotyping was performed using the oligonucleotides 5’-
CGCCGTGCACAGGGTGTCACGTTGCAAGAC -3’ and 5’-
CAAGCCAACCACGGCCTCCAGAAG-3’ to detect the gene targeted allele, and the 
oligonucleotides 5’-AGCAGCAATGACTGTGATGCACTTGAG-3’ and 5’-
GCTCTCCAGCATTCGTCAGTCCATCCC-3’ to detect wild-type Bmi-1. Arf 
genotyping was performed using the oligonucleotides 5’- 
CGCTGTTCTCCTCTTCCTCATCTC -3’ and 5’- 
CCAGTCATAGCCGAATAGCCTCTC -3’ to detect the gene-targeted allele and the 
oligonucleotides 5’- GCGTACCGCTAAGGGTTCAAAAC -3’ and 5’- 
TCCTCACAGTGACCAAGAACCTG -3’ to detect wild-type Arf. Ink4a-Arf genotyping 
(mice targeted to lack the exons common to both Ink4a and Arf) were genotyped using 
the oligonucleotides 5’- CTGCTCAACTACGGTGCAGATTC -3’ and 5’ - 
GCAAATATCGCACGATGTCTTGATG -3’ to detect wild-type Ink4a-Arf and the 
oligonucleotides 5’- CGCTGTTCTCCTCTTCCTCATCTC -3’ and 5’- 
CCAGTCATAGCCGAATAGCCTCTC -3’ to detect the gene-targeted allele. 
 
ACKNOWLEDGEMENTS 
This work was supported by the National Institutes of Health (R01 NS40750), the 
James S. McDonnell Foundation, and the Howard Hughes Medical Institute. A.V.M. was 
supported by a National Research Service Award from NIH (F30 NS048642). R.P. was 




Technology. S.H. was supported by a fellowship from the University of Michigan 
Cellular and Molecular Biology program. Thanks to David Adams, Anne Marie 
Deslaurier, and the University of Michigan Flow-Cytometry Core Facility (supported by 
UM-Comprehensive Cancer NIH CA46592, and UM-Multipurpose Arthritis Center NIH 
P60-AR20557). Thanks to Elizabeth Smith in the Hybridoma Core Facility (supported 
through the Michigan Diabetes Research and Training Center, NIH5P60-DK20572, and 
the Rheumatic Disease Center, P30 AR48310). Thanks to Kelly Yeager for tissue 
sectioning. Thanks to Maarten van Lohuizen for providing Bmi-1+/- mice and for sharing 
unpublished results, to Charles Sherr for providing Arf +/- mice, and to Ronald DePinho 
for providing Ink4a+/- and Ink4a-Arf +/- mice. 
 
 
Figure 2.1: p19Arf is upregulated in the absence of Bmi-1, and deletion of Arf or 
Ink4a-Arf significantly increased the self-renewal of neural stem cells from the SVZ 
and gut of Bmi-1-/- mice.  
A) p19Arf was increased in uncultured SVZ and cerebellum of 4 week old Bmi-1-/- mice. 
Western blot of neurosphere cells from Arf -/- mice is shown as a negative control. B) 
p19Arf was increased in Bmi-1-/- CNS neurospheres cultured for 13 days. C, D) Arf 
deficiency significantly increased self-renewal (the number of secondary neurospheres 
generated per subcloned primary neurosphere) within Bmi-1+/+ and Bmi-1-/- CNS 
neurospheres(C), and PNS neurospheres (D), as well as the percentage of cells from Bmi-
1-/- (but not Bmi-1+/+) primary neurospheres that formed secondary neurospheres upon 
replating (Figure 2.3). CNS data represent mean±SD for 2 to 4 mice per genotype, in 4 
independent experiments. PNS data are from 3 to 7 mice per genotype in 4 independent 
experiments. E, F) Ink4a-Arf deficiency significantly increased self-renewal within Bmi-
1+/+ and Bmi-1-/- CNS neurospheres (E; mean±SD for 2 to 4 mice per genotype, 4 
independent experiments), and PNS neurospheres (F; 3 to 6 mice per genotype, 6 
independent experiments) and the percentage of cells from Bmi-1-/- (but not Bmi-1+/+) 
primary neurospheres that formed secondary neurospheres upon replating (Figure 2.3).  　
indicates significantly (p<0.05) different from Bmi-1+/+Arf  +/+ or Bmi-1+/+Ink4a-Arf +/+, 
# indicates significantly different from Bmi-1-/-Arf  +/+ or Bmi-1-/-Ink4a-Arf  +/+, and § 
indicates significantly different from Bmi-1+/+Arf -/- or Bmi-1+/+Ink4a-Arf -/-. All 





Figure 2.2: Bmi-1 deficiency significantly reduced the diameter of neurospheres, but 
this effect was partially rescued by Ink4a, Arf, or Ink4a-Arf deficiency 
All data were obtained from PNS neurospheres cultured from the guts of 4 to 8 week old 
mice; however, similar results were obtained with CNS neurospheres. A) Ink4a 
deficiency significantly increased the diameter of Bmi-1-/- and Bmi-1+/+ neurospheres, 
consistent with a partial rescue of the proliferation defect within Bmi-1-/- neurospheres. 　 
indicates significantly different (P<0.05 by T-test) from Bmi-1+/+Ink4a+/+, # indicates 
significantly different from Bmi-1-/-Ink4a+/+, and § indicates significantly different from 
Bmi-1+/+Ink4a-/-. B) Arf deficiency also significantly increased the diameter of Bmi-1-/- 
and Bmi-1+/+ neurospheres, consistent with a partial rescue of the proliferation defect 
within Bmi-1-/- neurospheres. C) Ink4a-Arf deficiency significantly increased the diameter 
of Bmi-1-/- and Bmi-1+/+ neurospheres, again suggesting a partial rescue of the Bmi-1-/- 
proliferation defect. The data in each panel represent mean±SD for at least 5 independent 
experiments. D) Representative photographs of neurospheres cultured from the progeny 
of Bmi-1+/-Ink4a-Arf +/- matings. These apparent effects of Ink4a and/or Arf deletion on 
proliferation within neurospheres were consistent with similar effects on BrdU 





Figure 2.3: Bmi-1 deficiency significantly reduced the percentage of cells within 
primary neurospheres capable of forming secondary neurospheres, but Ink4a, Arf, 
or Ink4a-Arf deficiency significantly increased this percentage. 
The frequency of stem cells within primary CNS neurospheres was determined by 
dividing the number of secondary neurospheres by the number of cells subcloned from 
primary neurospheres. A) Bmi-1+/-Ink4a+/- matings (mean±SD for 2 mice per genotype in 
two independent experiments, 6 neurospheres per mouse). B) Bmi-1+/-Arf+/- matings 
(mean±SD for 2-4 mice per genotype in 4 independent experiments, 4-6 neurospheres per 
mouse). C) Bmi-1+/-Ink4a-Arf+/- matings (mean±SD for 2-5 mice per genotype in 4 
independent experiments, 4-6 neurospheres per mouse). Similar results were obtained 





Figure 2.4: Deletion of Ink4a, Arf, or Ink4a-Arf significantly increased neural stem 
cell frequency in Bmi-1-/- mice.  
A,B) Ink4a deficiency significantly increased the percentage of SVZ cells (A) or adult 
gut NCSCs (B) from Bmi-1-/- mice that formed multipotent neurospheres in culture 
(mean±SD for 4 independent experiments). C,D) Arf deficiency also significantly 
increased the percentage of Bmi-1-/- cells that formed multipotent neurospheres from the 
SVZ (C; 3 to 6 mice per genotype, in 6 independent experiments) or gut wall (D; 4 mice 
per genotype, in 4 independent experiments). E, F) Ink4a-Arf deficiency significantly 
increased the frequency of cells from the Bmi-1-/- adult SVZ (E; 2 to 7 mice/genotype, 8 
independent experiments) or gut wall (F; 3 to 8 mice per genotype, 3 independent 
experiments) that formed multipotent neurospheres in culture. 　 indicates significantly 
different (P<0.05 by T-test) from wild-type, # indicates significantly different from Bmi-
1-/-Ink4a+/+, Bmi-1-/-Arf +/+, or Bmi-1-/-Ink4a-Arf +/+ , and § indicates significantly different 
from Bmi-1+/+Ink4a-/-, Bmi-1+/+Arf -/- , or Bmi-1+/+Ink4a-Arf -/-. All experiments employed 





Figure 2.5: Ink4a deficiency partially rescued the frequency of uncultured NCSCs in 
the adult gut.  
Ink4a deficiency partially rescued the frequency of p75+ cells, which are highly enriched 
for NCSCs, in the adult gut wall of Bmi-1-/- mice. A-D) Representative flow-cytometry 
plots from the indicated genotypes demonstrating p75+ NCSC frequency (boxed region of 
each plot) among freshly dissociated gut wall cells. E) The frequency of p75+ cells was 
significantly reduced by Bmi-1 deficiency, and significantly increased by Ink4a 
deficiency. Data in panel E represent mean±SD for 10 independent experiments using 4 




Figure 2.6: Deletion of Ink4a, Arf, or Ink4a-Arf partially rescued SVZ proliferation 
and gut neurogenesis in 3 to 9 week old Bmi-1-/- mice in vivo.  
A, C, E) The rate of proliferation (percentage of cells that incorporate a pulse of BrdU) in 
the SVZ of Bmi-1-/- mice was significantly increased by Ink4a deficiency (A), Arf 
deficiency (C), or combined Ink4a-Arf deficiency (E). Note that deletion of these genes 
had no effect on SVZ proliferation in Bmi-1+/+ mice (C, E, and Ink4a data not shown; 6 
to 8 sections per mouse, 3 to 5 mice per genotype). Ink4a deficiency partially rescued the 
number of myenteric plexus neurons per cross-section through the distal small intestine 
of Bmi-1-/- mice (B; mean±SD for 4 to 7 mice per genotype, 7 to 10 sections per mouse). 
Arf deficiency tended to increase the number of neurons per cross-section in Bmi-1-/- 
mice, though the effect was not statistically significant (D; mean±SD for 4 to 5 mice per 
genotype and 8 to 10 sections per mouse). Ink4a-Arf deficiency significantly increased 
the number of myenteric plexus neurons per cross-section of Bmi-1-/- mice in a way that 
was consistent with a complete rescue (F; mean±SD for 5 mice per genotype and 6 to 8 
sections per mouse). 　 indicates significantly different (P<0.05 by T-test) from wild-
type, # indicates significantly different from Bmi-1-/-Ink4a+/+, Bmi-1-/-Arf+/+, or Bmi-1-/-






Figure 2.7: Deletion of Arf or Ink4a-Arf, but not Ink4a alone, partially rescues 
cerebellum development in Bmi-1-/- mice.  
Hematoxylin and eosin stained saggital sections of adult cerebellum. Measurements of 
granular layer thickness (GL), molecular layer thickness (ML), and cell density in the 
molecular layer (cells/High Power Field, HPF is 100 m　 2) for each genotype are 
represented below the corresponding picture. A) Ink4a deficiency did not affect 
cerebellum development in Bmi-1-/- mice (mean±SD for 4 mice per genotype, 7 to 25 
measurements per mouse). B) Arf deficiency partially rescued cerebellum growth in 4 to 
8 week old Bmi-1-/- mice (mean±SD for 3 to 4 mice per genotype and 10 to 23 
measurements per mouse). C) Ink4a-Arf deficiency also partially rescued cerebellum 
growth in Bmi-1-/- mice (mean±SD for 3 to 5 mice per genotype, 6 to 32 measurements 
per mouse). Ink4a, Arf, and Ink4a-Arf deficiencies did not affect cerebellum growth in 





Figure 2.8: p16ink4a is expressed in the cerebellum of adult Bmi-1-/- mice.  
p16ink4a was not detected in the cerebellum of a four-to-six week old Bmi-1+/+ mouse but 
was strongly upregulated in the cerebellum of a littermate Bmi-1-/- mouse. Positive and 
negative controls from the same western blot confirm p16ink4a expression in Ink4a+/+ 
neurospheres, as observed previously (Molofsky et al., 2003), and a lack of p16ink4a 
expression in Ink4a-/- neurospheres. At the RNA level, Ink4a was also significantly 




Figure 2.9: Ink4a, Arf, or Ink4a-Arf deficiency did not rescue the overall growth or 
survival of Bmi-1-/- mice. 
A) Ink4a deficiency did not significantly affect the growth of either Bmi-1+/+ or Bmi-1-/- 
mice, though Bmi-1-/- mice were significantly (p<0.05) smaller than Bmi-1+/+ mice at all 
time points. B) Bmi-1-/- mice were born at nearly normal frequencies (data not shown) but 
usually died prior to postnatal day 30. Survival was not significantly increased by Ink4a 
deficiency (arrows; p=0.306 by logistic regression analysis). The reduction in the 
frequency of Bmi-1-/- mice was statistically significant (P<0.001 for chi2 test, based on 
315 mice). Arf deficiency did not significantly affect the growth (C) or survival (D) of 
either Bmi-1+/+ or Bmi-1-/- mice (see arrows in D; p=0.552 by logistic regression 
analysis). The reduction in the frequency of Bmi-1-/- mice was statistically significant 
(P<0.001 for chi2 based on 249 mice.) E) Ink4a-Arf deficiency did not increase the 
overall growth of either Bmi-1+/+ or Bmi-1-/- mice, though Bmi-1-/- mice were 
significantly (p<0.01) smaller than Bmi-1+/+ mice at all time points after P20. (F) The 
survival of Bmi-1-/- mice was not increased by Ink4a-Arf deficiency. The reduction in the 







Figure 2.10: The brain masses of adult Bmi-1-/- mice were significantly reduced 
relative to littermate controls regardless of Ink4a and/or Arf deletion. 
A) Brain masses in adult (all mice were 4 to 8 weeks old) Bmi-1-/-Ink4a+/+ mice were 
significantly reduced relative to Bmi-1+/+Ink4a+/+ controls (*, p<0.01) and Ink4a 
deficiency had no detectable effect on brain mass. Each bar represents mean±SD of 3-7 
mice per genotype. B) Brain masses in Bmi-1-/-Arf +/+ mice were also significantly 
smaller than Bmi-1+/+Arf +/+ controls (*, p<0.01). Arf deficiency appeared to be 
associated with a small recovery in brain mass in Bmi-1-/- mice, though this effect was not 
statistically significant (3-6 mice per genotype). C) Brain masses in Bmi-1-/-Ink4a-Arf +/+ 
mice were significantly smaller than in Bmi-1+/+Ink4a-Arf +/+ mice. Deletion of Ink4a-Arf 
from Bmi-1-/- mice gave a slight but significant increase in brain mass (p<0.05; 4-8 mice 






Figure 2.11: cip1 expression increases in the absence of Bmi-1 and decreases in the 
absence of Arf in CNS and PNS neurospheres 
A) CNS neurospheres, 4 samples per genotype cultured for 10-11 days. B) PNS 
neurospheres 2-3 samples per genotype, cultured for 12-14 days. These data suggest that 
Arf deletion could indirectly affect Rb activity through its effects on cip1 expression. As 
a result, the effects of Ink4a deficiency and Arf deficiency on neurosphere self-renewal 
would not be expected to be additive.
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CHAPTER 3  
 
BMI-1 OVEREXPRESSION IN NEURAL STEM/PROGENITOR CELLS 
INCREASES PROLIFERATION AND NEUROGENESIS IN CULTURE BUT 
HAS LITTLE EFFECT ON THESE FUNCTIONS IN VIVO1 
 
SUMMARY 
The Polycomb gene Bmi-1 is required for the self-renewal of stem cells from 
diverse tissues, including the central nervous system (CNS). Bmi-1 expression is elevated 
in most human gliomas, irrespective of grade, raising the question of whether Bmi-1 
overexpression is sufficient to promote self-renewal or tumorigenesis by CNS 
stem/progenitor cells. To test this we generated Nestin-Bmi-1-GFP transgenic mice. 
Analysis of two independent lines with expression in the fetal and adult CNS 
demonstrated that transgenic neural stem cells formed larger colonies, had more self-
renewing divisions, and generated more neurons in culture. However, in vivo, Bmi-1 
overexpression had little effect on CNS stem cell frequency, subventricular zone 
proliferation, olfactory bulb neurogenesis, or neurogenesis/gliogenesis during 
development. Bmi-1 transgenic mice were born with enlarged lateral ventricles and a 
minority developed idiopathic hydrocephalus as adults, but none of the transgenic mice 
formed detectable CNS tumors, even when aged. The more pronounced effects of Bmi-1 
overexpression in culture were largely attributable to its suppression of p16Ink4a and 
                                                 
1 Originally published in Developmental Biology. 2009;328(2):257-72 with authors listed as He, S., 
Iwashita, T., Buchstaller, J., Molofsky, A.V., Thomas, D., Morrison, S.J. 
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p19Arf in culture, cell cycle inhibitors that are generally not expressed by neural 
stem/progenitor cells in young mice in vivo. Bmi-1 overexpression therefore has more 




Bmi-1 is a Polycomb group protein that functions as one component of the 
repressor complex 1 to modify histones, regulating chromatin structure and repressing 
transcription (Valk-Lingbeek et al., 2004). Bmi-1 is required for the postnatal self-
renewal of stem cells from diverse tissues including the hematopoietic system (Lessard 
and Sauvageau, 2003a; Park et al., 2003b) and the CNS (Bruggeman et al., 2005; 
Molofsky et al., 2005; Molofsky et al., 2003). Bmi-1 deficient mice exhibit a progressive 
postnatal depletion of stem cells from these tissues, leading to hematopoietic failure, 
defects in cerebellum development, neurological abnormalities, and death by early 
adulthood (Leung et al., 2004; van der Lugt et al., 1994a). Bmi-1 promotes the self-
renewal of neural stem cells and other stem cells largely, but not exclusively, by 
repressing the expression of Ink4a and Arf (Bruggeman et al., 2005; Jacobs et al., 1999a; 
Molofsky et al., 2005; Molofsky et al., 2003). Ink4a and Arf encode the p16Ink4a and 
p19Arf tumor suppressor proteins that inhibit cell cycle progression and induce cellular 
senescence (Lowe and Sherr, 2003). Bmi-1 thus promotes the maintenance of CNS stem 




Bmi-1 was originally identified as a transgene that could co-operate with myc to 
induce hematopoietic malignancies (Haupt et al., 1993; Jacobs et al., 1999c; van 
Lohuizen et al., 1991). Elevated Bmi-1 expression has been observed in hematopoietic 
malignancies (Bea et al., 2001), medulloblastomas and gliomas (Bruggeman et al., 2007; 
Leung et al., 2004), and cancers from other tissues (Song et al., 2006; Tateishi et al., 
2006; Vonlanthen et al., 2001; Wang et al., 2007). Indeed, Bmi-1 is necessary for the 
maintenance of cancer stem cells from acute myeloid leukemias (Lessard and Sauvageau, 
2003a) as well as gliomas (Bruggeman et al., 2007). Bmi-1 is thus necessary for the 
progression of certain types of cancer and increased Bmi-1 expression may contribute to 
tumorigenesis in certain contexts. 
These observations raise the question of whether overexpression of Bmi-1 in 
neural stem/progenitor cells is sufficient to enhance the self-renewal of these cells or to 
render them tumorigenic. Retroviral overexpression of Bmi-1 can increase hematopoietic 
stem cell self-renewal in culture and enhance the ability of these cells to reconstitute 
irradiated mice (Iwama et al., 2004). However, it is important to distinguish between the 
effects of Bmi-1 in culture and in vivo because the Bmi-1 target genes Ink4a and Arf are 
regulated differently in culture: Ink4a and Arf are rarely expressed by normal cells in fetal 
or young adult mice in vivo but are induced in cultured cells as a stress response to 
nonphysiological conditions (Lowe and Sherr, 2003; Sherr and DePinho, 2000). 
Consistent with these observations, Bmi-1 may be necessary for maintaining stem cell 
self-renewal in culture in a way that is not observed in vivo in certain contexts. For 
example, fetal neural stem cells from Bmi-1 deficient mice exhibit a self-renewal defect 
in culture but not in vivo (Molofsky et al., 2003). Thus, as a result of increased Ink4a/Arf 
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expression in culture, Bmi-1 can sometimes exhibit functions in culture that are not 
observed in vivo. Nonetheless, Bmi-1 may also promote stem cell self-renewal and cancer 
cell proliferation through Ink4a/Arf-independent mechanisms (Bruggeman et al., 2007; 
Chagraoui et al., 2006). Resolving the question of whether Bmi-1 overexpression is 
sufficient for tumorigenesis and increased stem cell self-renewal in vivo will be critical to 
determine whether elevated Bmi-1 expression can be an initiating event in the etiology of 
brain tumors. 
We examined Bmi-1 expression in both high-grade and low-grade human gliomas 
as well as in normal CNS tissue. Consistent with a recent report (Bruggeman et al., 
2007), we observed elevated Bmi-1 expression in most high grade and low grade 
gliomas. To test whether Bmi-1 overexpression is sufficient to promote self-renewal of 
stem/progenitor cells or tumorigenesis in the CNS, we generated Nestin-Bmi-1-GFP 
transgenic mice that express Bmi-1 throughout CNS stem and progenitor cells. While 
Bmi-1 overexpression was sufficient to increase self-renewal potential, overall 
proliferation, and neuronal differentiation by CNS stem and progenitor cells in culture, 
we observed little change in neural stem/progenitor cell function, neurogenesis or 
gliogenesis in vivo. A minority of the transgenic mice developed idiopathic 
hydrocephalus and died early in adulthood, but none of these mice developed CNS 
tumors at any stage up to two years of age. These results indicate that Bmi-1 
overexpression in stem/progenitor cells has more dramatic consequences in culture than 





Bmi-1 expression is elevated in a subset of human CNS tumors 
We examined the expression of Bmi-1 in normal and diseased human 
parenchymal brain tissue by performing immunohistochemistry on fixed tissue sections. 
We did not detect Bmi-1 expression in any of 3 samples of normal brain tissue (Figure 
3.1A). We did observe strong Bmi-1 staining in the vast majority of cells within a white 
matter biopsy from a patient after an epileptic seizure (Figure 3.1B). Bmi-1 staining was 
also observed in most specimens from patients that exhibited gliosis due to damage 
(mesial temporal lobe sclerosis) or abscess (4 of 5 specimens; Figure 3.1C). These results 
demonstrate that Bmi-1 can be upregulated, particularly in glia, after brain injuries. 
Similar to what has been reported recently (Bruggeman et al., 2007), we also 
observed elevated Bmi-1 expression in a subset of human gliomas (Figure 3.1D-F). 
Strong Bmi-1 expression was observed in most cells from 10 of 30 glioblastoma 
specimens (Figure 3.1F), while 7 of 30 specimens exhibited detectable, but lower levels 
of Bmi-1 expression in fewer cells. Variable levels of Bmi-1 expression were detected in 
some cells in low grade gliomas (1 of 2 specimens, data not shown), pilocytic 
astrocytomas (3 of 4 specimens; Figure 3.1D), and oligodendrogliomas (4 of 5 
specimens; Figure 3.1E). These data indicate that Bmi-1 expression is elevated in most 
human CNS tumors, though no strong correlation between Bmi-1 expression level and 
the type or grade of the tumors was observed (Figure 3.1H). These data raise the question 




Generation of Nestin-Bmi-1-GFP transgenic mice 
To examine the effects of Bmi-1 overexpression on neural stem/progenitor cell 
function and CNS tumorigenesis in vivo, we generated transgenic mice in which the 
human Nestin second intron enhancer was used to drive the expression of HA-tagged 
mouse Bmi-1 protein, as well as a GFP reporter in CNS stem and progenitor cells (Figure 
3.2A). Nestin is expressed in CNS stem and progenitor cells (Dahlstrand et al., 1992b; 
Kawaguchi et al., 2001), as well as in various CNS tumors (Almqvist et al., 2002; 
Dahlstrand et al., 1992a; Rutka et al., 1999). The human Nestin second intron enhancer 
has been shown to drive transgene expression in mouse CNS stem and progenitor cells 
during embryonic development and adulthood (Lothian and Lendahl, 1997). 
Ten of 77 (13%) pups born after fertilized oocyte injection harbored the Nestin-
Bmi-1-GFP construct, based on PCR genotyping of tail DNA as well as by observation of 
GFP expression in the CNS (analyzed by transillumination of the head). Although one 
transgenic pup died shortly after birth of unknown causes, most of the transgenic 
offspring appeared healthy and developed normally. Southern blotting was performed on 
the surviving founders to confirm transgene integration and to determine copy number 
(Figure 3.3A). Five transgenic lines were established. One line (line B*) exhibited 
transgene segregation among F1 progeny in a way that suggested the original founder had 
multiple transgene integration sites (Figure 3.3B). As a result, two sub-lines from line B* 
were established; line B has ~5 copies of the transgene in a single integration site and line 
K has >25 copies of the transgene. 
To select for lines that exhibited transgene expression in CNS stem/progenitor 
cells throughout development and adulthood, we analyzed GFP expression in neonatal 
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and adult F1 transgenic mouse brains by direct observation of GFP fluorescence and by 
flow cytometric analysis of dissociated cells from various CNS regions. Surprisingly, 
only the two transgenic lines (lines B and C) with the lowest transgene copy number 
(approximately 5 copies of the transgene inserted into a single site in the genome) 
maintained GFP expression in both the newborn and adult brain (Figure 3.4A). All other 
lines either showed no transgene expression (lines D and K) at either stage, or showed 
only weak GFP expression at birth that was no longer detectable in the adult brain (lines 
E and G) (Figure 3.4A). Therefore, for our analysis of the consequences of Bmi-1 
overexpression in vivo we studied lines B and C. The transgene was inherited with 
expected Mendelian frequencies in these lines (Figure 3.5A). 
Characterization of transgene expression in vivo 
Cytoplasmic GFP expression in the transgenic mouse CNS could be detected at 
all developmental stages in patterns that resembled endogenous Nestin expression 
(Lothian and Lendahl, 1997) in both lines B and C. At embryonic day (E)14.5, GFP was 
ubiquitously expressed throughout the developing CNS (Figure 3.2B). In contrast, no 
GFP fluorescence was observed in tissues outside of the nervous system or in littermate 
controls (Figure 3.2B). At birth (P0), GFP was still widely expressed in all brain regions 
of transgenic mice but not littermate controls (Figure 3.2C). The highest levels of 
expression appeared to be in the ventricular zones throughout the brain as well as in 
nerve fiber bundles in the corpus callosum and anterior commissure (Figure 3.2C). This 
widespread transgene expression was also confirmed by analyzing freshly dissociated 
cells from various neonatal (P0) brain regions by flow-cytometry: most cells from the P0 
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transgenic lateral ventricle germinal zone (VZ; 90±8%), cerebral cortex (88±9%), and 
cerebellum (66±11%) expressed GFP (Figure 3.2G). 
In contrast, GFP expression in the adult transgenic brain became more spatially 
restricted. Whole brain GFP fluorescence was greatly reduced as compared with E14.5 or 
P0 brain (Figure 3.2D), and most of the GFP-expressing cells were localized to brain 
regions that contain neural stem/progenitor cells, such as the SVZ of the lateral ventricle 
(Figure 3.2E) and the subgranular cell layer in the dentate gyrus of the hippocampus 
(Figure 3.2F). Brain layers with differentiated cells showed no detectable GFP expression 
(Figure 3.2E,F). GFP expression was also not observed in tissue lacking appreciable 
Nestin expression, such as in adult bone marrow (Figure 3.4B). The enrichment of GFP-
expressing cells in adult SVZ was further confirmed by flow-cytometry, which showed 
that 76±9% of all dissociated SVZ cells were GFP+ (Figure 3.2H). GFP expression thus 
correlated with the expected pattern of Nestin expression in stem/progenitor cells in vivo, 
throughout development and into adulthood. 
To directly confirm that the transgene was indeed expressed by neural stem and 
progenitor cells, sorted GFP+ and GFP- cells from freshly dissociated neonatal cerebral 
cortex, VZ, and cerebellum were cultured in vitro. The vast majority (>94%) of 
neurospheres arose from the GFP+ fraction of cells while GFP- cells formed few or no 
neurospheres (Figure 3.2I). Upon differentiation, some of the GFP+ neurospheres formed 
multilineage colonies (containing neurons, astrocytes and oligodendrocytes) while other 
GFP+ neurospheres formed colonies that contained only astrocytes, or neurons and 
astrocytes. GFP- neurospheres usually did not form multilineage colonies. This indicates 
that virtually all multipotent cells (>99%) expressed the transgene but that GFP-
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expressing cells were functionally heterogeneous and contained both neural stem and 
progenitor cells. 
The transgene was also expressed by neural stem/progenitor cells from the brains 
of adult transgenic mice. SVZ cells were dissociated from the brains of two- to three-
month old transgenic mice and GFP+ or GFP- cells were sorted into culture. Over 97% of 
neurosphere-forming cells were GFP+ and most of these neurospheres underwent 
multilineage differentiation (Figure 3.2J,K). Since GFP expression was observed 
throughout the adult SVZ, and most adult SVZ cells are restricted progenitors that fail to 
form multipotent colonies in culture, these data suggest that many restricted progenitors 
in the adult brain also expressed the transgene. These data suggest that newborn and adult 
mice exhibited transgene expression in neural stem cells as well as in restricted neural 
progenitors. 
The transgene increases Bmi-1 expression in neural stem cells 
To assess the level of Bmi-1 overexpression as a result of transgene expression, 
we performed quantitative (real-time) reverse transcription polymerase chain reaction 
(qRT-PCR) and western blotting using freshly isolated SVZ cells and cultured 
neurospheres. In cultured neurospheres from adult SVZ, Bmi-1 transcript levels were 15-
fold and 9-fold higher in line B and Line C transgenic neurospheres, respectively, as 
compared with neurospheres from littermate controls (Figure 3.6A). Using uncultured 
tissue, Bmi-1 transcript levels were 8.5- to 11.1-fold higher in P0 ventricular zone and in 
the adult SVZ of line B and Line C transgenic mice compared to littermate controls 
(Figure 3.6A). At the protein level, using anti-HA antibody, we were able to detect the 
expression of the HA-tagged Bmi-1 in both cultured neurospheres from adult SVZ and in 
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freshly dissected E14.5 telencephalon tissue and P0 brain from lines B and C (Figure 
3.6B-D). Using anti-Bmi-1 antibody, this translated to a significant overall increase in 
Bmi-1 expression by cultured neurospheres and uncultured telencephalon/P0 brain cells 
from transgenic mice (Figure 3.6B-D). Furthermore, immunohistochemical staining of 
Bmi-1 in tissue sections from E15 transgenic and control mouse telencephalon showed 
significantly increased Bmi-1 expression in most VZ cells in the transgenic mice (Figure 
3.6E). Together, these data demonstrate that transgene expression led to Bmi-1 
overexpression in neural stem and progenitor cells in vitro and in vivo throughout CNS 
development. Moreover, the level of Bmi-1 expression within transgenic mice appeared 
similar or higher than the level observed within human glioma specimens by both 
immunohistochemistry (compare Figure 3.6E to Figure 3.1A-F) and western blot (Figure 
3.1G). 
To test whether the increase in Bmi-1 expression in transgenic mice correlated 
with increased Bmi-1 function, we assessed the expression of the Bmi-1 target genes 
Ink4a and Arf. The Bmi-1-containing polycomb repressor complex 1 represses Ink4a and 
Arf expression (Bracken et al., 2007; Bruggeman et al., 2007; Bruggeman et al., 2005; 
Molofsky et al., 2005). Cultured neurospheres from line B and line C exhibited lower 
levels of p16Ink4a and p19Arf expression compared to neurospheres cultured from 
littermate controls (Figure 3.6B). This demonstrated that transgenic Bmi-1 was 
functionally active and that Bmi-1 overexpression attenuated the induction of p16Ink4a and 
p19Arf that normally occurs when neurospheres are cultured in vitro. Consistent with 
earlier studies that failed to detect p16Ink4a or p19Arf expression in fetal and young adult 
mouse brain (Bruggeman et al., 2007; Bruggeman et al., 2005; Molofsky et al., 2005; 
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Molofsky et al., 2003; Nishino et al., 2008), we were also unable to detect these proteins 
in transgenic mice or littermate controls at E14.5 (Figure 3.6C) or P0 (Figure 3.6D). The 
observation that overexpressed Bmi-1 was able to reduce p16Ink4a and p19Arf expression 
in culture, but that p16Ink4a and p19Arf expression could not be detected in vivo, raised the 
possibility that Bmi-1 overexpression would promote self-renewal/proliferation to a 
greater degree in culture. 
Transgenic neural stem cells show increased self-renewal and neurogenesis in 
culture 
To assess the consequences of Bmi-1 overexpression we compared the frequency 
that adult SVZ cells from transgenic and control mice formed multipotent neurospheres, 
as well as the diameter and self-renewal potential of these neurospheres. A modestly (1.7-
fold) but significantly (p<0.05) higher percentage of dissociated adult SVZ cells from 
line B and line C transgenic mice formed multipotent neurospheres in culture (Figure 
3.7A). However, when multiplied by the total number of dissociated SVZ cells obtained 
from each mouse, this did not translate into a significant increase in the total number of 
multipotent neurospheres per SVZ in the transgenic mice (Figure 3.7B). The slight 
increase in the frequency of multipotent neurospheres could either reflect a slightly 
increased frequency of stem cells in the SVZ of transgenic mice in vivo or slightly 
increased survival of these cells in culture. The neurospheres formed by transgenic cells 
were significantly larger than the neurospheres from littermate controls (Figure 3.7C), 
demonstrating that elevated Bmi-1 expression increased the proliferation capacity of 
stem/progenitor cells in culture. This is further supported by the significantly increased 
proliferation rate observed in adherently cultured transgenic neural stem cell colonies 
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based on BrdU incorporation (Figure 3.7G). To focus on the self-renewal potential of 
stem cells rather than the overall proliferation of the heterogeneous progenitors that 
comprise stem cell colonies, we dissociated and subcloned individual primary 
neurospheres into secondary cultures and counted the number of multipotent secondary 
neurospheres that arose per primary neurosphere. Stem cells from line B and line C 
transgenic mice exhibited dramatically increased self-renewal in culture as compared to 
stem cells from littermate controls (Figure 3.7D).  
At the extraordinarily low cell densities used in our experiments (approximately 1 
cell/µl) control experiments indicated that most neurospheres were clonally derived 
(Figure 3.8). Nonetheless, to confirm that Bmi-1 increased the self-renewal of clonal 
neural stem cell colonies we sorted individual CD15+CD24- SVZ cells from P5 wild type 
and transgenic mice into different wells of 96 well plates. CD15+CD24- SVZ cells are 
enriched for neural stem cells (Capela and Temple, 2002). Neurospheres arose in only 
10-17% of wells seeded with single CD15+CD24- cells. We found that transgenic 
neurospheres were significantly larger and had significantly more self-renewal potential 
than wild-type neurospheres (Figure 3.7E, F). These data demonstrate that elevated Bmi-
1 expression increases the proliferation and self-renewal of CNS stem cells in clonal 
culture. 
Loss of Bmi-1 reduces neuronal differentiation from CNS stem cells in culture 
(Bruggeman et al., 2007; Zencak et al., 2005). To test whether overexpression of Bmi-1 
affects stem cell differentiation, we differentiated primary neurospheres from both 
transgenic lines to assess their ability to generate Tuj-1+ neurons, GFAP+ astrocytes and 
O4+ oligodendrocytes in culture. The frequency of oligodendrocytes was comparable in 
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transgenic and wild type multipotent stem cell colonies (Figure 3.7I; 0.5±0.6% of cells in 
wild type, 1.0±1.1% of cells in line B transgenic and 1.1±1.0% in line C transgenic 
respectively). However, transgenic stem cell colonies consistently contained an increased 
proportion and absolute number of neurons as compared to control colonies (3.9±4.9% in 
wild type, 23±18% in line B transgenic and 31±17% in line C transgenic respectively) 
(Figure 3.7H,I;). Transgenic stem cell colonies also contained a modestly reduced 
frequency of astrocytes compared to wild-type colonies (95±4% in wild type, 76±18% in 
line B transgenic and 67±17% in line C transgenic respectively). Since multipotent 
transgenic colonies contained many more cells than multipotent wild type colonies 
(3,700±2,700 cells/ wild type colony versus 21,000±17,000 cells/ line B colony and 
10,000±8,000 cells/ line C colony after 10 days in culture), the reduced frequency of 
astrocytes in transgenic colonies reflected the dramatic increase in the number of neurons 
in these colonies, rather than a decrease in the absolute number of astrocytes per colony. 
Bmi-1 overexpression thus increased the neurogenic capacity of CNS stem cells in 
culture. 
Bmi-1 overexpression has little effect on neural stem/progenitor cell proliferation in 
vivo 
To evaluate the effects of Bmi-1 overexpression in vivo, we compared various 
measures of stem/progenitor cell function between control and Bmi-1 transgenic mice. 
We administered a pulse of BrdU to 2-4 month old transgenic and littermate control mice 
two hours before they were sacrificed to test whether Bmi-1 overexpression increased the 
overall proliferation of neural stem and progenitor cells in the SVZ. In contrast to the 
significantly enhanced proliferation exhibited by cultured transgenic neural 
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stem/progenitor cells (Figure 3.7G), neither line B nor line C transgenic mice showed a 
significant difference in the frequency of BrdU+ cells in the SVZ when compared with 
littermate controls (Figure 3.9A).  
To test whether Bmi-1 overexpression could affect neural stem/progenitor cell 
proliferation during fetal development, we administered BrdU to timed pregnant females 
to mark dividing cells in the developing telencephalon of wild type and transgenic 
embryos. After a 15 minute BrdU pulse, many cells in the VZ of both wild type and 
transgenic embryos became BrdU+, indicating rapid proliferation. However, we did not 
observe any difference in the distribution or frequency of BrdU+ cells between transgenic 
and control embryos (Figure 3.9B). In addition, the overall thickness of the cerebral 
cortex and the VZ did not significantly differ between transgenic and wild-type 
telencephalon (Figure 3.9C). These data suggest that Bmi-1 overexpression does not 
cause a notable increase in proliferation within the telencephalon during fetal 
development. 
Bmi-1 overexpression has little effect on fetal or adult neurogenesis in vivo 
To assess whether Bmi-1 overexpression affected the rate of olfactory bulb 
neurogenesis in vivo, we administered BrdU to 1-2 month old transgenic and littermate 
control mice for one week to mark dividing SVZ progenitors followed by a one month 
chase without BrdU to allow these cells to migrate into the olfactory bulb and to 
differentiate into neurons. We then quantified the percentage of NeuN+ neurons that were 
also BrdU+ by confocal microscopy. Twenty-five random fields of view spanning the 
whole thickness of the olfactory bulb were imaged and counted. Transgenic mice did not 
exhibit an increased rate of neurogenesis as compared to littermate controls (Figure 
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3.10A). Indeed, line B transgenic mice exhibited a significantly lower rate of 
neurogenesis than littermate controls because a subset (approximately 25%) of these mice 
were found to be in the process of developing hydrocephalus when sacrificed, and the 
mice with hydrocephalus tended to have reduced SVZ proliferation and olfactory bulb 
neurogenesis (data not shown). Thus we could find no evidence of increased SVZ 
proliferation or neurogenesis in adult transgenic mice in vivo, in contrast to what we had 
observed in culture. 
To test whether Bmi-1 overexpression could affect neurogenesis during fetal CNS 
development, we examined the onset of cortical neurogenesis as well as the organization 
of the cerebral cortex in the forebrain of transgenic and control mice. Most cortical 
neurogenesis in mice occurs from E10 to E17, when ventricular zone progenitors give 
rise to waves of neuronal precursors that migrate toward the pial surface, forming six 
distinct cortical layers. To examine whether Bmi-1 overexpression affected the onset of 
cortical neurogenesis, we stained E12 telencephalon with antibody against Tuj1 to label 
the early born Cajal-Retzius neurons within the marginal zone (Hatten, 1999). We did not 
observe any difference between transgenic or control mice in terms of the density or 
localization of these Tuj-1+ cells (Figure 3.10B). This suggests that Bmi-1 overexpression 
did not significantly delay the onset of cortical neurogenesis.  
Next we asked whether the overall organization of the cerebral cortex in 
transgenic mice was altered by Bmi-1 overexpression. We cut sections through the 
cerebral cortex of P0 or adult wild-type and transgenic mice and stained with the layer 
specific neuronal markers Reelin (staining Cajal-Retzius neurons in layer I; (Soriano and 
Del Rio, 2005)), Cux-1 (staining layer 2-4 neurons; (Nieto et al., 2004)), and FoxP2 
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(staining layer 6 neurons in the adult brain; (Ferland et al., 2003)). In no case did we 
detect any difference between transgenic and control littermates in the frequency or 
localization of Reelin+ neurons at P0 (Figure 3.10C), FoxP2+ neurons in adults (Figure 
3.10D) or Cux-1+ neurons at P20 (Figure 3.10F). This suggests that cortical neuronal 
progenitors acquire normal identities and a normal laminar fate despite Bmi-1 
overexpression. 
To assess whether neurons were born according to a normal schedule we pulse 
labeled wild type and transgenic embryos with the nucleotide analog 5-chloro-2-
deoxyuridine (CldU) at E17 (a stage when upper layer neurons are generated (Polleux et 
al., 1997)), and stained sections cut at P20 with antibodies against CldU and Cux-1. The 
CldU staining was concentrated in upper cortical layers as expected (Figure 3.10E,F) and 
there was a similar degree of CldU/Cux-1 co-localization in both wild-type and 
transgenic mice (Figure 3.10G-I). Therefore, we did not detect any significant change in 
the timing or pattern of cortical neurogenesis in the transgenic mouse brain, suggesting 
that Bmi-1 overexpression did not significantly alter neurogenesis in vivo, though we 
cannot rule out the possibility of subtle changes. 
Bmi-1 overexpression has little effect on glial differentiation in vivo 
While we did not observe significant effects of Bmi-1 overexpression on SVZ 
proliferation or neurogenesis in embryonic or adult mice, we wondered whether Bmi-1 
overexpression affected gliogenesis since a loss of Bmi-1 leads to an increase in 
astrocytes in vivo (Zencak et al., 2005). To test this we first examined the expression of 
the astrocyte marker GFAP and the oligodendrocyte marker MBP in adult mice. We did 
not observe any difference between line B or line C transgenic mice and littermate 
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controls in the numbers or positions of GFAP+ cells or MBP+ cells in the corpus 
callosum or striatum (Figure 3.11A,B). While this suggested that transgenic mice did not 
have gross changes in gliogenesis, we also examined P4-P5 mice to assess whether there 
were any early changes. There was no difference between line B or line C transgenic 
mice and littermate controls in the number or position of BFABP+ glia at P5 (Figure 
3.11E). There was also no differences between line C transgenic mice and control 
littermates in the number or position of GFAP+ astrocytes in the corpus callosum or 
MBP+ oligodendrocytes in the corpus callosum and striatum at P5 (Figure 3.11C,D). 
However, we did observe a delay in oligodendrogliogenesis in line B transgenic mice, 
which have fewer MBP+ oligodendrocytes compared to littermate controls in the P4 
corpus callosum and striatum, but a normal frequency of GFAP+ astrocytes (Figure 3.11 
F,G). The fact that this delay was not observed in line C mice suggests that it may not be 
attributable to increased Bmi-1 expression; however, we cannot rule out the possibility 
that increased Bmi-1 expression delays glial differentiation in some mice under certain 
circumstances. Overall, our data suggest that elevated Bmi-1 expression has little effect 
on gliogenesis in vivo. 
Bmi-1 overexpression does not further enhance the self-renewal or neurogenic 
potential of cultured Ink4a-Arf-/- neural stem cells. 
The increased overall proliferation, stem cell self-renewal, and neurogenesis that 
occurred upon Bmi-1 overexpression in vitro (Figure 3.7) but not in vivo (Figure 3.9-11) 
is correlated with the ability of overexpressed Bmi-1 to reduce p16Ink4a and p19Arf 
expression in vitro but not in vivo (Figure 3.6). To test whether the effects of Bmi-1 
overexpression on neural stem cell function in culture were mediated by its ability to 
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oppose the induction of p16Ink4a and p19Arf expression in culture, we overexpressed Bmi-1 
in neural stem cells cultured from newborn (P2-P6) wild-type and Ink4a-Arf deficient 
mice. This was done using a bicistronic retrovirus (MSCV-Bmi1) expressing both mouse 
Bmi-1 and GFP. Adherently plated newborn lateral ventricle germinal zone cells from 
wild type or Ink4a-Arf-/- mice were infected with this virus or a control retrovirus bearing 
only GFP (MSCV-GFP) then replated into non-adherent cultures to generate 
neurospheres. Infected cells could thus be distinguished from non-infected cells based on 
GFP expression. qRT-PCR indicated that Bmi-1 expression was increased 4.0- to 5.5-fold 
on average by MSCV-Bmi1 infection as compared to neurospheres that were infected 
with the control virus (Figure 3.12A). 
To assess overall proliferation and stem cell self-renewal we measured the 
diameter of neurospheres and the capacity of multipotent neurospheres to form secondary 
multipotent neurospheres upon subcloning, respectively. Wild-type neurospheres infected 
with MSCV-Bmi1 virus were significantly larger than neurospheres infected with 
MSCV-GFP control virus or uninfected neurospheres (Figure 3.12B), consistent with our 
previous observations for Bmi-1 transgenic cells (Figure 3.7C). In contrast, Ink4a-Arf-/- 
neurospheres were significantly larger than wild-type neurospheres, and overexpression 
of Bmi-1 in Ink4a-Arf-/- neurospheres did not further increase their size (Figure 3.12B). 
Similar results were observed in the self-renewal assay. While MSCV-Bmi1 infected 
wild type neurospheres generated significantly more multipotent secondary neurospheres 
compared to uninfected neurospheres or neurospheres infected with control virus (Figure 
3.12C), overexpression of Bmi-1 in Ink4a-Arf-/- neurospheres did not further enhance 
their self-renewal potential (Figure 3.12C). Finally, Bmi-1 overexpression or Ink4a-Arf 
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deficiency each increased the amount of neuronal differentiation observed in neural stem 
cell colonies; however, overexpression of Bmi-1 in Ink4a-Arf deficient neural stem cells 
did not significantly increase neuronal differentiation beyond that due to Ink4a-Arf 
deficiency alone (Figure 3.12D). 
A similar experiment was performed using freshly isolated SVZ cells from adult 
Bmi-1 transgenic mice crossed onto an Ink4a-Arf deficient background. Consistent with 
the data from retroviral Bmi-1 overexpression, transgenic Bmi-1 overexpression in Ink4a-
Arf deficient mice no longer increased the frequency of multipotent neurospheres, 
neurosphere diameter, or self-renewal potential (Figure 3.12G-I). Our data suggest that 
the increased proliferation, self-renewal, and neuronal differentiation of cultured neural 
stem cells upon Bmi-1 overexpression are largely attributable to the repressive effects of 
Bmi-1 on p16Ink4a and p19Arf expression. 
A subset of Bmi-1 transgenic mice developed hydrocephalus but not CNS tumors 
Bmi-1 transgenic mice from lines B and C were born at Mendelian frequencies 
(Figure 3.5A). The mice had a normal appearance at birth and no behavioral 
abnormalities were noted; however, the transgenic mice consistently exhibited enlarged 
lateral ventricles (Figure 3.13A). We cut sections throughout lateral ventricles to look for 
blockages that could prevent the flow of cerebrospinal fluid out of the lateral ventricles 
but never detected any blockage. Thus it is unclear why Bmi-1 transgenic mice were born 
with enlarged lateral ventricles.  
Between 4 and 8 weeks of age, a minority of transgenic mice from both 
transgenic lines (7 of 28 (25%) mice from line B and 14 of 61 (23%) mice from line C) 
developed hydrocephalus. The mice with hydrocephalus could be distinguished based on 
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the dome shaped appearance of their heads, severely enlarged lateral ventricles, and 
behavioral changes that included weight loss, lethargy, and ruffled fur. Hydrocephalus 
was confirmed in these mice by magnetic resonance imaging (MRI) (Figure 3.13B). MRI 
images showed that lateral ventricles were most affected in these mice; the third 
ventricle, sylvius aqueduct, and fourth ventricle appeared relatively normal (Figure 
3.13B). However, we could not find any obstruction between the lateral and third 
ventricles nor any blockage within the third ventricle or the aqueduct that would explain 
the hydrocephalus phenotype (Figure 3.13C). Nonetheless, it remains possible that a 
physical blockage exists in the ventricular system in vivo that is not readily detected by 
histology or MRI. 
We also assessed other common causes for mouse hydrocephalus such as over-
proliferation of choroid plexus, or defects in the ependyma lining the lateral ventricle. No 
abnormal mass of choroid plexus was observed in the transgenic mice (data not shown). 
Some transgenic mice with hydrocephalus did exhibit an abnormally folded ependymal 
cell lining of the lateral ventricle (Figure 3.13D), a similar phenotype was observed in 
transgenic mice that never developed hydrocephalus. Thus it was unclear whether the 
ependymal layer abnormality contributed to the development of hydrocephalus. The 
ependymal cells in young adult mice did not incorporate a two-hour pulse of BrdU (data 
not shown), so they were not proliferating rapidly as would be expected if these cells 
were neoplastic. Finally, we also tested whether hydrocephalus was associated with 
cortical atrophy due to increased apoptosis in the cerebral cortex. However, sections from 
hydrocephalic transgenic mouse brains did not exhibit increased activated caspase-3 
staining relative to littermate controls and little apoptosis was observed in either the 
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control or transgenic brains (data not shown). Overall, we detected no evidence of lateral 
ventricle malformations or blockages that could explain why hydrocephalus developed 
and we never detected any tumors in the brains of these mice by either histology or MRI. 
The 75% of transgenic mice that were not affected by hydrocephalus remained 
healthy and we never detected any abnormalities in appearance or behavior. Line C mice 
had normal body mass and brain mass while line B mice had slightly but significantly 
increased brain mass and slightly but significantly decreased body mass by young 
adulthood (Figure 3.5B,C). We aged these mice for up to 25 months and detected no 
evidence of premature death or illness as compared to control littermates. To look for 
evidence of CNS tumors in the transgenic mice, we sacrificed newborn (3 line B and 4 
line C), 1-4 month old (5 line B and 16 line C) and 15-24 month old (2 line B and 3 line 
C) transgenic mice and analyzed serial sections of the whole brain by histology (Figure 
3.13E). We also grossly examined the brains from all of the transgenic mice used in 
earlier experiments (more than 50 mice from each line). We detected no evidence of 
brain tumors in any mouse at any age (Figure 3.13E). Some transgenic and wild type 
mice spontaneously developed non-neural neoplasms (mostly hematopoietic) after being 
aged for more than 20 months; however, none of these neoplasms contained GFP-
expressing cells, suggesting that transgene expression did not contribute.  
Immunohistochemical staining of Bmi-1 in sections (compare Figure 3.6E to 
Figure 3.1A-F) and Bmi-1 western blot (Figure 3.1G) suggest that the level of Bmi-1 
expression in the transgenic mouse brain is comparable to the level of expression 
observed in brain tumors, at least in the fetal telencephalon. However, we have been 
unable to examine levels of Bmi-1 protein expression in the SVZ of adult transgenic mice 
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because the adult SVZ yielded insufficient material for western blot, and high 
background staining of the adult SVZ by immunohistochemistry (the anti-Bmi-1 antibody 
was made in mouse) made this difficult to interpret. Nonetheless, Bmi-1 transcript levels 
were elevated in the transgenic adult SVZ by 8.5- to 11-fold relative to control SVZ 
(Figure 3.6A). As a result, available data suggest that Bmi-1 expression levels in CNS 
stem/progenitor cells from transgenic mice were comparable to those observed within 
brain tumors, but we cannot rule out the possibility that further increases in expression 
within adult CNS cells might render these cells tumorigenic. Nonetheless, it is not clear 
whether it is possible to achieve further increases in expression as all transgenic mice 
with higher transgene copy numbers silenced the transgene. Since prior studies have 
suggested that Bmi-1 is degraded when unable to bind other polycomb repressor complex 
1 components (Ben-Saadon et al., 2006; Hernandez-Munoz et al., 2005), the 
stoichiometry of other complex components may limit the degree to which Bmi-1 
expression and function can be increased. 
 
DISCUSSION 
In this study, we generated Nestin-Bmi-1-GFP transgenic mice to study the effect 
of Bmi-1 overexpression in neural stem/progenitor cells on CNS development and 
tumorigenesis. Bmi-1 overexpression in CNS stem/progenitor cells in vitro was sufficient 
to significantly increase stem cell self-renewal, overall proliferation, and neuronal 
differentiation (Figure 3.7). In contrast, Bmi-1 overexpression in vivo had little effect on 
SVZ proliferation, adult olfactory bulb neurogenesis, or neurogenesis/gliogenesis during 
development (Figure 3.9-11). Bmi-1 transgenic mice showed only a mild increase in 
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neural stem cell frequency (<2-fold; Figure 3.7A) with no increase in the total number of 
neural stem cells per mouse (Figure 3.7B). They also exhibited no evidence of 
tumorigenesis, even when aged for more than 20 months (Figure 3.13E). These data 
demonstrate that Bmi-1 overexpression has much more profound effects on CNS stem 
cell function in culture than in vivo. 
The increased effect of Bmi-1 overexpression in culture correlated with its ability 
to reduce p16Ink4a and p19Arf expression in culture. Although p16Ink4a and p19Arf are not 
detectably expressed by neural stem/progenitor cells in developing or young adult mice 
(Bruggeman et al., 2007; Bruggeman et al., 2005; Molofsky et al., 2005; Molofsky et al., 
2003; Nishino et al., 2008) (Figure 3.6C, D), p16Ink4a and p19Arf are induced in culture in 
neural stem cells (Molofsky et al., 2003) in response to the stress associated with 
adaptation to the nonphysiological culture environment (Lowe and Sherr, 2003; Sherr and 
DePinho, 2000). Since p16Ink4a and p19Arf were not detectably expressed by neural 
stem/progenitors cells in vivo, Bmi-1 overexpression had no effect on p16Ink4a and p19Arf 
expression in vivo. In contrast, Bmi-1 overexpression did reduce p16Ink4a and p19Arf 
expression in culture (Figure 3.6B). This suggested that the increased effects of Bmi-1 
overexpression in culture were caused by its ability to reduce p16Ink4a and p19Arf 
expression in culture. Consistent with this, Bmi-1 overexpression no longer enhanced 
self-renewal, proliferation, or neurogenesis in Ink4a-Arf deficient neural stem cells in 
culture (Figure 3.12). These data demonstrate that caution must be exercised when 
inferring in vivo functions for Bmi-1 based on observations collected in culture because 
the increased expression of p16Ink4a and p19Arf in culture increases the reliance of cells 
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upon Bmi-1 and makes cells respond to Bmi-1 overexpression in a way that is not 
observed in vivo. 
In Bmi-1 deficient mice in vivo, neural stem cells require Bmi-1 postnatally, but 
not during fetal development, for self-renewal. Fetal Bmi-1 deficient mice do not exhibit 
detectable p16Ink4a and p19Arf expression in neural tissue in vivo and are born with normal 
numbers of neural stem cells (Molofsky et al., 2003). In contrast, postnatal Bmi-1 
deficient mice exhibit elevated p16Ink4a and p19Arf expression in neural tissues in vivo and 
neural stem cells become increasingly depleted with time (Molofsky et al., 2003). This 
depletion of neural stem cells can be largely, but not completely, rescued by Ink4a and/or 
Arf deficiency (Bruggeman et al., 2005; Molofsky et al., 2005; Molofsky et al., 2003). 
These data suggest that the primary physiological role for Bmi-1 in the nervous system is 
to repress Ink4a-Arf in postnatal stem cells and to promote the maintenance of these cells 
throughout adulthood (Bruggeman et al., 2005; Molofsky et al., 2005; Molofsky et al., 
2003). Nonetheless, a recent study found that shRNA knockdown of Bmi-1, primarily in 
cultured fetal neural stem cells, resulted in a self-renewal defect (Fasano et al., 2007b). 
These authors speculated that acute knockdown of Bmi-1 revealed a physiological role 
for Bmi-1 in fetal neural stem cells that was not evident in germline knockout mice. One 
possibility is that unknown mechanisms in germline Bmi-1 knockout mice compensate 
for the loss of Bmi-1 during fetal development. Another possibility is that shRNA 
knockdown of Bmi-1 in cultured fetal neural stem cells reflected a function for Bmi-1 that 
is not required in vivo because these cells express p16Ink4a and p19Arf in culture in a way 
that does not occur in vivo. To distinguish between these possibilities it will be necessary 
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to study Bmi-1floxed mice to determine whether conditional deletion of Bmi-1 in vivo leads 
to neurodevelopmental defects during fetal development. 
Consistent with other recent studies (Bruggeman et al., 2007; Leung et al., 2004), 
we observed elevated levels of Bmi-1 expression in many brain tumors as compared to 
normal brain tissue, irrespective of whether the tumors were low or high grade (Figure 
3.1). Indeed, Bmi-1 is required for the growth of gliomas and for glioma stem cell 
function, through Ink4a-Arf dependent and independent mechanisms (Bruggeman et al., 
2007). However, our data demonstrate that the degree of Bmi-1 overexpression that can 
be achieved in transgenic mice does not promote tumorigenesis in the CNS. Thus, 
increased Bmi-1 expression is not likely to be an initiating event in the formation of brain 
tumors. Rather, Bmi-1 may be required to cooperate with other mutations, such as to 
reduce the extent to which oncogenic stimuli induce p16Ink4a and p19Arf expression. In 
medulloblastomas, elevated Bmi-1 expression may reflect mutations that activate sonic 
hedgehog signaling (Leung et al., 2004). Elevated Bmi-1 expression in brain tumors may 
be the consequence of other mutations, or may confer a selective advantage in the context 
of mutations, but is not likely to reflect a primary role for increased Bmi-1 expression in 
the initiation of tumorigenesis. 
 
MATERIALS AND METHODS 
Generation of Nestin-Bmi-1-HA-GFP transgenic mice 
Full-length mouse Bmi-1 cDNA was PCR amplified from total mouse embryo 
cDNA and HA-tagged, then inserted into the pMIG vector immediately upstream of the 
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IRES site. The Bmi-1-IRES-GFP fragment was then isolated by NotI digestion and 
inserted into NotI digested nes1852tk/lacZ plasmid (kindly provided by Dr. Urban 
Lendahl). This nes1852tk/lacZ plasmid carried the Nestin second intronic enhancer that 
has previously been shown to drive transgene expression in CNS stem and progenitor 
cells (Kawaguchi et al., 2001) as well as the thymidine kinase minimal promoter (Lothian 
and Lendahl, 1997). The entire sequence (~7600 bp) was then linearized with ScaI and 
microinjected into mouse zygotes (Hogan et al., 1994). Founder males were bred to wild-
type C57Bl/6 females. Offspring were screened by GFP phenotyping of the brain in 
neonatal pups, and by genotyping using PCR at later ages using the primer set: 5’-
TGGACACAAAGACCTCTGTG-3’ and 5’-GGTTGTTCGATGCATTTCTGC-3’. 
Isolation of CNS progenitors and flow cytometry analysis 
Adult lateral ventricle subventricular zone (SVZ) cells from 2-4 month old wild 
type or transgenic mice were obtained by micro-dissecting the lateral walls of the lateral 
ventricles, then dissociating for 20 min at 37 °C in 0.025% trypsin/0.5 mM EDTA 
(Calbiochem; San Diego, CA) plus 0.001% DNaseI (Roche; Indiannapolis, IN). After 
quenching the enzymatic dissociation with staining medium (L15 medium (Invitrogen; 
Carlsbad, CA) supplemented with 1 mg/ml BSA (Sigma; St. Louis, MO), 10 mM HEPES 
(pH 7.4) and 1% penicillin/streptomycin (Invitrogen)) containing 0.014% soybean trypsin 
inhibitor (Sigma) and 0.001% DNase1, the cells were washed and resuspended in staining 
medium, triturated, filtered through nylon screen (45 µm, Sefar America; Depew, NY), 
counted by haemocytometer, and plated. 
For flow-cytometric analysis of GFP expression in transgenic mouse brain tissue, 
freshly dissociated single cell suspensions from neonatal mouse cerebral cortex and 
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cerebellum, or adult SVZ were analyzed by a FACS VantageSE flow-cytometer (Becton-
Dickinson; San Jose, CA). Dead cells were excluded from analysis by DAPI staining. 
Neural stem cell culture, differentiation, cell proliferation and self-renewal assays 
For neurosphere culture, dissociated SVZ cells were plated at clonal density (1.3 
cells/µl of culture medium) onto ultra-low binding plates (Corning, Lowell, MA). The 
culture medium (self-renewal medium) was based on a 5:3 mixture of DMEM-low 
glucose: neurobasal medium (Invitrogen) supplemented with 20 ng/ml human bFGF 
(R&D Systems, Minneapolis, MN), 20 ng/ml EGF (R&D Systems), 1% N2 supplement 
(Invitrogen), 2% B27 supplement (Invitrogen), 50 µM 2-mercaptoethanol (Sigma), 1% 
pen/strep (Invitrogen) and 10% chick embryo extract (prepared as described (Stemple 
and Anderson, 1992)). All cultures were maintained at 37˚C in 6% CO2/balance air. 
Neurosphere numbers and diameters were determined on the tenth day of culture. 
For neurosphere culture from single cells, P5 wild type and transgenic mouse 
SVZ cells were dissociated as described above. To enrich neural stem cells, the 
dissociated SVZ cells were stained with anti-CD24 (BD Biosciences, San Jose, CA) and 
anti-CD15 (clone MMA) antibodies, and single CD24-CD15hi cells were sorted into each 
well of 96 well ultra-low binding plates. Single cell sorting was confirmed in control 
plates stained with DAPI. Cultures were maintained at 37˚C in 6% CO2/balance air. 
Neurospheres were measured and subcloned for self-renewal quantification on the tenth 
day of culture. 
To assess the differentiation of primary neurospheres, individual neurospheres 
were replated onto Poly-D-Lysine (PDL, Biomedical technology, Stoughton, MN) and 
fibronectin (Biomedical technology) coated 48-well plates and cultured adherently in 
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differentiation medium for 7 days before being fixed and stained for markers of neurons, 
oligodendrocytes, and astrocytes as previously described (Molofsky et al., 2003). 
Differentiation medium was the same as self-renewal medium except that it contained no 
EGF, and reduced concentrations of chick embryo extract (1%) and FGF (10 ng/ml). 
For cell proliferation assays, dissociated adult SVZ cells were plated onto PDL 
and laminin (Invitrogen) coated tissue culture plates at clonal density (0.7 cells/µl) and 
cultured for 6 days, then pulse-labeled with 10 µM BrdU for 1 hour at 37°C before being 
fixed and stained with an antibody against BrdU as described (Molofsky et al., 2003). 
Only stem cell colonies (identified by large compact colony morphology) were included 
in this analysis. 
To assess the self-renewal potential of cultured neural stem cells, individual 
primary neurospheres were mechanically dissociated by trituration and then replated at 
clonal density (1.3 cells/µl) into non-adherent cultures. Secondary neurospheres were 
counted 10 days later and differentiated in the same manner as described above. Self-
renewal is reported as the number of multipotent secondary neurospheres that arose per 
subcloned primary neurosphere. 
Generation of Bmi-1-GFP-MSCV virus and infection of neural stem cells 
Bmi-1 bearing retrovirus was made using a mouse stem cell virus (MSCV) vector 
(pMIG) which contains an internal ribosome entry site (IRES) followed by GFP (Van 
Parijs et al., 1999). Full length mouse Bmi-1 cDNA was PCR amplified from perinatal 
mouse lateral ventricle SVZ cDNA. Hpa1 and Bgl2 sites were added to either end and the 
sequence was inserted into the MSCV vector 5’ to the IRES GFP. Preparation of high-
titer virus was carried out by calcium phosphate transfection of BOSC packaging cells 
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(Pear et al., 1993) with the Bmi-MSCV vector. Vesicular stomatitis virus G protein 
(VSV-G) plasmid was added during transfection to increase the infectivity of the 
packaged virus (Lee et al., 2001). Cells were allowed to produce virus for 24-48 hours, 
then cell supernatants were collected, 0.2 micron filtered, and stored at –80°C or used 
fresh to infect cultured neural stem/progenitor cells. 
Neonatal lateral ventricular zone (VZ) tissue from wild type or Ink4a-Arf 
deficient mice was dissected, dissociated, and cultured as described above. Cells were 
plated adherently at high density (20,000 cells per well of a six-well plate). After 24-48 
hours of culture, viral supernatant was added for 12-24 hours. Then the culture medium 
was replaced for 24-48 hours, and cells were briefly trypsinized and replated at clonal 
density (0.7 cells/µl of media). Viral titers allowed infection of 25 to 90% of colonies. 
Immunohistochemistry of tissue sections 
Immunohistochemical staining of Bmi-1 on normal human brain tissue and brain 
tumor samples was performed on the DAKO Autostainer (DAKO, Carpinteria, CA) using 
DAKO Envision+ and diaminobenzadine (DAB) as the chromogen. De-paraffinized 
sections of formalin fixed tissue at 5µm thickness were labeled with mouse monoclonal 
anti-Bmi-1 (1:400, Clone F6, Upstate Chemicals, Pickens, SC) for 60 minutes, after 
microwave citric acid epitope retrieval. Appropriate negative (no primary antibody) and 
positive controls (high grade brain tumor) were stained in parallel with each set of tumors 
studied. The immunoreactivity was scored by a three-tier (negative, low (+) and high 
(++) positive) grading scheme. 
For immunofluorescence staining of mouse brain sections, whole embryos or 
postnatal brains were fixed in 4% paraformaldehyde overnight, then cryoprotected in 
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30% sucrose, embedded in OCT (Sakura Finetek, Torrance, CA) and flash frozen. 
Twelve micron sections were cut on a Leica cryostat and air dried over night. Tissue 
sections were first blocked in PG/HN (5% horse serum, 5% goat serum, 1% BSA, 0.05% 
sodium azide and 0.05% Triton X-100 in 1x PBS) for 1 hour at room temperature (RT). 
Primary antibodies were diluted in PG/HN and incubated with the sections for 1 hour at 
RT, followed by washing then secondary antibody incubation for 1 hour at RT. 
Antibodies included mouse monoclonal anti-GFAP (1:500, Clone G-A-5, Sigma); mouse 
monoclonal anti-b-III-Tubulin (1:500, Clone TUJ1, Covance); rat monoclonal anti-
myelin basic protein (MBP, 1:100, Millipore, Temecula, CA), rabbit polyclonal anti-
BFABP (1:2000, gift from T. Muller, Max-Delbruck-Center, Berlin, Germany), mouse 
monoclonal anti-Reelin (1:1000, Clone G10, Abcam), rabbit polyclonal anti-FoxP2 
(1:500, Abcam) and Alexa 488 conjugated rabbit polyclonal anti-GFP (1:400, 
Invitrogen). Alexa Fluor conjugated secondary antibodies were purchased from 
Invitrogen and used at 1:500 dilution. Nuclei were visualized using DAPI (2µg/ml, 
Sigma) and slides were mounted with Prolong antifade solution (Invitrogen). Images 
were collected on a Leica TCS SP5 laser scanning confocal microscope, and multi-
channel overlays were assembled in Adobe Photoshop.  
For immunohistochemical staining of Bmi-1 on E15 telecephalon, 12 μm frozen 
sections of E15 wild type and transgenic mouse telencephalon were first treated with 3% 
H2O2/0.1% NaN3 for 1h at RT to quench endogenous peroxidase activity, then blocked 
with PG/HN before being labeled with mouse monoclonal anti-Bmi-1 (1:400, Clone F6, 
Upstate Chemicals) for 60 minutes at room temperature. The staining were then 
visualized using DAKO Envision+ and diaminobenzadine (DAB) as the chromogen. 
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To quantify adult SVZ proliferation, mice were injected with 100 mg/kg of 5-
bromo-2-deoxyuridine (BrdU, Sigma), and sacrificed 2 hour later. Brains were fixed and 
embedded as described above. Twelve micron thick coronal sections were cut on a Leica 
cryostat. For detection of BrdU, DNA was first denatured in 2N HCl for 45 min at RT 
and neutralized with 0.1M Sodium Borate for 10 minutes. Sections were then pre-blocked 
in PG/HN for 1 hour at RT and stained with primary rat anti-BrdU antibody (1:500, 
Accurate Chemical, Westbury, NY) diluted in PG/HN for 1 hour at room temperature, 
followed by biotinylated goat-anti-rat IgG (Jackson Immunoresearch) for 30 minutes at 
RT. BrdU staining were then visualized with Alexa594-conjugated streptavidin 
(Invitrogen) and nuclei were counter-stained with DAPI. Slides were mounted using 
ProLong antifade solution (Invitrogen) and imaged on a Leica TCS SP5 laser scanning 
confocal microscope using a 63x oil immersion objective (NA=1.4).  
To assess proliferation in E14.5 telencephalon, timed pregnant females were 
injected with a single dose of 100mg/ml BrdU 15 minutes prior to euthanization. Tissue 
processing and BrdU staining were then performed in a similar manner as described for 
adult tissue. 
To quantify olfactory bulb neurogenesis, 1-2 month old mice were given a single 
injection of 100mg/kg of BrdU and kept on BrdU-containing drinking water (1mg/ml) for 
the next 7 days. They were switched to regular water for an additional 4 weeks before 
being sacrificed. Brains were fixed and embedded as described. Ten micron coronal 
sections of the olfactory bulb were cut on a Leica cryostat. Tissue sections were blocked 
with PG/HN, stained with anti-NeuN (1:100, Clone A60, Millipore), re-fixed with 4% 
PFA then stained for BrdU as described above. NeuN staining was visualized with 
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Alexa555-conjugated goat-anti-mouse IgG1 secondary antibody (Invitrogen). BrdU 
staining was visualized with biotinylated goat-anti-rat IgG secondary antibody and 
Alexa594 conjugated streptavidin. Nuclei were counter-stained with DAPI. Slides were 
mounted in Prolong antifade (Molecular Probes), and imaged on a Leica TCS SP5 laser 
scanning confocal microscope using a 63x oil immersion objective (NA=1.4). Twenty 
five random fields of view (each containing 300-500 cells) spanning the full thickness of 
the olfactory bulb were counted in ImageJ software. 
Neuron birth dates were determined by injecting timed pregnant females with a 
single dose of 100mg/ml 5-chloro-2-deoxyuridine (CldU, Sigma) at E17. Pups were 
sacrificed at P20, brains were fixed and embedded as described, and 40µm-thick floating 
sections were cut on a Leica cryostat. CldU staining was performed in a similar manner 
as described for BrdU, using CldU-specific (1:500, Clone BU1/75, Accurate Chemical) 
antibody (Kiel et al., 2007); Cux-1 was stained using a rabbit polyclonal anti-Cux1 
antibody (1:50, Santa Cruz Biotechnology; Santa Cruz, CA). CldU staining was 
visualized by biotinylated goat-anti-rat IgG secondary antibody and Alexa594 conjugated 
streptavidin, and Cux-1 staining was visualized using Alexa555 conjugated goat-anti-
rabbit IgG secondary antibody.  
MRI analysis 
All mice analyzed were anesthetized with 2% isoflurane/air mixture throughout 
MRI. Mice lay prone, head first in a 7.0T Varian MR scanner (183-mm horizontal bore, 
Varian, Palo Alto, CA), with the body temperature maintained at 37ºC using circulated 
heated air. A double-tuned volume radio frequency coil was used to scan the head region 
of the mice. Axial T2-weighted images were acquired using a fast spin-echo sequence 
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with the following parameters: repetition time (TR)/effective echo time (TE), 
4000/47.456 ms; field of view (FOV), 30x30 mm; matrix, 256x128; slice thickness, 0.5 
mm; slice spacing, 0 mm; number of slices, 25; and number of scans, 1 (total scan time 
~1 min). 
Southern blots 
Southern blotting was performed to determine the number of transgene insertion 
sites and number of transgene copies that inserted into the genome of various lines of 
Nestin-Bmi-1-GFP transgenic mice. Purified mouse tail genomic DNA from each line 
was digested with EcoRV or ScaI, which both cut only once within the transgene. 
Digestion products were separated on a 0.8% agarose gel and blotted following standard 
methods, using a probe against the GFP sequence in the transgene. Copy number 
standards from linearized plasmid were run simultaneously, and band intensities were 
used to approximate copy number in each of the transgenic founders. For our 
experiments, two independent transgenic founders were selected that each had one to 10 
copies of the transgene at a single point in the genome (Figure 3.3). 
Western blots and quantitative RT-PCR 
Western blotting was performed as previously described (Molofsky et al., 2005). 
Mouse tissues and cultured neurospheres were harvested as described in the paper, 
primary human glioma samples were obtained from the frozen tumor bank of University 
of Michigan Comprehensive Cancer Center Tissue Core, xenografted human glioma cells 
were passaged at least twice in NOD-SCID mice before being harvested, normal human 
brain and cerebral cortex total protein extract were purchased from Biochain, Hayward, 
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CA. For sample preparation, tissues were homogenized in ice-cold RIPA buffer 
supplemented with protease inhibitor cocktail (complete mini tablet, Roche) by brief 
sonication using a Virsonic-100 ultrasonic cell disruptor (VirTis; Gardiner, NY). The cell 
homogenates were then spun down for 20 minutes at 4°C at 16,000g and the supernatant 
was quantified colorimetrically (BioRad protein assay; Bio-Rad, Hercules, CA). 10-50 µg 
of protein per lane were separated on a 4-20% gradient Tris-glycine denaturing SDS-
PAGE gels (Invitrogen) or a NuPAGE 10% Bis-Tris gel and transferred for 1-2 hours to 
PVDF membranes (Bio-Rad) at 4°C. The membranes were blocked in Tris buffered 
saline with 0.1% tween-20 (TBST) and 5% skim milk, then incubated with primary and 
secondary antibodies, and washed following standard procedures. Horseradish peroxidase 
conjugated secondary antibodies were visualized by chemiluminescence (ECL Plus, 
Amersham-Pharmacia, Piscataway, NJ; or SuperSignal West Femto, Thermo Scientific, 
Waltham, Ma). Primary antibodies were mouse monoclonal anti-ß-actin (1:2000, Clone 
AC-15; Sigma), rat monoclonal anti-p19Arf (1:500, Clone 5-C3-1, Upstate Chemicals, 
Lake Placid, NY), mouse monoclonal anti Bmi-1 (1:500, Clone F6, Upstate Chemicals), 
mouse monoclonal anti-HA (1:1000, Clone HA-7, Sigma), rat monoclonal anti-HA 
(1:2000, Clone 3F10, R&D), and rabbit polyclonal anti-p16Ink4a (1:1000, M-156; Santa 
Cruz Biotechnology). 
Quantitative (real-time) RT-PCR was performed as described previously 
(Molofsky et al., 2003). Primers used to amplify Bmi-1 were 5’-
CCAATGGCTCCAATGAAGACC -3’ and 5’-TTGCTGCTGGGCATCGTAAG -3’. 




Neurosphere clonality assay 
To assess the clonality of neurospheres, a 1:1 mixture of dissociated adult SVZ 
cells from UBC-GFP (Jackson laboratory, Bar Harbor, Maine) and ROSA-26 mice were 
plated at indicated cell densities (0.7 cells/μl or 1.3 cells/μl). After 10 days in culture, 
individual neurospheres were replated onto PDL and fibronectin coated 96-well plate and 
imaged for GFP fluorescence. The day after neurosphere attachment, cultures were fixed 
with 0.5% glutaraldehyde in 1x PBS for 10min at RT, then stained with X-gal to 
visualize LacZ expression. The frequencies of GFP-only, X-gal-only and mixed colonies 
were scored to estimate the rate of neurosphere fusion. All neurospheres were GFP+, 
LacZ+, or both. 
Histology 
Mouse brains used for H&E staining were fixed in 4% PFA or 10% neutral 
buffered formalin (NBF) for 24-48 hours at 4ºC; then dehydrated through an ethanol 
gradient and embedded in paraffin. Five micron coronal sections were cut on a Leica 
microtome and stained with hematoxylin and eosin. Images were taken on an Olympus 
BX-51 microscope using a 4x objective and assembled using Adobe Photoshop. For Nissl 
staining of perinatal mouse brain sections, 40 µm brain cryosections were stained with 
0.1% cresyl violet for 3 minutes, rinsed in distilled water and differentiated in 95% ethyl 
alcohol. Slides were then dehydrated and mounted in Vectamount (Vector Laboratories, 
Burlingame, CA). Images were taken on an Olympus BX-51 microscope using 4x or 10x 
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Figure 3.1: Bmi-1 expression was elevated in human brain tumors. 
A-F) Immunohistochemistry for Bmi-1 in representative sections from normal human 
brain tissue and various types of brain tumors. Bmi-1 (brown, arrowheads) was not 
detected in uninjured normal human brain tissue (A), but was detected in white matter 
after an epileptic seizure (B), in gliosis (C), pilocytic astrocytoma (D), oligodendroglioma 
(E) and glioblastoma (F). Sections are counterstained with hematoxylin. G) Western 
blotting showed Bmi-1 was faintly detected in normal human brain and cerebral cortex 
(brain, cortex) but it was elevated to various degrees in human glioma specimens 
obtained directly from patients (AA1, GBM3) as well as from mouse xenografts (PA1, 
GBM1,GBM2). In comparison, telencephalon cells from Bmi-1 transgenic mice showed 
the highest level of Bmi-1 expression. AA1: anaplastic astrocytoma (grade 3); PA1: 
pilocytic astrocytoma (grade 1); GBM1, GBM2, GBM3: glioblastoma multiforme (grade 
4). H) Comparison of Bmi-1 expression between normal human brain tissues and various 
brain tumors. A three-tier grading system was used to evaluate Bmi-1 expression levels: 
strong Bmi-1 expression in many cells (red, ++); variable Bmi-1 expression in some cells 
(orange, +), no Bmi-1 expression above background (blue, -). Numbers in parentheses 
indicate the number of specimens examined for each category.
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Figure 3.2: Transgene expression in Nestin-Bmi-1-GFP transgenic mice. 
A). Schematic representation of the Nestin-Bmi-1-GFP transgene. B). GFP 
epifluorescence shows transgene expression throughout the CNS in an E14.5 transgenic 
embryo but not in non-neural tissues or in a wild type control embryo (to the left of the 
transgenic embryo). C) The transgene was still widely expressed in most regions of the 
P0 transgenic brain, with nerve fiber bundles (ac, cc) and the wall of the ventricular 
system (aq) expressing the highest levels of GFP (left, whole brain overview; right, 
sagittal view from the midline). D-F). GFP expression became more restricted in the 
adult transgenic mouse brain (D) and concentrated in regions enriched for neural 
stem/progenitor cells, such as the SVZ of the lateral ventricle (E) and the subgranular 
layer of the dentate gyrus (F). All photos are from line C transgenic mice, but are also 
representative of line B mice. Flow-cytometry of cells from line B mice confirmed the 
presence of GFP+ cells in the ventricular zone, the cortex, and the cerebellum of neonatal 
transgenic mice (green histograms; G) but not in control littermates (unshaded 
histograms; G), as well as in the adult SVZ (H). I-J). The vast majority of neurospheres 
formed by neonatal VZ, cerebral cortex, and cerebellum (I) as well as adult SVZ (J) 
derived from the GFP+ fraction of cells. Data represent mean±s.d. from 3 independent 
experiments using line B transgenic mice. K). Many Bmi-1 transgenic neurospheres were 
capable of undergoing multilineage differentiation into astrocytes (GFAP+, green), 
neurons (Tuj-1+, red) and oligodendrocytes (O4+, black). ac, anterior commissure; aq, 
aqueduct; cbl, cerebellum; cc, corpus callosum; ctx, cerebral cortex; DG, dentate gyrus; 








Figure 3.3: Southern blot analysis of transgene copy number and insertion site in 
transgenic founders.  
A). Southern blots of genomic DNA from the ten transgenic founders showed variable 
transgene copy numbers. ScaI linearized transgene was used for copy number standards. 
Five lines (B*, C, D, E, G) gave germ line transmission. B). Genomic DNA from lines B, 
K, and C were digested with ScaI or EcoRV (which each cut at single sites within the 
transgene) and analyzed by Southern blot using an internal probe against the transgene. 
Line B and Line K mice were both derived from the original line B* founder; however, 
they had different transgene copy numbers and different transgene integration sites. Note 
that the presence of only 1 or 2 bands indicates a single chromosome integration site. 
Line C samples were included for transgene copy number comparison. All experiments 
were performed on line B and C mice, which had approximately 5 copies of the transgene 





Figure 3.4: Characterization of transgene expression in lines that gave germline 
transmission. 
A). GFP expression in transgenic mice was examined at P0 and P30 by analyzing 
dissociated cells by flow-cytometry. Only two transgenic lines with low copy numbers of 
the transgene (lines B and C) showed GFP expression in the CNS at both time points 
examined, while the other lines showed no appreciable expression at either 
developmental stage. GFP expression was not detected in tissues outside of the nervous 
system such as in bone marrow hematopoietic cells. B). Representative flow-cytometry 
histograms show the absence of GFP expression in transgenic mouse bone marrow cells 
(black open histograms show littermate control cells; green solid histograms show 





Figure 3.5: Bmi-1 transgenic mice were born at expected Mendelian frequency and 
showed no substantial growth defects.  
A) Bmi-1 transgenic mice from both lines were born at Mendelian frequency and showed 
no increased mortality relative to control littermates within the first month after birth. 
Numbers of surviving wild type and transgenic mice were counted at P30. B, C) Bmi-1 
transgenic mice from both lines exhibited similar brain and body masses as control 
littermates at P60, though a subset (~25%) of transgenic mice that developed 
hydrocephalus in early adulthood tended to exhibit increased brain mass and decreased 
body mass. Since line B mice tended to develop hydrocephalus earlier than line C mice, 
these effects led to line B mice exhibiting slightly but significantly lower body masses 
and slightly but significantly higher brain masses than littermate controls (n=3 




Figure 3.6: Bmi-1 expression was elevated in transgenic neural stem/progenitor 
cells.  
A). qRT-PCR showed that Bmi-1 transcript expression was markedly increased in 
uncultured transgenic P0 VZ and adult SVZ cells as well as in neurospheres cultured 
from adult transgenic SVZ cells as compared to littermate control cells. Fold change is 
presented (mean±s.d. from 3-5 independent experiments) relative to control cells, which 
were set to 1. Total cDNA levels in each pair of samples were normalized based on ß-
actin expression. B) Western blotting showed the expression of HA tag, as well as 
increased Bmi-1 and decreased p16Ink4a and p19Arf in transgenic as compared to control 
neurospheres from lines B and C. Western blotting showed the expression of HA tag and 
increased Bmi-1 levels in E14.5 telecephalon (C) and P0 brain (D) from transgenic as 
compared to control mice. Note that p16Ink4a and p19Arf were not detected in E14.5 
telecephalon (C) or P0 brain (D) from either transgenic or control mice, as expected. E). 
Representative immunohistochemical staining of Bmi-1 on coronal sections of E15 wild 





Figure 3.7: Bmi-1 overexpression increased the self-renewal and neuronal 
differentiation of neural stem/progenitor cells in culture.  
A) A significantly higher percentage of freshly isolated SVZ cells from 2-3 month old 
transgenic mice gave rise to multipotent neurospheres than littermate control cells. (*, 
p<0.05); however, the total number of multipotent neurospheres formed per transgenic 
SVZ (from both brain hemispheres) was not significantly different from control SVZ (B, 
p=0.31 for line B and p=0.55 for line C). Transgenic neurospheres were significantly 
larger than control neurospheres (C; *, p<0.01) and gave rise to significantly more 
multipotent secondary neurospheres upon subcloning (D; *, p<0.05). E, F) Single 
CD15+CD24- SVZ cells from P5 wild type and transgenic mice were sorted per well of 
96 well plates. The transgenic single cell-derived neurospheres were larger than controls 
(E; *, p<0.01) and generated significantly more multipotent secondary neurospheres upon 
subcloning (F; *, p<0.01). G) Adherent Bmi-1 transgenic neural stem cell colonies 
showed a significantly higher frequency of BrdU+ cells as compared to control colonies 
after a 1 hour pulse with BrdU (*, p<0.01). H, I) Transgenic neurospheres were capable 
of multilineage differentiation and gave rise to larger numbers of neurons as compared to 
control colonies. Significantly more transgenic colonies contained large numbers of 
neurons (>100) as compared to control colonies (p<0.01 for line B and p<0.05 for line 




Figure 3.8: Most neurospheres grown under our culture conditions were clonal.  
A 1:1 mixture of freshly isolated adult SVZ cells from UBC-GFP and ROSA-26 mice 
were plated at the indicated total cell density in non-adherent cultures, and neurospheres 
were allowed to form. After 10 days in culture spheres were scored for GFP and LacZ 
expression. While most neurospheres appeared to be clonally derived (containing GFP+ 
cells or LacZ+ cells but not both), a small fraction of neurospheres contained both GFP+ 
and LacZ+ cells suggestive of sphere-fusion (red bar) (Singec et al., 2006). Data 




Figure 3.9: Bmi-1 overexpression had little effect on fetal or adult neural 
stem/progenitor cell proliferation in vivo. 
A) The rate of BrdU incorporation by SVZ cells was comparable between transgenic and 
control mice after a 2 hour pulse of BrdU (p=0.31 for line B and p=0.08 for line C; data 
represent mean±s.d. from 4 independent experiments). B) Representative confocal 
images showing BrdU+ cell distribution in wild type and transgenic E14.5 telencephalon 
after a 15 minute pulse of BrdU. No differences in the gross distribution or frequency of 
BrdU+ cells were noted between wild type and transgenic embryos. C). No differences in 
the thickness of the cerebral cortex or VZ (as indicated in B) were found between 
transgenic and control embryos. Numbers in parenthesis indicate VZ thickness as a 




Figure 3.10: Bmi-1 overexpression had little effect on fetal or adult neurogenesis. 
A) One month old transgenic and control mice were pulsed with BrdU for one week. 
Four weeks later, the frequency of BrdU+NeuN+ neurons in the olfactory bulb was 
significantly reduced among line B transgenics (p=0.02) but was not affected in line C 
(p=0.74; data represent mean±s.d. from 3-4 independent experiments). B-F) 
Representative images from line C transgenic mice show normal cortical neurogenesis in 
Bmi-1 transgenic mice. B) At E12, the frequency and localization of Tuj1+ neurons in the 
cerebral cortex was similar between transgenic and control littermates. C, D) Cortical 
layer organization appeared to be normal in the postnatal transgenic mouse brain. Reelin 
labels Cajal-Retzius neurons in layer I of the neonatal cortex (C) and FoxP2 labels layer 
VI neurons (D). E, F) Bmi-1 transgenics and littermate controls were pulsed with a single 
injection of CldU at E17 and analyzed at P20: no difference was observed in the 
frequency or localization of CldU+ neurons. Cux-1 labels upper layer (II-IV) neurons. G) 
High magnification confocal images of the same tissue sections as shown in (E,F). Cux-1 
staining is shown in red while CldU staining is shown in green (double stained cells are 
yellow). The frequency of CldU+Cux-1+ neurons as compared to total CldU+ cells (H) 





Figure 3.11: Bmi-1 overexpression had little effect on gliogenesis in vivo.  
A-E) We did not detect any effect of Bmi-1 overexpression on postnatal gliogenesis in 
line C transgenic mice, as indicated by the normal number and distribution of MBP+ 
oligodendrocytes (A) and GFAP+ astrocytes (B) in the adult transgenic brain as well as 
the normal timing of early postnatal gliogenesis (C-E). F,G) While no difference was 
observed in the frequency of GFAP+ astrocytes in P4 line B wild type and transgenic 
mouse brains (F); the frequency of MBP+ oligodendrocytes was transiently reduced as 
compared to littermate controls at P4 (G). As with line C, adult line B transgenic mice 
exhibited no difference relative to control mice in terms of the frequency of GFAP+ 
astrocytes or MBP+ oligodendrocytes (data not shown). 
 
 
Figure 3.12: Bmi-1 overexpression increased proliferation, self-renewal, and 
neurogenesis by wild-type but not Ink4a-Arf deficient neural stem/progenitor cells in 
culture.  
Wild type and Ink4a-Arf deficient neural stem cells were infected with either a Bmi1-
encoding retrovirus (MSCV-Bmi1-IRES-GFP) or control retrovirus (MSCV-GFP). A) 
qRT-PCR confirmed a 4 to 5.5-fold increase in Bmi-1 expression in MSCV-Bmi-1 
infected neurospheres as compared to neurospheres infected with control virus. B) Wild 
type neurospheres infected with MSCV-Bmi1 were significantly larger than those 
infected with control virus or uninfected neurospheres (p<0.01). In contrast, MSCV-
Bmi1 infection did not affect the size of Ink4a-Arf deficient neurospheres (p=0.57). Data 
represent mean±s.d. from 3-4 independent experiments. C) Wild type neurospheres 
infected with MSCV-Bmi1 virus exhibited significantly increased self-renewal as 
compared to neurospheres infected with control virus or uninfected neurospheres 
(p<0.05). In contrast, MSCV-Bmi1 infection did not affect the self-renewal of Ink4a-Arf 
deficient neurospheres (p=0.45). Data represent mean±s.d. for 3-5 independent 
experiments. D). MSCV-Bmi1 infection increased neuronal differentiation within wild-
type (*, p<0.05 relative to WT no virus) but not Ink4a-Arf deficient neural stem cell 
colonies. Data represent mean±s.d. from 3-4 independent experiments. E-I) Bmi-1 
transgenic mice (Bmi-1TG+) were also mated with Ink4a-Arf deficient mice. E) Freshly 
dissociated SVZ cells showed that Bmi-1TG+Ink4a-Arf-/- mice expressed the transgene in 
vivo (green filled histogram), while Ink4a-Arf-/- mice (black open histogram) did not. F). 
qRT-PCR analysis showed that Bmi-1 expression was increased in the SVZ of Bmi-
1TG+Ink4a-Arf-/- mice. G). The frequency of multipotent neurospheres that arose in 
culture from Bmi-1TG+Ink4a-Arf-/- SVZ cells was not significantly different from Ink4a-
Arf-/- SVZ. H,I). Bmi-1TG+Ink4a-Arf-/- neurospheres did not show increased diameter or 









Figure 3.13: A minority of Bmi-1 transgenic mice developed idiopathic 
hydrocephalus but showed no sign of brain tumors. 
A) Representative nissl stains of P5 line C and littermate control brain sections showed 
enlarged lateral ventricles (LV) in the transgenic brain but a normal laminar organization 
of the cortex. B) MRI images showed hydrocephalus in adult line C mice: lateral 
ventricles were enlarged, while the third and fourth ventricles as well as the sylvius 
aqueduct were relatively normal. C) No physical block was detected between the lateral 
and third ventricles in H&E stained serial brain sections. D) The ependymal cell layer 
(S100ß+ cells) in the transgenic mouse brain was abnormally folded in places. E) Bmi-1 
over-expressing mice did not develop brain tumors, even when aged for approximately 
two years. Brains in the “gross examination” column are in addition to those examined by 
histology. Mice that did not develop hydrocephalus showed no sign of premature death 
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CHAPTER 4   
 
SOX17 IS SUFFICIENT TO CONFER SELF-RENEWAL POTENTIAL AND 
FETAL CHARACTERISTICS TO ADULT HEMATOPOIETIC PROGENITOR 
CELLS1
 
1 Manuscript in preparation with authors listed as He, S., Lim, M.S., Kim, I. and Morrison, S.J. 
SUMMARY 
Fetal liver hematopoiesis represents a unique stage of hematopoietic system 
development that is dominated by definitive erythropoiesis and myelopoiesis. 
Correspondingly, fetal liver hematopoietic stem cells (HSCs) are distinct from adult bone 
marrow HSCs in their gene expression, surface marker expression, developmental 
potential, and self-renewal capacity. While a number of genes have been identified to 
date to be specifically required for fetal HSC formation and/or maintenance but not adult 
HSCs; no gene has yet been found to define the unique characteristics of fetal liver HSCs 
or fetal hematopoiesis. Here we report that Sox17, a gene previously shown by us to be 
specifically expressed by fetal and neonatal HSCs but not adult HSCs, and essential for 
the maintenance of fetal HSCs, is sufficient to confer fetal properties and stem cell 
properties upon adult hematopoietic progenitor cells, including enhanced self-renewal 
potential and fetal gene expression. Furthermore, the hematopoietic reconstitution pattern 
of Sox17-over-expressing adult bone marrow cells exhibited a striking resemblance to 
fetal liver hematopoiesis, including augmented erythropoiesis and myelopoiesis and 
diminished lymphoid cell production. Thus, our findings have identified Sox17 as the 
 
only gene identified to date that is not only essential for fetal liver HSC maintenance but 
is also sufficient to confer fetal HSC features to adult cells. 
 
INTRODUCTION 
Mammalian hematopoiesis undergoes significant developmental changes during 
ontogeny. In the developing mouse embryo, two distinct waves of blood cell production 
occur (Mikkola and Orkin, 2006; Orkin and Zon, 2008). The first wave of blood 
formation (“primitive hematopoiesis”) takes place in the yolk sac of E7 embryos, and is 
characterized by the production of large, nucleated primitive erythrocytes which express 
embryonic globin proteins. Primitive hematopoiesis is transient and rapidly replaced by 
adult (“definitive”) hematopoiesis, which originates in the Aorta-Gonad-Mesonephros 
(AGM) region of the E8.5 mouse embryo. Shortly after, the HSCs that arise in the AGM 
migrate into the fetal liver, the major site of hematopoiesis within the developing embryo. 
Fetal liver hematopoiesis differs from both primitive hematopoiesis and adult bone 
marrow hematopoiesis by the predominant production of definitive erythrocytes 
(enucleated red cells expressing adult type hemoglobin) and the unbalanced production of 
myeloid vs. lymphoid cells. During late embryonic to early postnatal development, adult 
hematopoiesis is established by the migration of hematopoietic stem and progenitor cells 
from fetal liver to bone marrow. Adult hematopoiesis is characterized by balanced 
erythroid, myeloid and lymphoid cell production. 
Parallel to the changes that occur in hematopoiesis during the fetal to adult 
transition, fetal liver hematopoietic stem cells (HSCs) are distinct from adult HSCs in 
gene expression (Ivanova et al., 2002; Kiel et al., 2005a; Phillips et al., 2000), surface 
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marker expression (Jordan and Lemischka, 1990; Kim et al., 2005; Morrison et al., 1995), 
developmental potential (Bowie et al., 2007; Ikuta et al., 1990; Kantor et al., 1992) as 
well as self-renewal capability (Bowie et al., 2007; Harrison et al., 1997; Morrison et al., 
1995). A number of genes have been identified that differentially regulate the function 
and/or maintenance of fetal and adult HSCs. Scl (Mikkola et al., 2003; Porcher et al., 
1996; Robb et al., 1996; Shivdasani et al., 1995), Aml-1/Runx1 (Ichikawa et al., 2004; 
Okuda et al., 1996a; Wang et al., 1996) and Sox17 (Kim et al., 2007) are required for the 
formation and/or maintenance of fetal liver HSCs but are dispensable for the function of 
adult HSCs. In contrast, several transcriptional regulators including Gfi-1(Hock et al., 
2004a), Tel/Etv6 (Hock et al., 2004a), and Bmi-1(Park et al., 2003b) maintain adult but 
not fetal HSCs. However to our knowledge, no gene has yet been shown to be sufficient 
to determine HSC identity. Such gene(s), if they exist, should meet three criteria: their 
expression should be restricted to HSCs at a certain stage of development, they should be 
required for the function/maintenance of HSCs at a certain stage of development, and 
when overexpressed they should be sufficient to confer developmental stage-specific 
HSC properties. Using these criteria, we report that Sox17 is a critical determinant of fetal 
HSC identity.  
Sox17 is a member of sub-group F of the Sry-related high mobility group box 
(Sox) transcription factors, and was originally considered a marker of endodermal 
identity (Yasunaga et al., 2005). It is required for the formation and maintenance of 
definitive endoderm (Hudson et al., 1997; Kanai-Azuma et al., 2002; Niakan et al., 2010) 
and vascular endothelium (Matsui et al., 2006) in vivo. We have previously shown that 
within the hematopoietic system Sox17 expression is temporally restricted to fetal and 
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neonatal, but not adult, HSCs (Kim et al., 2007); Sox17 expression correlates with fetal 
HSC characteristics during their transition from fetal to adult HSCs in terms of both 
immunophenotype and cell cycle status. Germline loss of Sox17 leads to severe defects in 
definitive hematopoiesis in the fetal liver, including a complete absence of definitive 
HSCs, while conditional deletion of Sox17 leads to the loss of fetal and neonatal but not 
adult HSCs (Kim et al., 2007). This indicates Sox17 is essential for the 
function/maintenance of fetal but not adult HSCs.  
To test whether re-introducing Sox17 expression into adult mouse hematopoietic 
cells is sufficient to confer fetal HSC identity, including enhanced self-renewal potential 
and fetal specific gene expression, we overexpressed Sox17 in adult mouse hematopoietic 
cells by retroviral infection and followed their fate after transplantation into lethally 
irradiated recipients. Sox17 overexpression was sufficient to enhance the long-term 
reconstituting potential of adult bone marrow progenitors and to confer self-renewal 
capacity to certain types of early hematopoietic progenitors. In addition, Sox17-over-
expressing adult progenitors expressed several fetal specific cell surface markers and 
exhibited global upregulation of fetal HSC genes. Meanwhile, Sox17-over-expressing 
hematopoietic cells exhibited biased differentiation characterized by augmented erythroid 
and myeloid production at the expense of lymphoid cells, and produced platelet and 
myeloid cells with fetal characteristics. Together, our data identify Sox17 as the only 
gene known to date that is sufficient to control the developmental identity of HSCs. 
 
RESULTS 
Sox17 expression levels decline with fetal development and differentiation 
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To better understand the role of Sox17 in regulating fetal liver hematopoiesis, we 
examined the detailed expression pattern of Sox17 in HSCs and various types of 
hematopoietic progenitors at embryonic day (E)13.5 and at birth (P0) using Sox17-GFP 
knock-in mice (Kim et al., 2007). In this mouse, endogenous Sox17 coding sequence was 
replaced by an enhanced green fluorescence protein (EGFP), which can be used to track 
the endogenous level of Sox17 expression during development. Similar to what we 
reported previously (Kim et al., 2007), Sox17-GFP expression is restricted to fetal liver 
HSCs and early hematopoietic progenitors as no GFP expression was observed in lineage 
positive cells or in adult HSCs or progenitor cells (data not shown). Interestingly the 
Sox17-GFP expression level was highest in CD150+CD48-CD41-Lin-Sca-1+cKit+ 
(LSK150+48-41-) HSCs and CD150-CD48-CD41-Lin-Sca1+cKit+ (LSK150-48-41-) cells at 
both developmental stages examined. As HSCs differentiated toward the myeloid lineage 
(Lin-Sca-1-cKit+), Sox17-GFP expression progressively decreased (Figure 4.1). On the 
other hand, Sox17-GFP expression by P0 fetal liver HSCs and hematopoietic progenitors 
was significantly lower than by their E13.5 counterparts, such that Sox17-GFP 
expression could only be detected on the more immature LSK cells at P0 but no longer on 
the myeloid progenitors (Figure 4.1). Together, these data indicate that Sox17 expression 
is tightly correlated with both the fetal state and the undifferentiated stem cell state, 
raising the possibility that Sox17 is not only essential for fetal liver HSC maintenance but 
is also essential to specify fetal characteristics. To test this, we decided to examine 




Overexpression of Sox17 in adult bone marrow cells enhances their long-term 
reconstituting potential, and biases lineage differentiation 
To directly test whether re-introducing Sox17 expression in adult hematopoietic 
cells is sufficient to confer fetal characteristics, we used retrovirus to over-express Sox17 
in adult hematopoietic cells and followed their fate after transplantation. Two Sox17-
expressing retrovirus vectors were constructed by inserting full length or C-terminal his-
tagged Sox17 cDNA into the murine stem cell virus (MSCV) based pMIG (MSCV-GFP) 
vector (Van Parijs et al., 1999) immediately upstream of the internal ribosomal entry site 
(IRES) followed by EGFP. This allowed for the tracking of viral infected cells and their 
progeny in vivo. Western blotting of control (MSCV-GFP) and Sox17 virus (MSCV-
Sox17 and MSCV-Sox17his) infected 3T3 cells confirmed the presence of ectopic Sox17 
protein expression (Figure 4.2A). Quantitative RT-PCR comparing Sox17 virus infected 
primary hematopoietic cells with E16.5 fetal liver HSCs showed 800 to 950 fold Sox17 
expression over the endogenous level at this developmental stage (Figure 4.2B).  
One million control (MSCV-GFP) or Sox17 (MSCV-Sox17 and MSCV-
Sox17his) retrovirus infected CD45.1 whole bone marrow cells from 8 week-old young 
adult mice were transplanted into lethally irradiated CD45.1 recipients along with 
200,000 recipient cells for radioprotection, and peripheral blood chimerism was 
monitored for up to 16 weeks post transplantation (Figure 4.3A-F). Peripheral blood 
leukocytes, erythrocytes and platelets derived from virus infected donor cells could be 
reliably identified using flow cytometry, based on EGFP expression (Figure 4.4). 
Compared with control virus infected cells, bone marrow cells infected with Sox17 virus 
generated significantly higher levels of peripheral blood myeloid, erythroid, and platelet 
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reconstitution at 16 week post transplantation (Figure 4.3, A, B, E, F). And more 
recipients that received Sox17-overexpressing cells showed long-term myeloid (9 of 9 for 
MSCV-Sox17 and 8 of 9 for MSCV-Sox17his) and erythroid (9 of 9 for MSCV-Sox17 
and 9 of 9 for MSCV-Sox17his) reconstitution than controls (5 of 14 for myeloid and 9 of 
14 for erythroid only) (Figure 4.3G). These results indicate that Sox17 overexpression 
significantly enhanced the long-term reconstitution potential of adult bone marrow cells.  
In contrast to the augmented myeloerythroid reconstitution by Sox17-
overexpressing cells, lymphoid reconstitution by Sox17-overexpressing cells generally 
did not significantly differ from the control virus infected cells (Figure 4.3C, D), 
suggesting Sox17 overexpression may bias the balance between lymphoid and myeloid 
cells in the peripheral blood. Indeed, the ratio of GFP+ donor-derived peripheral blood 
lymphoid versus myeloid cells was significantly reduced in the recipients of Sox17-
overexpresing bone marrow cells at both 4 and 16 weeks after transplantation (Figure 
4.3H), indicating Sox17 overexpression may either enhance the production or survival of 
myeloid cells or suppress the production or survival of lymphoid cells. Intriguingly, 
despite the robust contribution of Sox17-overexpressing cells to the platelet compartment 
in the peripheral blood, the overall platelet counts were significantly reduced in all 
primary recipients of Sox17 virus infected cells (Figure 4.5A). This was accompanied by 
the appearance of large reticulated platelets in the peripheral blood (Figure 4.5B), 
resembling platelets derived from fetal liver megakaryocytes (Tober et al., 2007). 
Meanwhile, the number of reticulocytes was also elevated in the peripheral blood of 
Sox17-overexpressing cell recipients, indicative of augmented erythropoiesis (Figure 
4.5B). Together, these data indicated that Sox17 overexpression was shifting adult 
158 
 
hematopoiesis to a more fetal phenotype, including augmented myeloerythropoiesis, 
suppressed lymphopoiesis and production of platelets with fetal characteristics. On the 
other hand, we did not observe a dramatic increase in circulating nucleated erythrocyte 
numbers, indicating Sox17 overexpression did not seem to revert definitive erythropoiesis 
to primitive erythropoiesis. 
To understand what mechanisms might contribute to the observed changes in the 
peripheral blood reconstitution pattern after Sox17 overexpression, we analyzed the 
hematopoietic tissues of primary recipients at 16 weeks post transplantation. In 
comparison to control recipients, the spleen of the primary recipients reconstituted with 
Sox17-overexpressing cells were significantly enlarged (Figure 4.6 A, B), while the 
thymus was decreased (Figure 4.6A). This translated into a mild but not significant 
increase in spleen cellularity and a decrease in thymus cellularity (Figure 4.6C). GFP+ 
donor cell chimerism was highly variable in primary recipients, with a statistically 
insignificant increase in the recipients of Sox17-overexpressing cells (Figure 4.7A). A 
detailed analysis of the lineage compositions of GFP+ donor cells in the bone marrow and 
spleen of primary recipients showed that the frequency of Mac-1+ immature myeloid cells 
generated by Sox17-overexpressing cells was not significantly different from controls 
(Figure 4.6D, H, I). However, Gr-1 expression on the myeloid cells was significantly 
reduced (Figure 4.6D), similar to what was found on Mac-1+ myeloid cells in E12 fetal 
liver (Figure 4.7B). The frequency of CD41+ megakaryocytic cells in GFP+ donor-
derived cells was significantly increased in both bone marrow and spleen as a result of 
Sox17 overexpression, and CD41 expression showed a inverse correlation with ckit 
(Figure 4.6D), similar to what had been observed on E12 fetal liver CD41+ 
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megakaryocytic cells (Figure 4.7B). The frequency of Ter119+ erythroid cells did not 
differ between control and Sox17-overexpressing donor derived GFP+ cells in the bone 
marrow (Figure 4.6H), however, it was significantly increased in the spleen of primary 
recipients that received Sox17-overexpressing cells (Figure 4.6E, I), indicating 
augmented extramedullary erythropoiesis. On the other hand, we did not detect a 
significant increase in the transcription of embryonic hemoglobins in the Sox17-
overexpressing erythroid progenitor cells (data not shown), further supporting the 
conclusion that Sox17 overexpression did not promote primitive erythropoiesis. In 
contrast to the normal level or augmented myeloerythroid cell production by Sox17-
overexpressing cells, the frequencies of B220+ B-cells and CD4+ or CD8+ T-cells 
produced by Sox17-overexpressing cells in both bone marrow and spleen of the primary 
recipients were significantly reduced as compared to controls (Figure 4.6F-I), indicating 
suppressed lymphopoiesis as a result of Sox17 overexpression.  
To independently confirm these findings, we also analyzed a strain of Sox17 
transgenic mice (Otet-Sox17/Rosa-rtTA) in which ectopic Sox17 expression in all tissues 
can be induced by administration of doxycycline (Park et al., 2006). For unknown 
reasons, all Sox17 transgenic mice died within 7 days after Doxycycline administration, 
restricting the analysis of hematopoietic cells to only short-term Sox17 overexpression. 
Nevertheless, within 6 days after the induction of transgene expression, we observed a 
progressive and significant decrease in thymus weight and cellularity (Figure 4.8A, B), a 
progressive increase in peripheral blood neutrophil count (Figure 4.8C) and a 
significantly decrease in peripheral blood platelet count (Figure 4.8C). As a result, the 
peripheral blood lymphoid vs. myeloid cell ratio was significantly reduced starting from 
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4 days after transgene induction (Figure 4.8D). A detailed analysis of the lineage 
composition of the transgenic mouse bone marrow, spleen and thymus at 2, 4 and 6 days 
after transgene induction revealed a significant increase in Mac-1+ myeloid cell frequency 
in the bone marrow and spleen and progressive downregulation of Gr-1 expression on the 
Mac-1+ cells in bone marrow (compare the frequency of Mac-1+ cells with Mac-1+Gr-1+ 
cells; Figure 4.8E, F). In contrast, the frequency of B220+ B cells in bone marrow was 
significantly reduced after transgene expression with reductions of both mature 
(B220+sIgM+) and immature B-cells (B220+sIgM-). Development of T-cells was also 
affected as the frequency of CD4+CD8+ double positive cells in the thymus was 
significantly reduced after 6 days of transgene induction while the corresponding single 
positive T-cell frequency was relatively increased (Figure 4.8G). All of these findings are 
similar to the phenotypes observed in the primary recipients reconstituted with Sox17-
overexpressing hematopoietic cells (Figure 4.3&4.6). On the other hand, we failed to 
observe any consistent increase in erythroid or megakaryocytic cell frequency in the 
hematopoietic tissues of the Sox17 transgenic mice (Figure 4.8. E, F). This is most likely 
due to the very short time of transgene expression by which time the expansion of 
erythroid and megakaryocytic cells may not yet be apparent. Similarly, the short period 
of transgene induction may also explain the absence of reduced lymphocyte frequency in 
the spleen due to their long overall life span.  
Together, these data indicate that Sox17 overexpression leads to an expansion of 
myeloerythroid cells in primary recipients at the cost of lymphoid differentiation, which 
shares striking similarity to normal fetal liver hematopoiesis. In addition, Sox17 
overexpression appears to be able to modify the surface phenotype and/or differentiation 
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pattern of myeloid and megakaryocytic cells, leading to the production of platelets and 
myeloid cells possessing certain fetal-like characteristics. 
Sox17 overexpression confers fetal characteristics to adult HSPCs 
To test the direct effects of Sox17 overexpression on hematopopoietic stem and/or 
progenitor cells (HSPCs), we analyzed the frequency and surface phenotype of donor 
derived GFP+ HSCs (Lineage-Sca1+cKit+CD150+CD48-CD41-) and the HSPC-enriched 
lineage-cKit+Sca1+CD41- (LSK41-) cells in primary recipients 16 weeks after 
transplantation. In comparison to controls, Sox17 overexpression led to a significant 
expansion of LSK41- cells in the bone marrow and spleen of primary recipients of 
MSCV-Sox17 virus infected bone marrow cells (Figure 4.9A, B). A similar expansion of 
LSK41- cells was also observed in the spleen but not bone marrow of recipients 
reconstituted with MSCV-Sox17his virus infected bone marrow cells (Figure 4.9B). 
Intriguingly, detailed examination of the Sox17-overexpressing LSK41- cells revealed 
that they were predominantly CD48+. As a result, the frequency of cells with an HSC 
surface marker phenotype was actually depleted in both bone marrow and spleen of 
recipients of Sox17-overexpressing cells as compared to control recipients (Figure 4.9A, 
B). This observation may either indicate a loss of functional HSCs or reflect a change in 
HSC surface marker expression. Similarly, we observed a significant increase in LSK41- 
cell frequency in both bone marrow and spleen of Otet-Sox17/Rosa-rtTA mice after 6 
days of transgene expression; however the frequency of cells with HSC surface marker 
phenotype in these mice remained unchanged at this time (Figure 4.8H). It is so far 
unclear whether the absence of HSC depletion in Sox17 transgenic mice was due to the 
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short period of transgene expression (6 days vs. 16-weeks), or due to different levels of 
Sox17 overexpression between these two systems. 
Interestingly, Sox17-overexpressing LSK41- cells expressed higher levels of the 
HSC specific markers Tie-2 and ESAM as compared to the control LSK41- cells (Figure 
4.9C), and they re-expressed the fetal HSC specific markers VE-cadherin and CD93 
(AA4.1) (Figure 4.9C), indicating Sox17 overexpression was sufficient to upregulate 
certain fetal and/or HSC specific markers on adult hematopoietic progenitor cells. 
To directly address the question of whether the expanded LSK48+41- cell 
population in Sox17-overexpressing cell recipients contained HSC activity, we 
transplanted 200,000 control or Sox17-overexpressing whole bone marrow cells or 50 
purified GFP+ Sox17-overexpressing LSK48+41- cells from primary recipients into 
lethally irradiated secondary recipients together with 200,000 cells for radioprotection. 
The vast majority of recipients that received 50 GFP+ Sox17-overexpressing LSK48+41- 
cells contained variable levels of long-term myeloid (14/15 recipients) and/or erythroid 
(14/15 recipients) donor cell reconstitution at 16- week post transplantation (Figure 
4.10B, C), suggesting the Sox17-overexpressing LSK48+41- cells possessed long-term 
reconstituting potential. This result raised two possibilities. One was that Sox17 
overexpression was sufficient to confer self-renewal potential to adult bone marrow 
LSK48+41- cells. The other suggested Sox17-overexpressing bone marrow HSCs might 
simply have changed their surface phenotype to express CD48. 
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Overexpression of Sox17 in purified short-term adult hematopoietic progenitors is 
sufficient to confer long-term self-renewal potential 
To test whether overexpression of Sox17 in purified adult bone marrow short-term 
hematopoietic progenitor cells can directly confer long-term self-renewal potential, we 
infected adult bone marrow multipotent progenitors (MPPs, Lin-Sca-1+cKit+CD150-
CD48-CD41-), LSKCD48+CD41- cells (LSK48+41-), granulocyte-monocyte progenitors 
(GMPs, Lin-Sca-1-cKit+CD41-FcγR+) and megakaryocytic-erythroid progenitors (Pre-
MegEs, Lin-Sca-1-cKit+CD41-CD150+CD105-) with MSCV-GFP or MSCV-Sox17 virus 
and tested their self-renewal potential in long-term reconstitution assays. Bone marrow 
HSCs were also infected in parallel to serve as a positive control (see Figure 4.11 for 
sorting strategy and the rate of retroviral infection for each population). HSCs, MPPs and 
LSK48+41- cells together comprise the undifferentiated LSK cell population. We have 
previously shown that MPPs are capable of short-term (up to 8 week) multilineage 
reconstitution but lack HSC activity (Kiel et al., 2005b; Kiel et al., 2008).  
In this study, we experimentally determined the developmental potential of adult 
bone marrow LSK48+41- cells by transplanting 100, 500 or 2500 double sorted cells from 
UBC-GFP mice (CD45.2) into 600rad sublethally irradiated CD45.1 recipients and 
monitoring their peripheral blood reconstitution for up to 16 weeks. On the population 
level, adult LSK48+41- cells were capable of multilineage reconstitution similar to MPPs, 
however their myeloid and platelet reconstitution only lasted for 3 weeks, indicating they 
were less primitive than, and likely downstream of, MPPs (Figure 4.12). GMPs and pre-
MegEs are both bi-potent short-term progenitors downstream of LSK cells, which are 
164 
 
specific for the monocytic-granulocytic and megakaryocytic-erythroid lineage 
respectively (Akashi et al., 2000; Pronk et al., 2007). 
Transplantation of 500 to 2000 control virus infected MPPs or LSK48+41- cells 
failed to generate significant myeloid reconstitution in any recipients at 16 weeks post 
transplantation (0 of 13 and 0 of 20 respectively, Figure 4.13 A-C). Similarly, only one 
recipient of control virus infected MPPs showed a low level of long-term erythroid 
reconstitution (1 of 13, Figure 4.13B, C) while control virus infected LSK48+41- cells 
gave no long-term erythroid reconstitution (0 of 20, Figure 4.13A, C). In contrast, 5 of 15 
recipients of Sox17 virus infected MPPs and 3 of 22 recipients of Sox17 virus infected 
LSK48+41- cells showed variable levels of myeloid reconstitution at 16 weeks post 
transplantation, and 6 of 15 recipients of Sox17 virus infected MPPs and 9 of 22 
recipients of Sox17-virus infected LSK48+41- cells exhibited robust long-term erythroid 
reconstitution (Figure 4.13A-C). These data indicated that Sox17 overexpression in some 
types of short-term progenitors such as MPPs and LSK48+41- cells could indeed confer 
long-term reconstitution potential. On the other hand, we have so far been unable to 
confer long-term reconstitution potential to more differentiated progenitors, such as 
GMPs and Pre-MegEs by overexpression of Sox17 (Figure 4.14B, C). One possibility is 
that there are intrinsic differences among different progenitors that determine whether 
they can be affected by Sox17 overexpression; another possibility is that the culture 
conditions used during viral infection are suboptimal for these progenitors such that they 




To test whether Sox17 virus infected HSCs, MPPs and LSK48+41- cells resulted 
in a similar or different hematopoietic reconstitution pattern in primary recipients, we 
sacrificed a subset of recipient mice from each group 16 weeks post transplantation and 
examined the lineage composition of donor derived GFP+ cells in bone marrow and 
spleen. Similar to what had been observed in the recipients of Sox17 virus infected whole 
bone marrow cells, we saw a similar expansion of CD41+ megakaryocytic cells in the 
bone marrow and spleen, decreased Gr-1 expression on Mac-1+ myeloid cells, and a 
global depletion of B and T lymphoid cells (Figure 4.15A and data not shown). More 
importantly, we saw a similar expansion of LSK48+41- cells and the depletion of cells 
with adult HSC phenotype in the recipients of all three populations (Figure 4.15B). These 
data indicated that irrespective of the starting population, Sox17 overexpression appeared 
to be able to convert multipotent hematopoietic progenitors into a common type of 
progenitor with fetal characteristics and the capacity to give long-term reconstitution. 
Sox17 overexpression upregulates genes associated with stem cell and fetal 
characteristics. 
To understand what molecular changes took place in the hematopoietic stem 
and/or progenitor cells after Sox17 overexpression, we performed microarray analysis to 
compare the whole genome transcriptome of freshly isolated adult bone marrow 
LSK48+41- cells with Sox17-overexpressing LSK48+41- cells isolated from reconstituted 
primary recipients at 16 weeks post transplantation.  
We first performed gene set enrichment analysis (GSEA) to compare Sox17-
overexpressing and control bone marrow LSK48+41- cells using customized gene sets 
that are specific to adult HSCs (genes that are upregulated at least 2-fold in HSCs as 
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compared to adult bone marrow LSK48+41- cells, p<0.05), differentiating progenitors 
(genes that are upregulated at least 2-fold in adult LSK48+41- cells as compared to HSCs, 
p<0.05), or fetal liver HSCs (genes that are upregulated at least 2 fold in E16.5 fetal liver 
HSCs as compared to adult HSCs), to see whether Sox17 overexpression could lead to 
global changes in gene expression that resemble adult or fetal HSCs. We observed a 
strong correlation between genes that were upregulated after Sox17 overexpression with 
genes that were HSC-specific (Figure 4.16A), as well as a strong correlation between 
genes that were downregulated after Sox17 overexpression with genes that were 
upregulated during HSC differentiation (Figure 4.16B). We also observed a statistically 
significant correlation between genes upregulated by Sox17 overexpression with genes 
that were preferentially expressed by fetal but not adult HSCs (Figure 4.16C). These 
results were supported by repeating the GSEA profiling using independent gene sets 
retrieved from the Broad Institute web site (Figure 4.17A), as well as by detailed analysis 
of the significantly changed genes (fold change>2, p<0.05) after Sox17 overexpression 
(described below).  
In total, we found 376 and 264 genes which were significantly upregulated and 
downregulated as the result of Sox17 overexpression. Within the 376 upregulated genes, 
88 were significantly upregulated in adult HSCs as compared to normal LSK48+41- cells, 
compared to only 7 genes that exhibited the opposite expression pattern (Figure 4.16D). 
On the other hand, while about equal numbers of genes in the upregulated list were 
preferentially expressed by fetal or adult HSCs (27/376 and 31/376 respectively, Figure 
4.16D), detailed examination reveals that the most upregulated genes (fold change >5, 78 
total) tended to be more enriched in fetal HSCs (16/78, Figure 4.16D) rather than adult 
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HSCs (4/78, Figure 4.16D). These highly upregulated genes included the known fetal 
HSC specific marker VE-cadherin (Figure 4.16E). Within the 264 significantly down 
regulated genes, 112 genes were downregulated in HSCs as compared with LSK48+41- 
cells while only 12 genes were preferentially expressed by HSCs. Meanwhile, of the 33 
top downregulated genes (fold change >5), more were enriched in adult HSCs (12/33) as 
compared to fetal HSCs (4/33, Figure 4.16D). Together, these data indicate that Sox17 
overexpression upregulated stem cell and fetal specific gene expression, while 
suppressing genes that are associated with differentiation. However, it is important to 
note that Sox17 overexpression did not fully convert adult progenitor cells into HSCs, or 
completely convert adult progenitors into a fetal phenotype. GSEA profiling comparing 
Sox17-overexpressing LSK48+41- cells with adult HSCs showed that Sox17-
overexpressing LSK48+41- cells still expressed overall higher levels of differentiation-
associated genes (Figure 4.17B), and lower levels of HSC specific genes (Figure 4.17B) 
than bone marrow HSCs. This was also supported by principle component analysis 
comparing Sox17-overexpressing LSK48+41- cells to wild type fetal and adult HSCs or 
LSK48+41- cells. 
In order to identify which gene(s) may be contributing to the observed phenotype 
after Sox17 overexpression, we screened the significantly changed gene list for known 
regulators of HSCs function or lineage differentiation. Expression of Mpl, Evi-1, Gata-2, 
Pbx-1, Egr-1 and Mllt-3 were found to be significantly elevated after Sox17 
overexpression by both microarray and qRT-PCR (Figure 4.16E), all of which are known 
to be essential positive regulators of HSC maintenance (Alexander et al., 1996; Dobson et 
al., 1999; Ficara et al., 2008; Goyama et al., 2008; Kimura et al., 1998; Min et al., 2008; 
168 
 
Pina et al., 2008; Tsai et al., 1994). Therefore the upregulation of these genes may 
explain the enhanced self-renewal potential of Sox17-overexpressing cells. In contrast, 
many significantly downregulated genes after Sox17 overexpression, including Rag1, 
Rag2, Dntt, Ltb, Blnk and Satb1 (Alimzhanov et al., 1997; Alvarez et al., 2000; Gilfillan 
et al., 1993; Jumaa et al., 1999; Komori et al., 1993; Koni et al., 1997; Mombaerts et al., 
1992; Pappu et al., 1999; Shinkai et al., 1992), are essential for lymphoid differentiation. 
This may explain the defective lymphopoiesis by Sox17-overexpressing cells. 
Long-term Sox17 overexpression leads to development of non-lymphoid leukemia 
Given the ability of Sox17 to enhance the self-renewal potential of HSCs and 
confer long-term reconstituting potential to MPPs and LSk48+41- cells, we wanted to test 
whether long-term overexpression of Sox17 would lead to the development of 
hematopoietic neoplasms. All primary recipients of MSCV-Sox17 and MSCV-Sox17his 
virus infected whole bone marrow cells died between 28 and 374 days with features of 
leukemia (see below), with a median survival time of 171 days after transplantation for 
MSCV-Sox17 virus recipients, and 303 days after transplantation for MSCV-Sox17his 
recipients (Figure 4.18A). In contrast, none of the recipients reconstituted with control 
virus infected bone marrow cells died from leukemia up to 490 days after transplantation. 
Importantly, when we transplanted whole bone marrow cells isolated from moribund 
Sox17-overexpressing primary recipients into lethally irradiated secondary recipients, all 
secondary recipients died between 23 and 99 days after transplantation, with a median 
survival of 59 days for MSCV-Sox17 secondary recipients and 41 days for MSCV-




In order to identify what type of hematopoietic neoplasm developed after long-
term Sox17 overexpression, we performed hematological and pathological evaluation of 
hematopoietic tissues isolated from moribund primary recipients. At the onset of the 
disease, all affected primary recipients exhibited thrombocytopenia, anemia and/or 
leukocytosis in peripheral blood, as well as pronounced splenomegaly and/or 
hepatomegaly. Extensive infiltration of undifferentiated blast cells could be identified in 
bone marrow, spleen, and liver of the affected mice and sometimes also in lung and 
lymph nodes, resulting in complete disruption of normal tissue architecture (Figure 
4.18C, E). Immunohistochemical staining of paraffin embedded tissue sections showed 
the blast cells did not expresses the myeloid cell marker Mac-1 or the lymphoid marker 
CD3 (data not shown), but expressed the megakaryocyte lineage marker Von Willebrand 
factor (Vwf+, Figure 4.18D). No blast cells were found to express the erythroid marker 
Ter119 (data not shown), the total amount of erythroid cells at various stages of 
differentiation identifiable by histology were nonetheless greatly increased in spleen and 
liver tissue sections, indicating an expansion of erythroid cells in these tissues (Figure 
4.18C). Consistent with these findings, flow cytometry revealed the frequency of CD41+ 
megakaryocytes and/or Ter119+ erythroid cells were greatly expanded in the bone 
marrow, spleen and/or liver of the affected animals despite (data not shown). In addition, 
freshly isolated GFP+CD41+ cells showed similar morphology to the blast cells, and 
expressed Vwf (Figure 4.18E, F), indicating they are likely the observed leukemic blast 
cells found in both tissue sections and cytospin samples. 
Together, these data suggested the pathological conditions developed after long-
term Sox17 overexpression were most consistent with the features of nonlymphoid 
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leukemia with features of megakaryocytic and/or erythroid differentiation as defined in 
the Bethesda proposals for classification of murine hematopoietic neoplasms (Kogan et 
al., 2002). This indicates that Sox17, like many self-renewal genes, can act as an 
oncogene when overexpressed in adult hematopoietic cells. 
 
DISCUSSION 
In this study, we have shown that Sox17 expression is restricted to fetal liver HSC 
and early hematopoietic progenitors during mouse hematopoietic system development, 
and its expression declines with differentiation and with developmental time (Figure 4.1). 
Using a retroviral overexpression system, we examined the effect of Sox17 
overexpression on adult bone marrow hematopoietic cells. Sox17 overexpression was 
sufficient to enhance the long-term reconstitution potential of adult bone marrow cells 
(Figure 4.3) which acted at least partially by enhancing the self-renewal potential of 
HSCs and conferring self-renewal capacity to certain early hematopoietic progenitors 
(Figure 4.13 and Figure 4.14). Sox17 also altered their lineage differentiation pattern, 
which was characterized by augmented erythroid, megakaryocytic and/or myeloid cell 
production at the expense of lymphoid differentiation (Figure 4.6), and production of 
myeloid cells and platelets possessing fetal characteristics (Figure 4.5&4.7). Overall, 
Sox17 overexpression caused a striking resemblance to fetal liver hematopoiesis. In 
addition, phenotypic and global gene expression analysis of Sox17-overexpressing 
hematopoietic progenitors revealed upregulation of fetal HSCs specific gene expression 
(Figure 4.9 and Figure 4.16), indicating Sox17 overexpression was sufficient to confer at 
least some fetal characteristics to adult hematopoietic cells. Together, our data suggest 
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Sox17 is a critical regulator of HSC temporal identity, making it the only gene known to 
date that controls the distinction between fetal and adult HSC identity.  
Interestingly, long-term overexpression of Sox17 in adult hematopoietic 
progenitor cells led to the development of lethal, transplantable, nonlymphoid leukemias, 
emphasizing the importance of terminating the fetal transcriptional program during adult 
development, as well as pointing to Sox17 as a potential oncogene involved in 
hematopoietic neoplasm development. 
The observation that endogenous Sox17 expression in fetal liver HSCs declines 
with age is intriguing, as it suggests intrinsic changes may already take places in fetal 
liver HSCs before their transition into adult HSCs between 3 to 4 weeks of age after birth 
(Bowie et al., 2007; Bowie et al., 2006). This suggests that either the reduction of Sox17 
expression in fetal liver HSCs does not result in any functional consequences, or there are 
more changes in fetal liver HSCs during late embryonic development than we currently 
appreciate. Interestingly, one study has shown that certain functional changes already 
take place in HSCs before 3 weeks of age, which modifies their ability to generate certain 
types of B cells (Kikuchi and Kondo, 2006). Therefore, it will be interesting to test 
whether the relative changes in Sox17 expression level in fetal HSCs could actually 
control their progressive maturation into adult HSCs. 
Although Sox17 overexpression was capable of conferring certain fetal HSC 
identities including enhanced self-renewal capacity and expression of fetal-specific gene 
and surface markers to adult hematopoietic progenitor cells, it was certainly not sufficient 
to completely convert adult hematopoietic progenitor cells into normal fetal or adult 
HSCs. This was supported by comparing the global gene expression signature between 
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Sox17-overexpressing LSK48+41- cells with wild type fetal/adult HSCs or LSK48+41- 
cells, as Sox17-overexpressing cells expressed a combination of fetal and adult HSC-
specific genes (Figure 4.16). These results indicated Sox17 is not the only gene that 
controls the distinction between fetal and adult HSCs or the differences between fetal and 
adult hematopoiesis. By studying the subset of HSC-specific or fetal HSC-specific genes 
that failed to upregulate after Sox17 overexpression in adult hematopoietic progenitor 
cells, we may gain more insights into the molecular regulation of fetal and/or HSC 
identity. Alternatively, it is also possible that adult hematopoietic stem/progenitor cells 
cannot be fully converted back to their fetal counterparts as limited by epigenetic 
modifications. 
Due to the uncontrolled, ubiquitous expression pattern intrinsic to the retroviral 
overexpression system, it is so far unclear whether the skewed lineage differentiation 
phenotype observed after Sox17 overexpression was due to biased HSC differentiation, or 
changes in the relative proliferation and/or survival of lineage restricted progenitors or 
terminally differentiated cells. It is also unclear whether any of the observed phenotypes 
require continuous Sox17 overexpression in these cells. To answer these questions, we 
need to develop tools to specifically overexpress Sox17 in selected cell populations in a 
temporally controllable fashion. 
Lastly, we observed the development of a rare type of lethal and transplantable 
nonlymphoid leukemia characterized by accumulation of erythroid cells and CD41+Vwf+ 
undifferentiated blast cells in all major hematopoietic organs after long-term Sox17 
overexpression. This resembled human megakaryoblastic leukemia and erythroid 
leukemia. Interestingly, the lineage composition of the donor-derived hematopoietic cells 
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isolated from recipients with leukemia shared strong similarities to donor cells isolated 
from healthy recipients shortly after transplantation, only with a further expansion of 
Ter119+ erythroid and/or CD41+ megakaryocytes. This raised the question of whether the 
appearance of leukemia was just a result of further elevated donor cell reconstitution 
which failed to maintain normal hematopoiesis, or it actually involved secondary genetic 
mutations. Another related question is whether the Sox17 -induced leukemia was 
dependent on continuous Sox17 expression. It will also be interesting to test whether 
dysregulated Sox17 expression is involved in human megakaryocytic or erythroid 
leukemia development. 
 
MATERIALS AND METHODS 
Mice 
C57BL/Ka-Thy-1.1 (CD45.2) and C57BL/Ka-Thy-1.2 (CD45.1) mice were 
housed in the Unit for Laboratory Animal Medicine at the University of Michigan and all 
experiments were performed in accordance with protocols approved by the University 
Committee on the Use and Care of Animals. (tetO)7CMVSox17-IRES-NucEGFP mice 
(Otet-Sox17 mice) on an FVB background were kindly provided by Dr. Whitsett at 
Cincinnati Children's Hospital Medical Center. B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae/J 
mice (Rosa-rtTA mice) and C57BL/6-Tg(UBC-GFP)30Scha/J mice (UBC-GFP mice) 
were purchased from Jackson laboratory. 
Otet-Sox17 mice were crossed with ROSA-rtTA mice to generate doxycycline-
inducible double transgenic mice (Otet-Sox17/Rosa-rtA). Transgene expression was 
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induced by giving 2mg/ml of doxycycline in drinking water starting at 8 week of age. 
Treated mice were analyzed at 2, 4 and 6 days after transgene induction. 
Antibodies and flow cytometry 
All primary antibodies used for flow cytometry were purchased from ebiosciences 
(San Diego, CA), Biolegend (San Diego, CA) or BD biosciences (San Jose, CA) unless 
otherwise indicated. Alexafluor 700 and PE-TexasRed conjugated streptavidin was 
purchased from Invitrogen (Carlsbad, CA), FITC-conjugated streptavidin was purchased 
from Jackson ImmunoResearch Laboratories (West Grove, PA). All flow cytometry was 
performed on a customized FACSAria II three laser, ten color flow cytometer (Becton-
Dickinson, San Jose, California). 
For isolating HSCs and hematopoietic progenitor cells from adult mouse bone 
marrow, bone marrow cells were obtained from both hind limbs, pelvis and vertebrae by 
crushing the bones with a mortar and pestle, then resuspended in ice-cold staining 
medium (1x Hank’s buffered salt solution without calcium or magnesium, supplemented 
with 2% heat-inactivated calf serum (Invitrogen)) and filtered through 40µm nylon mesh 
(Sefar, Depew, NY). Unfractionated bone marrow cells were first enriched by staining 
with APC-Efluor780 conjugated anti-ckit (2B8), followed by incubation with anti-APC 
magnetic beads and magnetic selection by autoMACS (Miltenyi, Auburn, CA). The ckit 
enriched cells were then stained with PE conjugated monoclonal antibodies against CD41 
(ebioMWReg30) and lineage markers (CD2, RM2-5; CD3e, 145-2c11; CD5, 53-7.3; 
CD8a, 53-6.7; B220, RA3-6B2; Gr-1, RB6-8C5; Ter-119 and CD127, A7R34), PE-Cy5 
conjugated anti-CD150 (TC15-12F12.2, Biolegend), PE-Cy7 conjugated anti-Sca-1 (E13-
161.7), Alexafluor 700 conjugated anti-CD16/32 (93), biotin conjugated anti-
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CD105(MJ7/18) and APC-conjugated anti-CD48 (HM48-1). CD105 staining was 
developed with FITC conjugated streptavidin. HSCs and hematopoietic progenitor cells 
were sorted using following phenotypes: HSCs (Lineage-cKit+Sca-1+CD150+CD48-
CD41-), multipotent progenitors (MPPs; Lineage-Sca-1-cKit+CD150-CD48-CD41-)(Kiel 
et al., 2005b), LSK48+41- cells (Lineage-Sca-1+cKit+CD48+CD41-), 
granulocyte/macrophage progenitors (GMPs; Lineage-cKit+Sca-1-CD41-CD16/32+) and 
megakaryocyte/erythroid progenitors (Pre-MegE; Lineage-cKit+Sca-1-CD41-CD16/32-
CD150+CD105-) (Pronk et al., 2007). Cells were resuspended in 2 μg/ml DAPI to 
discriminate live from dead cells by flow-cytometry.  
To assess the lineage differentiation potential of GFP+ donor-derived cells in 
primary and secondary recipients, a single cell suspension of flushed bone marrow cells, 
splenocytes and thymocytes was prepared as previously described (Yilmaz et al., 2006). 
Unfractionated cells were stained with antibodies specific for myeloid cells (Mac-1 
(M1/70-APC), Gr-1 (RB6-8C5-PE/Cy7) and CD41 (eBioMWReg30-PE)), erythroid cells 
((Ter119-APC and CD71 (R17217-PE)), B cells (B220, (RA3-6B2-PE/Cy5), CD43 (S7-
PE) and sIgM (ll/41-APC)), or T cells (CD3e (145-2c11-APC), CD4 (GK1.5-PE/Cy7) 
and CD8 (53-6.7-PE), together with APC/efluor780 conjugated anti-CD45.1 (A20) and 
alexafluor 700 conjugated anti-CD45.2 (104) to distinguish donor from recipient cells. To 
analyze the frequency of HSCs and LSK41- cells in the GFP+ fraction of recipient bone 
marrow and spleen cells, unfractionated cells were stained with PE conjugated antibodies 
against lineage markers as described above, and antibodies against CD150 (TC15-
12F12.2-PE/Cy5), CD48 (HM48-1-PE/Cy7), ckit (2B8-PE/Alexafluor 610) and Sca-1 
(E13-161.7-APC/Cy7); APC conjugated anti-CD93 (AA4.1), APC conjugated anti-
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ESAM (1G8), or Alexafluor 647 conjugated anti-CD144 (eBioBV13) were sometimes 
included to confirm the increased expression of these markers on Sox17-over-expressing 
cells. 
Generation of MSCV-Sox17 and MSCV-Sox17his virus 
To generate C-terminal 6xhis tagged mouse Sox17, full length mouse Sox17 
cDNA was PCR amplified from mouse brain cDNA. AseI and XhoI sites were added to 
either end and the sequence was inserted into NdeI/XhoI digested pET23b vector (EMD 
chemicals, Gibbstown, NJ) to generate the pET23-mSox17-6xhis vector. Sox17-6xhis 
fragment was then isolated using FspI/BsaAI double digestion and inserted into HpaI 
digested mouse stem cell virus (MSCV) based pMIG (MSCV-GFP) vector (Van Parijs et 
al., 1999), immediately upstream of the internal ribosome entry site (IRES) to generate 
the MSCV-Sox17his vector. The MSCV-Sox17 vector was generated similarly except a 
short linker containing an in-frame stop codon and a FspI site was inserted into pET-23-
mSox17-6xhis vector before the 6xhis tag to generate pET23-mSox17STOP, and a FspI 
fragment containing Sox17 was then inserted into HpaI digested pMIG to generate the 
MSCV-Sox17 vector. 
Preparation of high-titer virus was carried out by transfecting 293T cells with 
control (MSCV-GFP) or Sox17-encoding MSCV vector together with the pCL-Eco 
packaging vector (Naviaux et al., 1996) using standard calcium phosphate methods as 
previously described (He et al., 2009). Cells were allowed to produce virus for 24-48 
hours, then viral supernatants were collected, 0.45 micron filtered, and stored at –80°C. 
Virus titer was determined by infecting 2x105 3T3 cells using 1, 10 or 100 µl of viral 
supernatant. A viral titer of 2-5x106/ml was routinely obtained. 
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Viral infection of whole bone marrow and purified hematopoietic progenitor cells 
For adult whole bone marrow cell infection, 3-5 donor mice (CD45.1) were 
treated with a single injection of 150mg/kg 5-fluorouracil, and bone marrow cells from 
both hind limbs and pelvis bones were harvested on day 4 by flushing. Pooled bone 
marrow cells were first treated with ammonium-chloride potassium red cell lysis buffer to 
enrich for mononuclear cells, then resuspended in pre-stimulation cytokine cocktail (1x 
DMEM supplemented with 15% fetal bovine serum (FBS), 1% penicillin/streptomycin 
(Pen/strep), 100ng/ml stem cell factor (SCF), 10ng/ml interleukin-3 (IL-3), 10ng/ml 
interleukin-6 (IL-6) and 50µM 2-mercaptoethanol (2-ME) at a concentration of 5x106 
cells/ml, and incubated in a 37°C incubator, with 6% CO2 for about 24 hours. Two spin 
infections were performed at 24 and 36 hours post stimulation by adding retrovirus 
supernatant (MOI=2) and 4ng/ml of polybrene to the cell suspension and spinning at 
1300 xg for 90 minutes at room temperature (RT). Cells were harvested 5 hours after the 
second spin, counted and transplanted into lethally irradiated mice at the indicated cell 
dose. 
For infection of purified adult hematopoietic progenitor cells, 500 or 2000 HSCs, 
MPPs, LSK48+41- cells, GMPs or Pre-MegEs were double sorted from untreated adult 
donor mice and deposited into a 96-well round bottom plate containing 100µl of pre-
stimulation cytokine cocktails (base medium: 1x α-MEM + 1% FBS + 1% Pen/strep; 
cytokine supplements for HSC: 50ng/ml SCF + 50ng/ml thrombopoietin (TPO); MPP: 
50ng/ml SCF + 50ng/ml Flt3-ligand + 50ng/ml TPO + 10ng/ml IL-3; LSK48+41- cells 
and GMPs: 100ng/ml SCF + 10ng/ml IL-3 + 10ng/ml IL-6; pre-MegE: 100ng/ml SCF + 
10ng/ml IL-3 + 10ng/ml IL-6 + 2U/ml erythropoietin(EPO)). Viral supernatant was 
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added at 0 and 12 hours (For LSK48+41- cells, GMPs and Pre-MegEs) or 24 and 36 hours 
(for HSCs and MPPs) after culture initiation at MOI=200. Cells from each well were 
harvested 12hours after the second round of viral infection and transplanted into lethally 
irradiated recipients together with 200,000 recipient cells for radioprotection. Viral 
infection efficiency was determined by analyzing cells infected in parallel at 48 hours 
after the second round of viral infection. 
Long-term reconstitution assay 
Two to four month old adult recipient mice were irradiated with a Gammacell 40 
Exactor Cesium137 γ-ray source (MDS Nordia, ON, Canada) delivering approximately 
110 rad/min. Lethal irradiation was done by giving two doses of 540 rad, delivered at 
least 2 hr apart, and sublethal irradiation was performed by giving a single dose of 600 
rad.  
For transplantation of virus-infected whole bone marrow or hematopoietic 
stem/progenitor cells (HSPC) into lethally irradiated primary recipients, test cells 
(CD45.1) together with 200,000 (CD45.2) radioprotective whole bone marrow cells were 
resuspended in 100µl of staining medium and injected into the retroorbital venous sinus 
of individual lethally irradiated recipient mice.  
To test the long-term reconstituting potential of Sox17-overexpressing 
hematopoietic progenitors isolated from primary recipients, 50 GFP+ donor LSK48+41- 
cells were double sorted into individual wells of a 96-well plate containing 200,000 
recipient whole bone marrow cells in staining medium. The contents of individual wells 




To test the reconstituting potential of wild type adult bone marrow LSK48+41- 
cells, 100, 500 and 2,500 double sorted LSK48+41- cells from 8-week old UBC-GFP 
mice (CD45.2) were transplanted into sublethally irradiated (600 rads) CD45.1 recipients. 
The use of sublethally irradiated recipients allows monitoring of donor cell engraftment 
as early as one week post transplantation. 
To monitor donor cell engraftment, blood was obtained from the tail veins of 
recipient mice every 1 to 4 weeks for at least 16 weeks after transplantation, blood cells 
were subjected to ammonium-chloride potassium red cell lysis (Morrison and Weissman, 
1994), and stained with directly conjugated antibodies to CD45.2 (104-Alexafluor 700), 
CD45.1 (A20-APC/Efluor 780), B220 (RA3-6B2-PE/Cy5), Mac-1 (M1/70-PE), CD3e 
(145-2c11-APC) and Gr-1 (RB6-8C5-PE/Cy7) to examine GFP+ donor cell chimerism. 
Cytology, histology and immunohistochemistry 
For Wright-Giemsa staining of blood smears, bone marrow, spleen, and liver 
cells, freshly prepared blood smears and cytospun slides were air-dried, fixed in methanol 
for 5 min, stained in Wright-Giemsa staining solution (Sigma, St. Louis, MO) for 2 
minutes, developed in 8.3mM phosphate buffer (pH=6.8) for 2-5 min, dipped 10 times in 
deionized water, dehydrated through an ethanol gradient and mounted in Permount 
(Fisher Scientific, Waltham MA). For peripheral blood reticulocyte staining, fresh whole 
blood was mixed with reticulocyte staining solution (Sigma, St. Louis, MO) at a 1:1 ratio 
and smeared onto microscope slides following standard procedures. Slides were air-dried 
and subjected to Wright-Giemsa staining as described above. 
For histological analysis of hematopoietic tissues from control and Sox17-
overexpressing bone marrow cell recipients, spleen, liver, lung and lymph node samples 
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were fixed in 10% neutral buffered formalin and paraffin embedded. Tibia or sternum 
samples were fixed with 10% neutral buffered formalin, decalcified in 0.5M 
EDTA/1xPBS for 7 days at 4˚C and paraffin embedded. Five micron sections were cut on 
a Leica microtome and stained with hematoxylin and eosin following standard protocols. 
Immunohistochemical staining for Von Willebrand’s Factor (Vwf) on tissue sections was 
performed using a DAKO Autostainer (DAKO, Carpinteria, CA) using DAKO Envision+ 
and diaminobenzadine (DAB) as the chromogen. De-paraffinized sections of formalin 
fixed tissue at 5µm thickness were labeled with rabbit polyclonal anti-Vwf (1:500, 
DAKO) for 60 minutes, after microwave citric acid epitope retrieval. Immunofluorescent 
staining of Vwf on sorted GFP+CD41+ cells was performed by fixing the sorted cells in 
4% paraformaldehyde in 1x phosphate buffered saline (PBS) for 10 min on ice, followed 
by washing three time with 1x PBS and cytospinning onto microscope slides. Rehydrated 
slides were blocked/permeabilized with 1xPBS containing 1% Triton X-100 and 10% 
goat serum. Slides were stained with anti-Vwf (1:500) at 4°C overnight. After washing, 
slides were incubated with secondary antibodies conjugated with AlexaFluor 555 
(Invitrogen) together with DAPI for 1 hour at room temperature. All images were 
collected using an Olympus BX-71 inverted microscope with 20x and 40x dry objectives. 
Histological slides were analyzed by a hematopathologist and classified according to the 
Bethesda protocols for the classification of hematopoietic neoplasms in mice (Kogan et 
al., 2002; Morse et al., 2002). 
Microarray 
Total RNA (~5ng) from 3 independent, freshly isolated aliquots of 10,000 E16.5 
fetal liver HSCs, 10,000 fetal liver LSK48+41- cells, 10,000 adult bone marrow HSCs, 
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10,000 adult bone marrow LSK48+41- cells or 10,000 Sox17-overexpressing LSK48+41- 
cells (Sox17 LSK48+41- ) isolated from primary recipients 12 weeks post transplantation 
of Sox17 virus infected bone marrow cells were extracted using Trizol with 25µg/ml 
linear acrylamide (Ambion, Austin, TX). The extracted RNA (10µl volume) was treated 
with 2 Units of RNase-free recombinant DNase I (Ambion) for 15 min at 25˚C, followed 
by 15 min at 37˚C to remove any contaminating genomic DNA. The DNA-free RNA 
samples were purified using the RNA Clean & Concentrator™-5 from Zymo Research 
(Orange, CA) and eluted in 10µl of nuclease-free water. Purified RNA was reverse 
transcribed and amplified using the WT-Ovation™ Pico RNA Amplification system 
(NuGEN Technologies, San Carlos, CA) following the manufacturer’s instructions. Sense 
strand cDNA was generated using WT-Ovation™ Exon Module (NuGEN), and 
fragmented and labeled using the FL-Ovation™ cDNA Biotin Module V2 (NuGEN). 
2.5µg of labeled cDNA were hybridized to Affymetrix Mouse Gene ST 1.0 microarrays. 
The chips were hybridized and scanned according to the manufacturer's instructions. 
Expression values for all genes were calculated using the robust multi-array average 
(RMA) method (Irizarry et al., 2003). 
For the identification of genes with differential expression levels between groups, 
the raw expression data were analyzed using Expander v5.1 software (Shamir et al., 
2005), and genes with fold changes greater than 2 and p-values less than 0.05 (t-test, 
using log2 transformed expression values) between sample groups were considered to be 
significantly changed. 
For Gene Set Enrichment Analysis (GSEA), normalized expression data were 
assessed by GSEA 2.0.6 software as described (Mootha et al., 2003; Subramanian et al., 
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2005). Gene expression profiles of Sox17-overexpressing LSK48+41- cells and control 
LSK48+41- cells were used as the background data set and the following gene sets were 
used as the foreground: C2-curated gene sets from the Broad Institute, HSC or short-term 
progenitor (LSK48+41- cells) specific gene sets we constructed by comparing adult bone 
marrow HSCs versus bone marrow LSK48+41- cells (p<0.05, fold change >2) and a fetal 
liver HSC specific gene set we constructed by comparing fetal liver HSCs versus adult 
bone marrow HSCs (p<0.05, fold change >2).  
Quantitative RT-PCR 
Quantitative (real-time) RT-PCR was performed as described previously 
(Molofsky et al., 2003). Three replicates of 10,000 Sox17-overexpressing LSK48+41- 
cells from reconstituted primary recipients and control bone marrow LSK48+41- cells 
were sorted into Trizol. RNA was isolated using chloroform extraction and isopropanol 
precipitation. cDNA was made with random primers and SuperScript III reverse 
transcriptase (Invitrogen). Quantitative PCR was performed with cDNA from 100 cell 
equivalents using a SYBR Green Kit and a LightCycler 480 (Roche Applied Science).  
Statistics 
All experiments were performed at least three times and all data are expressed as 
mean ± s.d. Statistical comparisons between samples were performed in Excel using 
Student’s t-test. Unless otherwise indicated, a p-value less than 0.05 was considered 
statistically significant. The survival analysis of primary and secondary recipients was 
performed in Graphpad Prism 5 software, and the p-values for log-rank test between 
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Figure 4.1: Sox17 expression in hematopoietic stem and progenitor cells decreased 
with fetal development and lineage commitment. 
A) A representative histogram showing the Sox17 expression level based on GFP 
fluorescence in Sox17GFP/+ knockin mice at E13.5 and P0 in fetal liver HSCs, LSK150-
48-41- cells, and LSK48+41- cells. B) Quantification of Sox17 expression level in fetal 
liver hematopoietic stem and progenitor cells during development. Sox17 expression 
decreased both with age as well as with degree of differentiation. Green label indicates 
GFP expression was significantly above Sox17+/+ littermate controls; *, significantly 
reduced (p<0.05) when compared with E13.5 counterparts; §, significantly reduced 
(p<0.05) when compared with HSCs from same developmental stage; +, Sox17-GFP 






Figure 4.2: Level of Sox17 overexpression from retroviral infection 
A). Western blotting for Sox17 protein comparing MSCV-GFP, MSCV-Sox17 and 
MSCV-Sox17his virus infected 3T3 cells. Ectopic Sox17 protein expression (46KD) was 
only observed in Sox17 virus infected cells. B). qRT-PCR comparison of Sox17 
expression level in E16.5 fetal liver HSCs versus GFP+ bone marrow cells isolated from 
primary recipients of Sox17 virus infected cells. Sox17 retrovirus infection led to 800 to 




Figure 4.3: Sox17 overexpression enhanced the long-term reconstitution potential of 
adult bone marrow cells and biased their lymphoid versus myeloid lineage output in 
peripheral blood. 
1 million control (MSCV-GFP) or Sox17 (MSCV-Sox17 or MSCV-Sox17his) virus 
infected adult bone marrow cells (CD45.1) were transplanted into 8-week old lethally 
irradiated CD45.2 recipients together with 200,000 CD45.2 bone marrow cells. A-F) At 
16-weeks post transplantation, Sox17-overexpressing bone marrow cells gave rise to 
significantly higher levels of peripheral blood myeloid (Mac-1+ or Gr-1+, A,B), erythroid 
(Ter119+, E) and platelet (CD41+, F) reconstitution as compared to control virus infected 
cells. MSCV-Sox17 but not MSCV-Sox17his virus infected cells also exhibited 
significantly enhanced B-cell (B220+) reconstitution (C). No differences were observed 
in T-cell (CD3+) reconstitution between control or Sox17 virus infected cells (D). N=3 
experiments; n=9-14 recipients per treatment; *, p<0.05; **, p<0.01. G) Quantification of 
primary recipient peripheral blood reconstitution at 16-weeks post-transplantation; 89% 
to 100% of recipients of Sox17-overexpressing cells exhibited long-term myeloid and/or 
erythroid reconstitution, compared to only 36% or 64% of recipients of control virus 
infected cells showed long-term myeloid or erythroid reconstitution. H) Sox17 
overexpression reduced the lymphoid (B220+ or CD3+) versus myeloid (Mac-1+Gr-1+) 
ratio of donor derived GFP+ peripheral blood cells at both 4 and 16 weeks post 









Figure 4.4: Representative flow cytometry plots of primary recipient peripheral 
blood reconstitution at 16 weeks after transplantation. 
A) Representative flow cytometry plots showing GFP+ peripheral blood erythrocytes and 
platelets in control mice or mice reconstituted by Sox17-overexpressing bone marrow 
cells. B) Representative flow cytometry plots showing GFP+ peripheral blood myeloid 
and lymphoid cells in control mice or mice reconstituted by Sox17-overexpressing bone 
marrow cells. Note the decreased Gr-1 expression by Sox17-overexpressing myeloid cells 
and the overall lower expression of GFP by Sox17-overexpressing lymphoid cells. 






Figure 4.5: Sox17 overexpression leads to thrombocytopenia and increased 
peripheral blood reticulocyte count. 
A) CBC analysis of control mice or mice reconstituted by Sox17-overexpressing bone 
marrow cells at 16 weeks post transplantation. Recipients of Sox17-overexpressing cells 
showed a mild reduction in white blood cell (WBC) and erythrocyte (RBC) counts and a 
significant reduction in platelet counts (*, p<0.05; **, p<0.01, n=3 experiments with 8-9 
mice per treatment). B) Representative peripheral blood smears stained with wright-
giemsa or reticulocyte staining showed an increase in reticulocyte counts and a reduction 
of platelet numbers. Note the presence of large reticulated platelets in the Sox17-
overexpressing samples. Black arrow, reticulocytes, black arrowhead, nucleated red 





Figure 4.6: Sox17 overexpression biased hematopoiesis in bone marrow and spleen. 
A) Representative image of spleen and thymus from primary recipients reconstituted with 
control or Sox17 virus infected bone marrow cells at 16-weeks post transplantation. 
Sox17 overexpression led to increased spleen size and decreased thymus size. B) 
Recipients of Sox17-overexpressing cells showed significantly increased spleen weight. 
C) Sox17 overexpression led to slightly decreased bone marrow cellularity (*, p<0.05 for 
MSCV-Sox17 recipients), and a trend toward increased spleen cellularity that was not 
statistically significant. D-G) Representative flow cytometry plots showing the lineage 
composition of GFP+ donor-derived cells in the bone marrow and/or spleen of mice 
reconstituted by control or Sox17 virus infected cells. Sox17 overexpression led to 
decreased Gr-1 expression on bone marrow myeloid cells, increased CD41+ cell 
frequency in bone marrow (D), increased erythroid cell frequency in spleen (E) and 
decreased spleen B and T cell frequency (F, G). H, I) Quantification of lineage 
composition of GFP+ bone marrow and spleen cells in primary recipients. Sox17 
overexpression led to significantly increased CD41+ cells in bone marrow and/or spleen, 
significantly increased erythroid cells (Ter119+) in spleen and a global depletion of 







Figure 4.7: Sox17 overexpression led to changes in bone marrow myeloid and 
megakaryocyte phenotypes that resembled their fetal liver counterparts. 
A) Overall GFP+ donor cell chimerism was comparable between control mice and mice 
reconstituted by Sox17-overexpressing cells, with a trend towards higher reconstitution 
level by the Sox17-overexpressing cells. B) Sox17 overexpression led to downregulation 
of Gr-1 expression on bone marrow myeloid cells, and expansion of ckit+CD41+ 
megakaryocyte lineage cells, both of which showed a striking similarity to their 
counterparts in E12 fetal liver.
 
Figure 4.8: Sox17 transgene expression led to a similar phenotype as observed in 
recipients of Sox17 virus infected bone marrow cells. 
A) Thymus cellularity in Sox17-transgenic mice was significantly reduced after 4 days of 
doxycycline administration as compared to littermate controls. In contrast, bone marrow 
and spleen cellularities were not significantly affected. B) Induction of Sox17 transgene 
expression led to a progressive reduction of thymus and spleen weight in Sox17 
transgenic mice. C) Peripheral blood neurophil counts were significantly increased as a 
result of transgene expression, and platelet number was significantly reduced. As a result, 
the peripheral blood lymphocyte versus myeloid cell ratio was significantly reduced (D). 
E, F) Sox17 transgene expression led to a progressive increase of myeloid cells in the 
bone marrow and spleen, and depletion of both mature and immature B cells in the bone 
marrow. No consistent changes in the frequency of bone marrow and/or spleen erythroid, 
megakaryocyte or T-lymphoid cells were observed at the three time points tested so far. 
G) Sox17 transgene expression led to depletion of thymic CD4+CD8+ double positive T-
cells and increases in the relative frequency of single positive T cells 6 days after 
induction. H) The frequency of LSK41- cells but not HSCs was significantly increased in 
the bone marrow and spleen of Sox17 transgenic mice after transgene induction. *, 







Figure 4.9: Sox17 overexpression led to expansion of hematopoietic progenitor cells 
and fetal HSC specific marker expression.  
A). Representative flow cytometry plots of GFP+ donor-derived bone marrow cells in 
primary recipients showing expansion of LSK41- hematopoietic progenitors and 
depletion of HSCs as the result of Sox17 overexpression. B) The frequency of 
GFP+LSK41- cells was significantly increased in the bone marrow and/or spleen of 
recipients of Sox17-overexpressing cells, while GFP+ HSC frequency was reduced. *, 
p<0.05; N=5-7 experiments. C) Sox17-overexpressing LSK41- cells upregulated the 






Figure 4.10: Sox17-overexpressing LSK48+41- cells from primary recipients were 
capable of long-term erythroid and/or myeloid reconstitution. 
A). Schema for secondary transplantation of Sox17-overexpressing whole bone marrow 
or GFP+LSK48+41- cells. B). 50 GFP+LSK48+41- cells from primary recipients of Sox17 
virus infected bone marrow cells were transplanted into lethally irradiated secondary 
recipients together with 200,000 radioprotective recipient cells. At 16 weeks post 
transplantation, GFP+ myeloid (Mac-1+ or Gr-1+), erythroid (Ter119+) and platelet 
(CD41+) reconstitution were detected in the peripheral blood of 15/15, 14/15, and 9/15 of 
secondary recipients, respectively (see panel B). In contrast, only 1 recipient showed 
clear long-term lymphoid reconstitution. C) Quantification of peripheral blood 
reconstitution at 16 weeks post transplantation of either 50 Sox17-overexpressing 
GFP+LSK48+41- cells or 200,000 control or Sox17-overexpressing whole bone marrow 





Figure 4.11: Sorting strategy for isolation of adult hematopoietic stem and 
progenitor cells for virus infection and viral infection efficiency. 
A-E) Sorting strategy for isolation of adult bone marrow HSCs, MPPs, LSK48+41- cells, 
GMPs and Pre-MegE cells. B) Viral infection efficiency of cultured adult hematopoietic 






Figure 4.12: Adult bone marrow LSK48+41- cells possessed only short-term 
multilineage reconstituting potential. 
100, 500 or 2000 adult bone marrow LSK48+41- cells from UBC-GFP mice were 
transplanted into 600 rad sublethally irradiated recipients, and peripheral blood GFP+ cell 
chimerism was monitored up to 16 weeks. Adult LSK48+41- cells were only capable of 
transient myeloid (peaks at week 2, disappears after week 4), erythroid (peaks at week 3, 
disappears after week 8) and platelet (peaks at week 2, disappears after week 4) 
reconstitution similar to MPPs, but were more temporally limited.
 
Figure 4.13: Overexpression of Sox17 in transiently-reconstituting adult 
hematopoietic progenitors conferred long-term reconstituting potential. 
A) Schema for transplantation of control or Sox17 virus infected purified adult HSCs and 
progenitor cells. B) 500 or 2000 LSK48+41- adult bone marrow cells were infected with 
MSCV-GFP or MSCV-Sox17 virus, and transplanted into irradiated recipients together 
with 200,000 recipient cells for radioprotection. At 16 weeks post transplantation, 3 of 22 
and 9 of 22 recipients of Sox17 virus infected cells exhibited long-term myeloid and 
erythroid reconstitution, respectively. In contrast, no recipients of control virus infected 
cells exhibited any type of long-term reconstitution. C). 500 adult bone marrow MPPs 
(LSK150-48-41-) were infected with control or Sox17 virus and transplanted into lethally 
irradiated recipients with 200,000 recipient cells. At 16 weeks post transplantation, 5 of 
15 and 6 of 15 recipients of Sox17 virus infected cells exhibited long-term myeloid and 
erythroid reconstitution, respectively, while only 1 recipient of control virus infected cell 
had long-term erythroid reconstitution. D) Peripheral blood reconstitution patterns at 16 









Figure 4.14: Sox17 overexpression did not enhance the long-term reconstituting 
potential of adult GMPs or Pre-MegE progenitors. 
A) 500 control or Sox17 virus infected bone marrow HSCs were transplanted into 
lethally irradiated recipients together with 200,000 recipient cells. Sox17-overexpressing 
HSCs showed significantly enhanced long-term erythroid and myeloid reconstitution as 
compared to control virus infected cells, which only exhibited significant levels of 
lymphoid reconstitution at 16 weeks post transplantation. B, C) 500 control or Sox17 
virus infected bone marrow GMPs or Pre-MegE progenitors were transplanted into 
lethally irradiated recipients together with 200,000 recipient cells. Neither control nor 
Sox17 virus infected cells gave any level of peripheral blood reconstitution between 4 






Figure 4.15: Sox17 overexpression in purified adult bone marrow HSCs, MPPs and 
LSK48+41- cells resulted in a similar bone marrow reconstitution pattern after 
transplantation. 
A) A similar expansion of donor-derived GFP+CD41+ megakaryocytic cells and 
downregulation of Gr-1 on donor derived GFP+ myeloid cells were observed in the 
primary recipients of Sox17 virus infected adult HSCs, MPPs or LSk48+41- cells. B) 
Transplantation of Sox17 virus infected adult HSCs, MPPs or LSk48+41- cells led to a 
similar expansion of donor derived GFP+ LSK41- cells and depletion of cells with an 
HSC phenotype.
 
Figure 4.16: Sox17 overexpression increased the expression of genes associated with 
stem cell and fetal characteristics. 
A-C) Gene set enrichment analysis (GSEA) comparing Sox17-overexpressing (red) 
versus control bone marrow (blue) LSK48+41- cells. Sox17-overexpressing LSK48+41- 
cells showed significantly increased expression of HSC-specific (compared to BM 
LSK48+41- cells) and fetal HSC-specific (compared to BM HSCs) genes (A, C), and 
downregulation of differentiation-associated (LSK48+41- cell specific, compared to 
HSCs) genes (B). NES means normailized enrichment score. D) Comparison of the gene 
expression profiles of Sox17-overexpressing and control bone marrow LSK48+41- cells 
revealed 376 significantly upregulated and 264 significantly down-regulated genes in the 
Sox17-overexpressing cells (fold change >2 and p<0.05). Eighty-eight of the 376 
upregulated genes were preferentially expressed by HSCs (compared to BM LSK48+41- 
cells, fold >2, p<0.05), while 112 of the 264 downregulated genes were preferentially 
expressed by transiently reconstituting LSK48+41- cells (compared to HSCs, fold >2, 
p<0.05). This suggests Sox17 overexpression was associated with increased expression of 
genes preferentially expressed by HSCs and decreased expression of genes associated 
with differentiation/lineage restriction. Sixteen of the 78 highest up-regulated genes 
(fold>5) were preferentially expressed by fetal HSCs (compared to BM HSCs, fold >2, 
p<0.05) while only 4 of the 78 genes were preferentially expressed by adult HSCs 
(compared to fetal HSCs, fold>2, p<0.05); indicating Sox17 overexpression increased the 
expression of certain fetal HSC genes. (*, numbers in parenthesis are number of 
significantly changed genes when using fold change >5 in the Sox17 vs. control 
LSK48+41- cell comparison). E) qRT-PCR verification of selected genes from Sox17-
overexpressing vs. control LSK48+41- cell microarray. Red text indicates fold change 









Figure 4.17: Sox17 overexpression in LSK48+41- cells upregulated HSC specific 
genes and downregulated genes associated with lineage commitment/differentiation. 
A) GSEA profiles comparing Sox17-overexpressing (red) with control bone marrow 
(blue) LSK48+41- cells using C2-curated gene sets from the Broad Institute. Sox17-
overexpressing LSK48+41- cells showed significant enrichment of LT-HSC specific 
genes and depletion of genes expressed by short-term hematopoietic progenitors at 
various stages of differentiation. B). GSEA profiles comparing Sox17-overexpressing 
LSK48+41- cells (red) with control bone marrow HSCs (blue) using customized gene sets 
containing genes preferentially expressed by bone marrow HSCs or LSK48+41- cells. 
Sox17 overexpression did not fully convert LSK48+41- cells to HSCs as some genes that 
are preferentially expressed by HSCs were not upregulated by Sox17-overexpressing 
LSK48+41- cells. C) Principle components analysis of fetal liver HSCs, fetal liver 
LSK48+41- cells, bone marrow HSCs, bone marrow LSK48+41- cells and Sox17-
overexpressing LSK48+41- cells. NES means normalized enrichment score. 
 
 
Figure 4.18: Long-term Sox17 overexpression induces nonlymphoid leukemias. 
A) Kaplan-Meier survival curve of primary recipients that received 1 million control or 
Sox17 virus infected whole bone marrow cells together with 200,000 cells for 
radioprotection (*, p<0.01 versus control, n=15-22 mice per group). B) Kaplan-Meier 
survival curve of secondary recipients that received three million whole bone marrow 
cells from control primary recipients or Sox17 primary recipients that developed 
nonlymphoid leukemia (*, p<0.01 vs. control, n=8-27 mice per group). C). H&E staining 
of representative tissue sections from control primary recipients and primary recipients 
that developed nonlymphoid leukemia. Infiltration of blast cells could be seen in spleen, 
liver and lung, resulting in the disruption of normal tissue architecture. Increased 
numbers of erythroid cells at various stages of differentiation could also be seen in the 
spleen of Sox17-overexpressing cell recipients (inset). D). The infiltrating blast cells in 
the spleen of Sox17-overexpressing bone marrow cell recipients stained positively for 
Von Willebrand factor (Vwf+, brown), suggesting megakaryocyte lineage origin. Only 
resident megakaryoctes and platelets stained positively for Vwf in control spleen 
sections. E) Wright-Giemsa staining of bone marrow, spleen, and/or liver cell cytospin 
samples from Sox17-overexpressing cell recipients showed the presence of leukemic blast 
cells and expanded erythroid cells. F) Sox17-overexpressing GFP+CD41+ cells had a 
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CHAPTER 5  
 
HEMATOPOIETIC STEM CELLS DO NOT ASYMMETRICALLY 
SEGREGATE CHROMOSOMES OR RETAIN BROMO-DEOXYURIDINE1
 
SUMMARY 
Stem cells are proposed to asymmetrically segregate chromosomes during self-
renewing divisions such that older (‘immortal’) DNA strands are retained in daughter 
stem cells while newly-synthesized strands segregate to differentiating cells (Cairns, 
1975; Conboy et al., 2007; Karpowicz et al., 2005; Potten et al., 1978; Shinin et al., 2006; 
Smith, 2005). Stem cells are also proposed to retain DNA labels, like bromo-
deoxyuridine (BrdU), either because they segregate chromosomes asymmetrically or 
because they divide slowly (Cotsarelis et al., 1990; Shinin et al., 2006; Tumbar et al., 
2004; Zhang et al., 2003). However, the purity of stem cells among BrdU label-retaining 
cells has not been documented in any tissue and the ‘immortal strand hypothesis’ has not 
been tested in a system with definitive stem cell markers. We tested these hypotheses in 
hematopoietic stem cells (HSCs), which can be highly purified using well-characterized 
markers. We administered BrdU to newborn, cyclophosphamide/G-CSF mobilized, and 
normal adult mice for 4 to 10 days, followed by 70-days without BrdU. In each case, less 
than 6% of HSCs retained BrdU and less than 0.5% of all BrdU-retaining hematopoietic 
                                                 
1 Originally published in Nature. 2007; 449:238-42 with authors listed as Kiel., M.J., He, S., Ashkenazi, 
R., Gentry, S.N., Teta, M., Kushner, J.A., Jackson, T.L. and Morrison, S.J. 
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cells were HSCs, revealing poor specificity and poor sensitivity as an HSC marker. 
Sequential administration of chloro-deoxyuridine (CldU) and iodo-deoxyuridine (IdU) 
suggested that all HSCs segregate their chromosomes randomly. Division of individual 
HSCs in culture revealed no asymmetric segregation of label. HSCs therefore cannot be 
identified based on BrdU label-retention and do not retain older DNA strands during 
division, indicating these are not general properties of stem cells. 
 
INTRODUCTION 
The ‘immortal strand hypothesis’ was proposed as a mechanism by which stem 
cells could avoid accumulating mutations that arise during DNA replication (Cairns, 
1975). While most cells segregate their chromosomes randomly (Armakolas and Klar, 
2006; Potten et al., 1978), it was argued that adult stem cells in steady-state tissues might 
retain older strands during asymmetric self-renewing divisions, segregating newly-
synthesized strands to daughters fated to differentiate (Figure 5.1a). Evidence has 
supported this model in some epithelial stem cells (Potten et al., 1978), neural stem cells 
(Karpowicz et al., 2005), mammary epithelial progenitors (Smith, 2005), and muscle 
satellite cells (Conboy et al., 2007; Shinin et al., 2006). A related idea is that adult stem 
cells in steady-state tissues might consistently retain DNA labels, either because 
chromosomes segregate randomly but stem cells divide more infrequently than other cells 
(Figure 5.1b) or because the older DNA strand is labeled and segregated asymmetrically 
(Figure 5.1c). Tritiated thymidine (Cotsarelis et al., 1990) or histone (Tumbar et al., 
2004) label-retaining cells from the hair follicle are enriched for epithelial stem cells, 
though purity remains uncertain. Label-retaining cells have also been identified in the 
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hematopoietic system (Arai et al., 2004; Zhang et al., 2003), in mammary epithelium 
(Welm et al., 2002), in intestinal epithelium (Potten et al., 1978; Potten et al., 2002), and 
in the heart (Urbanek et al., 2006), but the purity of stem cells among these label-
retaining cells has not been tested. As a result, it remains uncertain whether label-
retention can identify stem cells with specificity or sensitivity. 
Under steady-state conditions in adult bone marrow, all HSCs divide regularly but 
infrequently (Cheshier et al., 1999a) to sustain hematopoiesis as well as to maintain 
nearly constant numbers of HSCs. As a result of this observation, as well as the 
observation that HSC divisions yield asymmetric outcomes in culture (Takano et al., 
2004), it has been proposed that adult HSCs divide asymmetrically (Takano et al., 2004), 
though the rarity of HSCs in vivo and their relative quiescence has made it impossible to 
confirm this directly. Nonetheless, if BrdU label-retention and/or asymmetric 
chromosome segregation are general properties of adult stem cells, then either or both of 
these characteristics should be evident in HSCs, depending on experimental conditions. 
 
RESULTS AND DISCUSSION 
To test the rate at which HSCs go into cycle we administered BrdU to mice for 1, 
4, or 10 days, then sorted HSCs onto microscope slides and stained with an anti-BrdU 
antibody. HSCs were sorted as CD150+CD48-CD41-lineage-Sca-1+c-kit+ cells (Figure 
5.2a). This population contains all of the detectable HSC activity in bone marrow and 
47% of single cells from this population give long-term multilineage reconstitution in 
irradiated mice (Kiel et al., 2005b). After 1 to 10 days of BrdU, 51 to 94% of whole bone 
marrow cells and 6.5 to 46% of CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs became 
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BrdU+ (Figure 5.2c,d). We calculated the rate at which HSCs went into cycle (Cheshier et 
al., 1999a) as 6.0% per day (Figure 5.2e). Consistent with this, only 3.2% of 
CD150+CD48-CD41-lineage-Sca-1+c-kit+ cells were in S/G2/M phase of the cell cycle at 
any one time (Figure 5.3). These results are similar to a prior study that identified HSCs 
with somewhat different markers (Cheshier et al., 1999a). 
The linearity of BrdU incorporation over time (Figure 5.2e) suggests that most 
HSCs divide at a similar rate. If a minority of HSCs divided more rapidly, significantly 
more than 6.0% of HSCs should have incorporated BrdU after one day; however, we did 
not observe this (Figure 5.2d). If a minority of HSCs were more deeply quiescent than 
most other HSCs, these HSCs should remain BrdU negative even after long periods of 
BrdU. This also has not been observed as more than 99% of HSCs are labeled after six 
months of BrdU (Cheshier et al., 1999a). Therefore, there is no evidence for more rapidly 
dividing or more slowly dividing subsets of long-term self-renewing HSCs under steady-
state conditions, though we cannot exclude the possibility that a minority of HSCs divide 
somewhat more slowly than 6% per day. 
To evaluate BrdU label-retention, we administered BrdU for 10 days, followed by 
a 70 day chase without BrdU, similar to prior studies in the hematopoietic system (Arai et 
al., 2004; Zhang et al., 2003). Given that 6.0% of HSCs entered cycle each day and 46% 
of HSCs were labeled after 10 days of BrdU (Figure 5.2d), we modeled the fraction of 
HSCs that would be expected to retain BrdU over time (Figure 5.4a; see Materials and 
Methods for explanation). 
If HSCs follow the immortal strand model they should lose their BrdU only one 
division after BrdU is discontinued as the labeled chromosomes are segregated to 
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differentiating daughter cells (Figure 5.1a), and only 0.6% of HSCs would be expected to 
retain BrdU after 70 days without BrdU (Figure 5.4a). If HSCs segregate chromosomes 
randomly, then BrdU would be lost stochastically over time and the fraction of BrdU+ 
HSCs after a 70 day chase would depend upon the threshold of BrdU required for 
detection. If the threshold is equivalent to 0.5N labeled chromosomes (one quarter of the 
genome), this level of BrdU dilution could be achieved in cells that had divided 1 or 2 
times after BrdU was discontinued (depending on whether they had divided once or twice 
in the presence of BrdU), and only 1.4% of HSCs would be expected to retain BrdU after 
the 70 day chase (Figure 5.4a). In contrast, if the threshold of detection is equivalent to 
0.0625N labeled chromosomes, this could be achieved on average in cells that had 
divided 4 or 5 times after BrdU was discontinued, and 19.8% of HSCs would be expected 
to retain BrdU after the 70 day chase (Figure 5.4a). These calculations thus predict that 
few (<20%) HSCs should retain BrdU after a 70-day chase, irrespective of how 
chromosomes are segregated. 
To test this we administered BrdU for 10 days then stained whole bone marrow 
cells and CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs after 40, 70, and 120 days of 
chase. After 70 days of chase, 0.4±0.1% of bone marrow cells and 4.6±0.9% of HSCs 
were BrdU+ (Figure 5.4c). This demonstrates, as predicted (Figure 5.4a), that few HSCs 
retain BrdU. Moreover, only 2.0±1.0% of HSCs were BrdU+ after 120 days of chase, 
demonstrating that the frequency of BrdU-retaining HSCs continues to decline over time 
rather than identifying a deeply quiescent subset of HSCs that retains BrdU indefinitely. 
Although BrdU label-retaining cells were 10-fold enriched in the HSCs, the rarity of 
HSCs means that only 0.08% of BrdU+ bone marrow cells were HSCs (0.0066% x 
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4.6%/0.4%). BrdU label-retention is therefore a very insensitive and non-specific marker 
of HSCs as the vast majority of HSCs did not retain detectable BrdU, and only rare BrdU 
label-retaining cells were HSCs. Very similar results were obtained when we used flow-
cytometry to detect BrdU incorporation (Figure 5.5) or when HSCs were isolated using 
different surface markers (c-kit+Flk-2-lineage-Sca-1+ cells; Figure 5.6). These data are 
most consistent with random chromosome segregation by HSCs and the failure to detect 
BrdU after approximately 3 divisions in the absence of BrdU (Figure 5.4a). 
According to the immortal strand model, stem cells can incorporate BrdU into 
DNA strands that become the ‘older’ strands during symmetric cell divisions and these 
labeled DNA strands would be retained indefinitely by stem cells that resume asymmetric 
divisions (Figure 5.1c). To test this, we administered BrdU to newborn mice for 10 days 
or to cyclophosphamide/G-CSF treated mice for 4 days. The absolute number of HSCs 
expands dramatically in both newborn (Bowie et al., 2006) and cyclophosphamide/G-
CSF mobilized mice (Morrison et al., 1997b) (indicating symmetric divisions), before 
stabilizing to steady-state levels as mice enter adulthood or G-CSF is discontinued. After 
10 days of BrdU in neonatal mice, 93±3.7% of bone marrow cells and 80±11% of 
CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs were BrdU+. Seventy days later, 0.1% of 
bone marrow cells and 6.4±2.5% of CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs were 
BrdU+ (Figure 5.4d). After 4 days of BrdU in mobilized mice, 94±3% of CD150+CD48-
CD41-lineage-Sca-1+c-kit+ HSCs were BrdU+. Seventy days later, 0.1% of bone marrow 
cells and 2.1±1.1% of CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs were BrdU+ 
(Figure 5.4d). Thus even when BrdU was administered to symmetrically dividing HSCs, 
only 2 to 6% of HSCs retained the label and only 0.2% to 0.4% of BrdU-retaining bone 
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marrow cells were HSCs. We were unable to identify any context in which BrdU label-
retention identified HSCs with sensitivity or specificity, and none of these results were 
consistent with the immortal strand hypothesis. 
To address the possibility that the HSCs in the above experiments might have 
continued to divide symmetrically after BrdU was discontinued we also administered 
BrdU to mice from 20 to 29 days postnatally. HSCs are thought to transition from rapidly 
dividing cells with a fetal phenotype to relatively quiescent cells with an adult phenotype 
between 21 and 28 days postnatally (Bowie et al., 2006). We obtained similar results with 
only 6.5±1.1% of HSCs retaining BrdU after a 70-day chase. There was therefore no 
period during neonatal development when BrdU could be administered in a way that 
resulted in retention within significant numbers of HSCs. 
To test the immortal strand model directly, we treated mice with 10 days of CldU 
then 10 days of IdU. If HSCs segregate older and younger DNA strands asymmetrically, 
then HSCs should rarely incorporate both CldU and IdU under steady-state conditions 
because newly synthesized (labeled) DNA strands should be segregated to differentiating 
daughter cells after each division (Figure 5.7a). In contrast, if HSCs segregate older and 
younger DNA strands randomly then CldU-labeled HSCs should have the same chance of 
incorporating IdU as unlabeled cells and approximately 25% (50% x 50%) of HSCs 
should be double labeled (Figure 5.7b). 
After 10 days of CldU followed by 10 to 11 days of IdU we observed that 14% of 
HSCs incorporated only CldU, 32% of HSCs incorporated only IdU, and 27% of HSCs 
incorporated both CldU and IdU (Figure 5.7c; Figure 5.8). The frequency of CldU+IdU+ 
cells (27%) was therefore similar to the product of the frequencies of total CldU+ cells 
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and total IdU+ cells (41% x 59%=24%) indicating that CldU+ cells had a similar 
probability of incorporating IdU as other cells. We repeated this experiment by 
administering CldU to mice for 60 days followed by 15 days of IdU, and found the 
frequency of CldU+IdU+ cells (63%) was again similar to the product of the frequencies 
of total CldU+ cells and total IdU+ cells (73% x 84%=61%). These results were not 
significantly affected by a slow clearance of CldU from mice, as CldU was cleared in less 
than 1 day after being discontinued from the drinking water (Figure 5.9). These 
observations directly contradict a key prediction made by the immortal strand hypothesis 
but are as would be expected by random chromosome segregation. 
The foregoing experiments left the formal possibility that if HSCs divide by a 
combination of symmetric and asymmetric divisions in vivo we might underestimate the 
frequency of HSCs that retain older DNA strands. To address this we examined the 
division of individual HSCs in culture that were isolated from mice treated for 10 days 
with BrdU. Single CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs were sorted into 
cultures under conditions in which half of HSC divisions give asymmetric outcomes 
(daughter cells with different developmental potentials) (Takano et al., 2004). After 2 to 3 
days of culture we observed a total of 346 colonies in which HSCs had divided once (2 
daughter cells) or twice (3 or 4 daughter cells). Either all daughter cells were BrdU+ (162 
colonies; 46%) or all daughter cells were BrdU- (184 colonies) (Figure 5.7f) as would be 
expected by random chromosome segregation given that 46% of HSCs incorporate BrdU 
in vivo after 10 days (Figure 5.2d). We observed no colonies after 1 or 2 rounds of 
division that contained a mixture of BrdU+ and BrdU- cells. These in vitro experiments 
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on individual HSCs thus failed to detect any asymmetric segregation of labeled 
chromosomes. 
Our results were not confounded by effects of BrdU/CldU/IdU on HSC 
proliferation, survival, or DNA repair. The cell cycle status (Figure 5.3) and frequency 
(data not shown) of HSCs was not affected by these treatments. BrdU/CldU/IdU 
incorporation from DNA repair was not detectable (Figure 5.3). 
Our results indicate that BrdU label-retention is neither a sensitive nor a specific 
marker of HSCs. Nonetheless BrdU label-retention could be a better marker of stem cells 
in other tissues. Moreover, histone-GFP (Tumbar et al., 2004) may do a better job of 
marking stem cells, including HSCs, because it can be selectively expressed in subsets of 
progenitors and may be retained with different kinetics than BrdU. Our data demonstrate 
the need to test the sensitivity and specificity of BrdU and other label-retention markers 
before assuming they mark stem cells with fidelity. 
Our data also demonstrate that the immortal strand model (Cairns, 1975) does not 
apply to HSCs and cannot be considered a general model of stem cell division. Our data 
do not address whether stem cells from other tissues asymmetrically segregate 
chromosomes or whether HSCs segregate a limited number of chromosomes 
asymmetrically (Armakolas and Klar, 2006). Nonetheless, asymmetric chromosome 





MATERIALS AND METHORDS 
BrdU/CldU/IdU administration 
All experiments employed C57BL/Ka-CD45.2:Thy-1.1 mice. For experiments in 
adult mice, BrdU (Sigma, St. Louis, MO) was administered when the mice were 8 to 10 
weeks of age. Mice were given an intraperitoneal injection of 100 mg of BrdU/kg of body 
mass in Dulbecco’s phosphate buffered saline (DPBS; Gibco, Carlsbad, CA) and 
maintained on 1 mg/ml of BrdU in the drinking water for 1 to 10 days. Amber bottles 
containing BrdU water were changed every 1 to 3 days. For retention studies, BrdU water 
was replaced with regular water and the mice were maintained for 40 to 120 days before 
analysis. 
BrdU injections into neonatal mice were performed as described (Taylor et al., 
2000). Beginning within 3 days after birth, neonatal mice were injected subcutaneously 
with 50 mg BrdU/kg body weight twice daily for 10 days. Mice were weighed every two 
days and the dose of BrdU was adjusted. 
To assess BrdU retention following cytokine mobilization, adult mice were 
injected with cyclophosphamide (200 mg/kg; Bristol-Myers Squibb, New York) and then 
on each of 4 subsequent days with 250 µg/kg per day of human G-CSF (Amgen, 
Thousand Oaks, CA)(Morrison et al., 1997b). On the fourth day of G-CSF injection, a 
single intraperitoneal injection of 100 mg BrdU/kg of body mass was given and the mice 
were put on 1 mg/ml BrdU water for 4 additional days. The mice were then returned to 
regular water for 70 days before analysis. 
For 5-chloro-2-deoxyuridine (CldU) and 5-iodo-2-deoxyuridine (IdU) 
experiments, mice were given an intraperitoneal injection of 100 mg of CldU/kg of body 
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mass in DPBS and maintained on 1 mg/ml of CldU (Sigma) in the drinking water for 10 
days. Mice were then given an intraperitoneal injection of 100 mg of IdU/kg of body 
mass in DPBS, and switched to 1 mg/ml of IdU (Sigma) in the drinking water for 10 to 
11 days before being sacrificed. 
For details related to the flow-cytometric isolation of HSCs and CldU/IdU/BrdU 
staining see Supplementary Materials. 
BrdU segregation in cultured HSCs 
Single CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs were sorted from BrdU-
treated mice into a V-bottom 96-well plate containing Stempro-34 medium (Invitrogen) 
supplemented with 2 mM L-glutamine, 50 µM 2-mercaptoethanol (Sigma), murine IL-3 
(10 ng/ml), murine SCF (100 ng/ml) and murine Tpo (100 ng/ml; all cytokines from 
R&D Systems) with 10% charcoal absorbed fetal bovine serum (Cocalico Biologicals, 
Inc., Reamstown, PA) and cultured for 2 to 3 days in low oxygen chambers (Morrison et 
al., 2000). For analysis, plates were centrifuged at 500xg for 10 minutes, then cells from 
each colony were pipetted onto individual wells of Teflon printed glass slides and 
allowed to dry overnight prior to staining for BrdU and DAPI. 
Flow-cytometric isolation of HSCs 
Bone marrow cells were flushed from the long bones (tibias and femurs) with 
Hank’s buffered salt solution without calcium or magnesium, supplemented with 2% 
heat-inactivated calf serum (GIBCO, Grand Island, NY; HBSS+). Cells were triturated 
and filtered through nylon screen (45 um, Sefar America, Kansas City, MO) to obtain a 
single cell suspension. For isolation of Flk2-lineage-Sca-1+c-kit+ HSCs, whole bone 
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marrow cells were incubated with PE-conjugated monoclonal antibodies against lineage 
markers including B220 (6B2), CD3 (KT31.1), CD4 (GK1.5), CD8 (53-6.7), Gr-1 (8C5), 
Mac-1 (M1/70), Flk-2 (A2F10.1), Ter119, and IgM in addition to FITC-conjugated anti-
Sca-1 (Ly6A/E) and biotin-conjugated anti-c-kit (2B8) antibodies, followed by 
streptavidin APC-Cy7. For isolation of CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs, 
whole bone marrow cells were incubated with PE-conjugated anti-CD150 (TC15-
12F12.2; BioLegend, San Diego, California), FITC-conjugated anti-CD48 (HM48-1; 
BioLegend), FITC-conjugated anti-CD41 (MWReg30; BD Pharmingen, San Diego, 
California), APC-conjugated anti-Sca-1 (E13-6.7), and biotin-conjugated anti-c-kit (2B8) 
antibody, in addition to FITC-conjugated antibodies against Ter119, B220 (6B2), Gr-1 
(8C5) and CD2 (RM2-5). HSCs were frequently pre-enriched by selecting c-kit+ cells 
using paramagnetic microbeads and autoMACS (Miltenyi Biotec, Auburn, CA). All 
flow-cytometry was performed on a FACSVantage SE-dual laser, three-line flow-
cytometer (Becton-Dickinson). 
BrdU staining 
Staining for BrdU on slides was performed as previously described using an anti-
BrdU antibody (clone BU1/75, Accurate Chemical and Scientific Corp, Westbury, 
NY)(Cheshier et al., 1999a). HSCs were sorted and then resorted (to ensure purity) onto 
glass slides in 25 to 100 cell spots, allowed to dry for 1 hour and stored at –80oC for up to 
4 weeks. Slides were thawed at room temperature for 15 minutes, fixed in 70% ethanol at 
–20°C for 30 minutes, rinsed in 0.1M phosphate buffer (PB) twice, incubated in 2N HCl 
with 0.8% Triton in PB for 30 minutes, incubated in 0.1M Sodium Borate (pH 8.5) for 15 
minutes, then rinsed in 0.1M PB at room temperature, at 37oC, and at room temperature 
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again. The slides were then incubated with 0.3% Triton in 0.1M PB supplemented with 
5% Goat Serum for 1 hour at 4°C. Slides were incubated at 4oC overnight with the 
primary anti-BrdU antibody that specifically recognizes BrdU and CldU but does not 
recognize IdU (clone BU1/75, Accurate Chemical and Scientific Corp.). Slides were then 
rinsed in 0.1M PB twice and incubated with Alexa488-conjugated goat anti-rat IgG 
(Invitrogen-Molecular Probes, Carlsbad, California) for 2 hours at room temperature. 
Slides were rinsed in 0.1M PB twice and incubated with DAPI for 1 hour at room 
temperature. Finally, slides were rinsed three times in 0.1M PB, the excess buffer was 
shaken off and the slides were mounted in 70% glycerol in PBS. Images were gathered 
using an Olympus BX-51 florescence microscope equipped with a Cooke Pixelfly CCD 
camera.  
In some experiments, BrdU incorporation was measured by flow-cytometry using 
an antibody directly conjugated to allophycocyanin (APC; APC BrdU flow kit, BD 
Pharmingen). Sorted samples were fixed and permeablized according to manufacturer’s 
instructions, incubated in 2N HCl for 30 minutes at room temperature, neutralized in 
0.1M Sodium Borate (pH 8.5), washed in 0.5% Triton in DPBS, stained with anti-BrdU 
APC and resuspended in DAPI (10 µg/ml) prior to FACS analysis. All flow-cytometry 
was performed on a FACSVantage SE-dual laser, three-line flow-cytometer (Becton-
Dickinson). 
CldU and IdU double-labeling 
Slides were processed as for BrdU analysis with the addition of a subsequent set 
of staining steps using a second anti-IdU antibody (clone B44, BD Pharmingen) that does 
not recognize CldU. Slides were incubated at room temperature in anti-IdU antibody for 
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2 to 3 hours. Immunofluorescence was developed using a Cy3-conjugated anti-mouse 
IgG secondary antibody with minimal cross reactivity to rat IgG (Jackson 
Immunoresearch). Cells isolated from mice that had only received CldU, or only received 
IdU, or neither were processed in parallel with experimental samples, and demonstrated 
no cross-reactivity or background staining from primary or secondary antibodies. 
Analysis of cell cycle distribution and cell death in HSCs 
Cell cycle distribution was analyzed by Hoechst 33342 (Invitrogen-Molecular 
Probes, Carlsbad, California) staining. CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs 
were sorted and resorted into ice-cold 70% ethanol and stored at –20oC overnight. Cells 
were resuspended in PBS containing 0.02 mg/ml Hoechst 33342, incubated for 30 
minutes and analyzed by flow-cytometry using a UV laser. 
For activated caspase-3 staining, frozen slides bearing sorted CD150+CD48-
CD41-lineage-Sca-1+c-kit+ HSCs or sections through E11 mouse forebrain were thawed 
at room temperature for 10 minutes, fixed at room temperature in 10% buffered neutral 
formalin (VWR, West Chester, Pennsylvania) for 10 minutes, rinsed in 0.1M PB twice, 
and blocked with 0.3% Triton in 0.1M PB supplemented with 5% Goat Serum for 1 hour 
at 4°C. Slides were then incubated with anti-activated caspase-3 antibody (BD 
Pharmingen, San Diego, California) at room temperature for 2 hours. Slides were then 
rinsed in 0.1M PB twice and incubated with Alexa488-conjugated goat anti-rabbit IgG 
(Invitrogen-Molecular Probes, Carlsbad, California) for 1 hour at room temperature. 
Slides were rinsed in 0.1M PB twice and incubated with DAPI for 30 minutes at room 
temperature. Finally, slides were rinsed three times in 0.1M PB, the excess buffer was 
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shaken off and the slides were mounted in 70% glycerol in PBS. Images were collected 
using a florescence microscope. 
To test for the incorporation of BrdU due to DNA repair, BrdU was administered 
to adult mice for 12 hours followed by irradiation with 100 rad from a Gammacell40 
Extractor (MDS Nordion, Ottawa, ON, Canada) followed by 48 hours of further BrdU 
administration. CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs were then sorted onto 
slides and stained for BrdU as described above.  
Mathematical models of BrdU uptake and retention 
To model the uptake and retention of BrdU in a population of stem cells we 
assumed that for days 0 through T the stem cells are exposed to adequate BrdU so that 
cells incorporate BrdU when they divide. Based on our data a random 6.0% of HSCs 
enter cycle each day. At day T, the BrdU supply is removed and the level of BrdU 
incorporated into the chromosomes decreases for every cell division after day T. The rate 
at which BrdU is diluted from cells during this chase period depends upon how the cells 
segregate their chromosomes. If chromosomes segregate randomly, then irrespective of 
whether stem cells divide asymmetrically or symmetrically with respect to daughter cell 
fate, BrdU labeled chromosomes will stochastically become diluted over time: on average 
the BrdU label will be diluted by half during each round of division and multiple 
divisions will be required to dilute the BrdU label to the point that it is no longer 
detectable by immunohistochemistry. This is modeled as case 1 below for asymmetrically 
dividing cells. In contrast, according to the immortal strand model (Cairns, 1975), stem 
cells divide asymmetrically under steady-state conditions and BrdU is preferentially 




differentiating daughter cells with each round of division. Under these assumptions, 
modeled as case 2 below, stem cells retain only the unlabeled older DNA strands once 
BrdU is withdrawn. 
Case 1: Random segregation of chromosomes (see Figure 5.1b) 
BrdU Incorporation: When chromosomes are allowed to segregate randomly, BrdU could 
be incorporated into one or two DNA strands within each chromosome, depending on the 
number of times a stem cell divides during the period of BrdU incorporation and the way 
in which the chromosomes segregate. To model the rate of BrdU incorporation: 
y0 = fraction of cells without BrdU  
y1 = fraction of cells with one strand BrdU+ after only one division  
y2 = fraction of cells with both strands BrdU+ after two or more divisions  
α = the proliferation rate of stem cells (we observed 6.0% of HSCs enter cycle per 
day) 
Note as well that cell death was not incorporated into this model because we did not 
observe significant cell death or changes in HSC frequency during the experiments. 












Equation 1: Cells leave the y0 population when they divide. 
Equation 2: Cells from the y0 population are added into the y1 
population through the incorporation of BrdU into one of the 
DNA strands. Cells leave the y1 population when they divide. 
Equation 3: Cells from the y1 population are added into the y2 




To determine the frequency of BrdU+ stem cells at any time after the addition of BrdU we 
solve the system of ordinary differential equations with all HSCs initially being unlabeled 
prior to BrdU administration. Note that similar equations have previously been used to 
model BrdU incorporation and depletion from other cells (Bonhoeffer et al., 2000). 
 
The process by which cells lose the BrdU label: At day T (when BrdU is removed), we 
determine the total number of BrdU+ stem cells by adding the y1 and y2 populations. Cells 
in the y1 population have a BrdU level of 1, whereas y2 cells have a BrdU level of up to 2. 
To model the rate at which these cells lose BrdU during subsequent divisions after 
removing BrdU: 
 
y10 = fraction of cells, initially with one labeled DNA strand that undergo 0 
divisions after day T  
y11 = fraction of cells, initially with one labeled DNA strand that undergo 1 
division after day T  
… 
y1N = fraction of cells, initially with one labeled DNA strand that undergo N 
divisions after day T 
y20 = fraction of cells, initially with two labeled DNA strands that undergo 0 
divisions after day T  
y21 = fraction of cells, initially with two labeled DNA strands that undergo 1 





y2N=fraction of cells, initially with two labeled DNA strands that undergo N 
divisions after day T 
Cells move from y1(k-1) to y1k at the proliferation rate α (cells move in y2k similarly). The 























With each cell division, the cell's BrdU level is decreased by half. 
For instance, cells in y10 have BrdU level 1, cells in y11 have half 
as much BrdU on average, cells in y12 have one quarter as much 
BrdU on average, etc. Similarly, cells in y20 have BrdU level 2, 
cells in y21 have BrdU level 1, cells in y22 have BrdU level 0.5, 
etc. We can determine the total fraction of cells that have a BrdU 
level that is above a minimum detection level (which can be set at 
any desired level in the simulations) by adding all relevant 
populations at any time after day T.
 
This set of ordinary differential equations is solved for initial conditions that are 
determined by the observed results of the BrdU incorporation at time T. In this way, it is 
possible to plot the frequency of BrdU+ HSCs over time, depending on whether it takes 1, 
2, 3, or 4 rounds of division to dilute BrdU to the point at which it is no longer detectable 
(Figure 5.4a). Note that 1 round of division corresponds to a 2-fold dilution of BrdU 
while 4 rounds of division correspond to 16-fold dilution. Our empirical data suggest that 
approximately 3 rounds of division are required to dilute BrdU to the point that it is no 
longer detectable in HSCs. 
 
Case 2: Asymmetric chromosome segregation (immortal strand model; see Figure 
5.1a) 
BrdU Incorporation: Under this model, only one strand of DNA within each chromosome 
in stem cells can contain BrdU irrespective of how long BrdU is administered (though the 
proportion of labeled stem cells will increase over time). 
The equations for Case 2 are: 
y0 = fraction of cells without BrdU  
y1 = fraction of cells with one strand BrdU+ (after one or more divisions)  
α = proliferation rate of stem cells 








Equation 4: Cells leave the y0 population when they divide. 
Equation 5: Cells from the y0 population are added into the y1 
population through the incorporation of BrdU into one of the DNA 
strands. 
As before, in order to determine the proportion of cells within each population at the end 
of day T we solve the system of ordinary differential equations with initial conditions 
corresponding to the case where initially all HCSs are unlabeled prior to BrdU 
administration. Cells in population y0 do not contain any BrdU, while those in y1 have a 
BrdU level of 1. 
 
The process by which cells lose BrdU label: We take all cells containing BrdU at day T 
(all cells in population y1 and monitor BrdU loss through cell division in the absence of 
BrdU). In this case, the asymmetric segregation of chromosomes means that all dividing 
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stem cells will lose all of the BrdU label in a single division in the absence of BrdU. 
Therefore, the fraction of stem cells that remain BrdU+ at time T, simplifies to the 
fraction of BrdU+ HSCs that do not divide after removing BrdU: 
y10 = fraction of cells, initially with one labeled strand that undergo 0 divisions after 
day T 
Cells move from y10 (and lose their Brdu label) at the proliferation rate α. The equations 




This differential equation with initial condition y10(0) = y1(T) 
determines the fraction of HSCs that retain BrdU over time, 
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Figure 5.1: Contrasting predictions regarding stem cell labeling based on the 
immortal strand model versus random chromosome segregation. 
a) According to the immortal strand model (Cairns, 1975), stem cells divide 
asymmetrically under steady-state conditions and BrdU is incorporated into newly-
synthesized DNA strands that are asymmetrically segregated into differentiating daughter 
cells with each round of division, such that stem cells retain only the unlabeled older 
DNA strands. b) In contrast, if chromosomes segregate randomly, then BrdU labeled 
chromosomes will be stochastically diluted over multiple rounds of divisions. c) By the 
immortal strand model, if stem cells divide symmetrically then BrdU can be incorporated 
into DNA strands that become the ‘older’ strands once stem cells resume asymmetric 
division. Under these circumstances the BrdU+ older strands would be retained 
indefinitely in stem cells. d) In contrast, if chromosome segregation is random then 





Figure 5.2: 6.0% of HSCs stochastically enter cell cycle each day.  
a) HSCs can be isolated by flow-cytometry as CD150+CD48-CD41-lineage-Sca-1+c-kit+ 
cells that represent only 0.0066±0.0003% (0.007% x 94%) of bone marrow cells but 
which contain all detectable HSC activity and which are very highly enriched for HSCs 
(nearly 50% of single cells give long-term multilineage reconstitution in irradiated 
mice(Kiel et al., 2005b)). b) BrdU incorporation into HSCs evaluated by 
immunofluorescence after sorting HSCs onto microscope slides (DAPI is a nuclear stain). 
The percentage of BrdU+ bone marrow cells (c) and CD150+CD48-CD41-lineage-Sca-
1+c-kit+ HSCs (d) after various periods of BrdU administration (3 independent 
experiments with 3 to 4 mice per experiment and 200 to 400 bone marrow cells or 100 to 
400 HSCs counted per mouse). e) The percentage of HSCs that enter cycle each day 
(6.0%) can be derived by plotting the negative logarithm of the percentage of HSCs that 





Figure 5.3: Administration of CldU and IdU does not affect HSC proliferation or 
cell death and BrdU incorporation during DNA repair is negligible. 
a) Cell cycle distribution (based on DNA content) of CD150+CD48-CD41-lineage-Sca-
1+c-kit+ HSCs isolated from a mouse that did not receive CldU or IdU (left) or from a 
mouse that received 4 days of CldU followed by 4 days of IdU (right) (two independent 
experiments). b) Activated caspase-3 staining of CD150+CD48-CD41-lineage-Sca-1+c-
kit+ HSCs sorted onto a microscope slide following 10 days of CldU administration and 
10 days of IdU administration. Arrowheads identify activated caspase-3+ cells in a 
section through embryonic day 11 mouse forebrain (positive control), but no activated 
caspase-3+ HSCs were detected in either CldU/IdU-treated or control mice (200 to 300 
HSCs examined per treatment; two independent experiments). c) BrdU was administered 
for 12 hours followed by gamma irradiation with 100 rad and then 48 hours of further 
BrdU administration. No BrdU+ HSCs were detected in negative control mice (no BrdU). 
Among mice treated with BrdU for 60 hours, 17.4±1.6% of HSCs from non-irradiated 
mice were BrdU+ and 18.6±4.5% of HSCs from irradiated mice were BrdU+ (250 to 600 
HSCs analyzed per treatment; 3 independent experiments). Since DNA damage would be 
expected in all cells that receive this dose of irradiation(Taniguchi et al., 1993), this 
demonstrates that the amount of BrdU that is incorporated as a result of DNA damage 
repair is negligible and cannot be detected by immunofluorescence in these assays. Our 
failure to detect BrdU incorporation from DNA repair is consistent with prior studies that 
found that nucleotide incorporation as a result of DNA repair is negligible relative to 





Figure 5.4: Few HSCs retain BrdU and the vast majority of BrdU-retaining bone 
marrow cells are not HSCs.  
a) Model predicting the fraction of HSCs that retain BrdU over time after administering 
BrdU 10 days, depending on whether chromosomes segregate asymmetrically or 
randomly and on the threshold of BrdU that can be detected by immunofluorescence 
(0.5N, 0.25N, 0.125N, or 0.0625N labeled DNA). b) CD150+CD48-CD41-lineage-Sca-
1+c-kit+ HSCs sorted onto a microscope slide following 10 days BrdU administration and 
70 days chase (without BrdU). Arrowheads identify BrdU+ cells. c) The frequency of 
BrdU+ bone marrow cells and HSCs after 10 days BrdU administration and 40, 70, or 120 
days chase. d) The frequency of BrdU+ bone marrow cells and HSCs after 10 days BrdU 
administration to neonatal mice followed by 70 or 120 days chase; or after 4 days BrdU 
administration to cyclophosphamide/G-CSF treated mice followed by 70 days chase. All 
data are based on 3 to 5 independent experiments with 3 mice per experiment and 400 to 





Figure 5.5: Few HSCs retain BrdU, and the vast majority of BrdU label-retaining 
bone marrow cells are not HSCs even when BrdU incorporation is measured by 
flow-cytometry.  
In case flow-cytometric detection of BrdU was more sensitive than immunofluorescence 
microscopy, we repeated all of the experiments using this approach. The percentage of 
BrdU+ whole bone marrow cells (a) or CD150+CD48-CD41-lineage- HSCs (b) in negative 
control mice (no BrdU), or after 10 days of BrdU administration, or after an additional 70 
days of chase (without BrdU). Note that fewer HSC markers were used to free up a 
fluorescence channel to detect BrdU by flow-cytometry; however, this should not 
introduce significant impurities as 45% of CD150+CD48-CD41- cells give long-term 
multilineage reconstitution in irradiated mice (Kiel et al., 2005b). Only 1.9% of HSCs 
detectably retained BrdU after 70 days chase and less than 0.04% of BrdU+ bone marrow 
cells were HSCs (0.0066% x 1.9%/0.36%). The data are based on 3 independent 
experiments in which 6,000 to 60,000 bone marrow cells or 400 to 1200 HSCs were 




Figure 5.6: HSCs identified as c-kit+Flk-2-lineage-Sca-1+ cells also cannot be reliably 
identified based on BrdU label-retention.  
a) In case the isolation of HSCs using different markers would identify a population that 
is more consistently marked by BrdU label-retention, we isolated c-kit+Flk-2-lineage-Sca-
1+ cells, which represent around 0.02% of bone marrow cells (2.0% x 1.0%; a), and 
which are highly enriched for HSCs (Christensen and Weissman, 2001). b) c-kit+Flk-2-
lineage-Sca-1+ cells were isolated from mice that had been administered BrdU for 10 
days followed by a 70 day chase without BrdU. Cells were sorted onto microscope slides 
and stained with DAPI (to identify nuclei) and BrdU. c) The frequency of BrdU+ c-
kit+Flk-2-lineage-Sca-1+ cells after 10 days of BrdU administration or after an additional 
70 days of chase in normal young adult mice or neonatal mice was very similar to what 
we observed when HSCs were isolated as CD150+CD48-CD41-lineage-Sca-1+c-kit+ cells 
(Figure 5.4c, d). The frequency of BrdU+ c-kit+Flk-2-lineage-Sca-1+ cells after 4 days of 
BrdU administration followed by 70 days of chase in cyclophosphamide/G-CSF treated 
mice was also similar to what we observed in CD150+CD48-CD41-lineage-Sca-1+c-kit+ 
HSCs (Figure 5.4d). Note that these cells were isolated from some of the same mice 
analyzed in Figure 5.4c, d, so the frequency of BrdU+ bone marrow cells from the same 
mice are presented in Figure 5.4c, d. These results were based on two independent 






Figure 5.7: HSCs segregate chromosomes randomly in vivo and in vitro.  
a) By the immortal strand model, stem cells sequentially exposed to CldU (10 days) then 
IdU (10 days) would not incorporate both labels, with the exception of rare cells in 
S/G2/M phase of their first division after switching from CldU into IdU (expected 
frequency <<3%). b) In contrast, if chromosome segregation is random then CldU+ stem 
cells would have the same probability of incorporating IdU as unlabeled cells (expected 
frequency of CldU+IdU+ HSCs approximately 25%). c) CldU was administered to mice 
for 10 days followed by IdU for 10 to 11 days and CD150+CD48-CD41-lineage-Sca-1+c-
kit+ HSCs were stained. d) Examples of HSCs that incorporated neither label, only CldU, 
only IdU, or both labels (data are based on two independent experiments with 2 or 3 mice 
per experiment and 100 to 250 HSCs per mouse). HSCs from BrdU-treated mice divided 
once (d) or twice (e) in culture to form daughter cells. f) The progeny of these HSCs were 
either all BrdU+ or all BrdU-. We detected no clones in which label was asymmetrically 





Figure 5.8: CldU+ and IdU+ cells can be distinguished by antibody staining. 
CldU and IdU staining of CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs from control 
mice that were administered neither label (left column), only CldU (middle column), or 
only IdU (right column). These controls were performed side-by-side with all CldU/IdU 
samples using the same staining conditions. IdU staining was only observed in samples 





Figure 5.9: CldU persists in mice for less than a day after administration is 
discontinued. 
To test whether the CldU/IdU double labeling of HSCs might simply have reflected a 
slow clearance of CldU from mice after its administration was discontinued (such that 
dividing HSCs were inadvertently exposed to both CldU and IdU) we sequentially 
administered CldU and IdU to mice for only 1 day each (a). If significant residual CldU 
remained in the mice for at least a day during IdU administration, all IdU+ HSCs should 
also be CldU+ in this experiment. In contrast, if CldU is cleared from mice within hours 
of being discontinued, then only a minority of IdU+ HSCs should also be CldU+. b) The 
frequency of CD150+CD48-CD41-lineage-Sca-1+c-kit+ HSCs that stained only with CldU, 
or only with IdU, the total frequencies of CldU+ or IdU+ cells, and the frequency of 
CldU+IdU+ HSCs. Nearly two-thirds of IdU+ HSCs (6% IdU-only+ versus 9% total IdU+) 
were able to incorporate IdU without incorporating CldU over this brief period of 
administration, indicating that CldU does not persist in mice for longer than 8 hours after 
administration. The data are based on 3 separate mice analyzed in two independent 
experiments with 162 to 238 HSCs analyzed per mouse. The fact that some residual CldU 
remains in these mice during the first several hours of IdU administration can account for 
the consistent 2 to 3% increase in the frequency of CldU+IdU+ HSCs above that predicted 
by the product of single positive HSCs (27% observed versus 24% predicted with 10 day 
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Extensive self-renewal potential is a defining feature of stem cells, distinguishing 
them from transit amplifying and restricted progenitors. Self-renewal is characterized by 
the cell division that leads to the production of one or two daughter cells that possess a 
developmental potential similar to the mother stem cell. It is essential for the expansion 
of stem cells during development and maintenance of stem cells during homeostasis. 
Regulation of stem cell self-renewal involves precise control of cell cycle progression, 
suppression of premature lineage determination, as well as maintenance of stem cell 
genomic integrity; all of which are subject to both cell intrinsic and cell extrinsic 
regulation. Dysregulation of stem cell self-renewal can result in developmental defects, 
phenotypes that resemble premature aging, and/or the development of neoplasms. 
In my thesis, I have studied the function of two important transcriptional 
regulators, Bmi-1 and Sox17, in regulating the self-renewal of neural stem cells and 
hematopoietic stem cells, respectively; using loss-of-function and gain-of-function 
studies. We have shown that by modulating the activities of factors that regulate stem cell 
cell cycle progression (e.g. Bmi-1) and/or lineage restriction (e.g. Sox17), we can modify 
the self-renewal potential of the respective stem cell population, and/or confer self-
renewal capability to short-term progenitor cells under certain conditions. Lastly, by 
using hematopoietic stem cells as a model, we have shown that immortal strand 
 
segregation is not a universal mechanism through which stem cells preserve their 
genomic integrity. 
 
BMI-1 MAINTAINS STEM CELL SELF-RENEWAL BY SUPPRESSING 
INK4A/ARF 
Bmi-1 is a member of the polycomb family of epigenetic regulators, which 
suppress target gene expression through histone modification and chromatin remodeling. 
We and others had previously shown that Bmi-1 is essential for the postnatal self-renewal 
of stem cells from diverse tissues including the hematopoietic system (Lessard and 
Sauvageau, 2003; Park et al., 2003) and the CNS (Molofsky et al., 2003). Bmi-1 deficient 
mice exhibit a progressive postnatal depletion of stem cells from these tissues, leading to 
hematopoietic failure, defects in cerebellum development, neurological abnormalities, 
and death by early adulthood (Leung et al., 2004; van der Lugt et al., 1994). In Chapter 2, 
we have shown that the depletion of neural stem cells in the absence of Bmi-1 is at least 
partially due to the derepression of the Ink4 locus, which encodes two important negative 
cell cycle regulators: p16Ink4a and p19Arf. Deletion of Ink4a and Arf from Bmi-1 deficient 
mice partially rescues the self-renewal defects of neural stem cells in vivo and in vitro; 
but this is not sufficient to rescue the decreased postnatal survival or growth retardation 
of these mice. This indicates that Bmi-1 regulates adult neural stem cell self-renewal 
mainly by repressing the expression of Ink4a and Arf; but other mechanisms also 
contribute to the developmental defects of Bmi-1 deficient mice (see discussion below). 
Similar results have also been obtained by others (Bruggeman et al., 2005), and has been 
observed in the hematopoietic systems (Oguro et al., 2006; Oguro et al., 2010).  
247 
 
Bmi-1 expression is elevated in a wide range of malignances, and Bmi-1 is 
necessary for the maintenance of cancer stem cells from acute myeloid leukemias 
(Lessard and Sauvageau, 2003) as well as gliomas (Bruggeman et al., 2007). This raises 
the question of whether Bmi-1 overexpression is sufficient to enhance the self-renewal 
potential of existing stem cells and/or confer self-renewal ability to non-self-renewing 
cells, or to induce transformation. Indeed, overexpression of Bmi-1 has been shown to 
enhance the long-term reconstitution potential of adult hematopoietic stem cells in some 
studies (Iwama et al., 2004). In Chapter 3, we tested the consequences of Bmi-1 
overexpression in neural stem cells. Bmi-1 overexpression was sufficient to significantly 
increase stem cell self-renewal, overall proliferation, and neuronal differentiation in vitro, 
but had little effect on SVZ proliferation, adult olfactory bulb neurogenesis, or 
neurogenesis/gliogenesis during development in vivo. Bmi-1 transgenic mice showed 
only a mild increase in neural stem cell frequency with no increase in the total number of 
neural stem cells per mouse. They also exhibited no evidence of tumorigenesis, even 
when aged for more than 20 months. These data demonstrate that Bmi-1 overexpression 
has much more profound effects on CNS stem cell function in culture than in vivo; and 
that Bmi-1 overexpression alone is not sufficient to induce tumorigenesis in the CNS.  
The different ability of Bmi-1 to promote neural stem cell self-renewal in vitro 
versus in vivo is at least partially explained by the differential expression of p16Ink4a and 
p19Arf under these two different conditions. p16Ink4a and p19Arf are not detectably 
expressed by neural stem/progenitor cells in developing or young adult mice (Bruggeman 
et al., 2007; Bruggeman et al., 2005; Molofsky et al., 2005; Molofsky et al., 2003; 
Nishino et al., 2008), but are induced in culture in neural stem cells (Molofsky et al., 
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2003) in response to the stress associated with adaptation to the unphysiological culture 
environment (Lowe and Sherr, 2003; Sherr and DePinho, 2000). Therefore, Bmi-1 
overexpression is able to repress the nonphysiological upregulation of p16Ink4a and p19Arf 
induced by suboptimal culture condition to enhance neural stem cell self-renewal in vitro, 
but has little effect in vivo since p16Ink4a and p19Arf are not normally expressed in vivo. 
This is supported by the observation that Bmi-1 overexpression no longer enhanced self-
renewal, proliferation, or neurogenesis in Ink4a-Arf deficient neural stem cells in culture 
(Chapter 3).  
Together, our data emphasize the importance of precise cell cycle regulation in 
controlling stem cell self-renewal during development and under pathological conditions. 
Our data also point out differences in stem cell self-renewal mechanisms may exist 
between in vivo and in vitro culture systems and that extra caution must be exercised 
when inferring in vivo mechanisms for stem cell self-renewal regulation based on 
observations collected in culture.  
Our data also leave many questions that remain to be answered. One important 
question concerns the mechanisms through which p16Ink4a and p19Arf suppress stem cell 
self-renewal after the loss of Bmi-1. While our data demonstrate that the upregulation of 
p16Ink4a and p19Arf in the absence of Bmi-1 plays a major role in limiting the self-renewal 
potential of Bmi-1-deficient neural stem cells, how this is achieved is still unclear. The 
simplest explanation would be that up-regulation of p16Ink4a and p19Arf in stem cells 
induces cellular senescence or apoptosis which depletes functional stem cells. However, 
we did not observed increased endogenous β-galactosidase staining (indicative of cellular 
senescence) or activated caspase 3 staining (indicative of apoptosis) in the SVZ of Bmi-1 
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deficient animals ((Molofsky et al., 2006) and unpublished observation). It is possible 
that the senescent/apoptotic cells are rapidly cleared by macrophages in vivo, which 
prevent the reliable assessment of these processes in germ-line Bmi-1 deficient animals. 
To overcome this issue, it may be necessary to examine the level of cellular senescence 
and/or apoptosis in the SVZ of Bmi-1 conditional knockout mice shortly after deletion to 
see whether increased apoptosis or senescence can be observed after acute loss of Bmi-1. 
Alternatively, cellular senescence/apoptosis may not play a major role mediating the 
depletion of functional neural stem cells after Bmi-1 deletion.  
Another possibility is that neural stem cells may prematurely differentiate in 
response to elevated p16Ink4a and/or p19Arf expression. Differentiation of many stem cells 
is associated with a progressive lengthening of the cell cycle, especially the G1 phase and 
lengthening of G1 has been proposed to be a cause rather than a consequence of 
differentiation (Orford and Scadden, 2008). In the case of neural stem cells, it has been 
shown that when the G1 phase of the cell cycle is modified by modulating cyclins or 
CDKs, neural stem cells change their behavior with respect to self-renewal versus 
differentiation (reviewed in (Salomoni and Calegari, 2010)). Therefore, it is conceivable 
that upregulation of p16Ink4a and/or p19Arf after Bmi-1 loss would have a similar impact 
on cell cycle progression, which could in turn induce premature differentiation and 
exhaustion of neural stem cells. Future experiments should examine whether acute gain 
of function of p16Ink4a and/or p19Arf could indeed cause premature differentiation of 
neural stem cells in vivo. For these experiments, a conditional Ink4a/Arf-overexpressing 
transgenic mouse model (LoxP-STOP-LoxP upstream of Ink4a and/or Arf) will be 
necessary. This mouse strain should then be crossed with Nestin-CreER and LoxP-EYFP 
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reporter mice and at different time points after tamoxifen administration, the cell type 
composition of EYFP+ cells in the brain of control and transgenic mice should be 
compared to assay for changes in the timing or pattern of neural stem cell differentiation 
in vivo. 
Another important question would be what other target genes beyond Ink4a and 
Arf may act downstream of Bmi-1 to regulate stem cell maintenance. In Chapter 2, we 
have shown that loss of Ink4a and Arf could only partially rescue the self-renewal defects 
of Bmi-1 deficient neural stem cells, which has been confirmed by other groups as well as 
in the hematopoietic system (Bruggeman et al., 2005; Oguro et al., 2006). On the other 
hand, Bmi-1 transgenic mice developed idiopathic hydrocephalus postnatally, while a 
similar phenotype was never observed in Ink4a and Arf single and double mutant mice 
(Chapter 3). All of these data indicate that other genes must act downstream of Bmi-1, 
independent of Ink4a and Arf, to regulate stem cell self-renewal and/or mouse 
development. Hox genes are known targets of Bmi-1 which mediate the skeletal 
development defects observed in Bmi-1 deficient mice (van der Lugt et al., 1996), 
however, it is unclear whether Hox genes are responsible for any of the observed stem 
cell self-renewal defects in the absence of Bmi-1.  
It has been reported that p21cip1 is upregulated in cultured fetal mouse neural stem 
cells when Bmi-1 is acutely knocked down using RNAi, and is responsible for self-
renewal defects in fetal neural stem cells that are not evident in Bmi-1 germ line knockout 
mice (Fasano et al., 2007). Fasano et al. speculated that this was explained by 
compensation in the Bmi-1 germline mutant mice and suggested that conditional deletion 
of Bmi-1 in vivo might reveal a more profound role during fetal development. We have 
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now conditionally deleted Bmi-1 from fetal neural stem cells using Nestin-Cre but we 
still do not observe the defects in neural stem cell function or neural development 
predicted by Fasano et al. (unpublished data). We did observe an upregulation of p21cip1 
in the absence of Bmi-1; however this increase was normalized after deletion of p19Arf, 
indicating p21cip1 acts downstream of p19Arf (Chapter 2). It remains to be tested whether 
the deletion of p21cip1 on top of p16Ink4a and p19Arf is able to further rescue the phenotype 
of Bmi-1 deficient neural stem cells.  
It has recently been shown that Bmi-1 also regulates mitochondrial function and 
intracellular reactive oxygen species (ROS) level independent of Ink4a and Arf. And 
normalizing ROS levels using the antioxidant N-acetylcysteine (NAC), or disrupting the 
DNA damage response pathway by Chk2 deletion partially rescues some of the 
developmental defects of Bmi-1-deficient mice, including growth retardation and reduced 
survival (Liu et al., 2009), which were not rescued by Ink4a and Arf deletion. It will be 
interesting to directly test whether oxidative stress also contributes to the neural stem cell 
defects in Bmi-1-deficient mice. To more systematically identify genes that act 
downstream of Bmi-1, it will be informative to perform gene expression profile 
comparisons between wild type, Bmi-1-deficient and Bmi-1-overexpressing neural stem 
cells to identify genes consistently up- or down-regulated by Bmi-1. In addition, it will be 
helpful to perform CHIP-on-Chip analysis with Bmi-1 using freshly isolated or cultured 
neural stem cells in parallel to identify the direct targets of Bmi-1, and compare this result 
with the gene expression analysis. 
While Bmi-1 is essential for the maintenance of neural stem cell proliferation and 
self-renewal in vivo and in vitro; it is unclear whether this is solely due to its ability to 
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regulate cell cycle progression (see discussion above), or whether Bmi-1 also plays a 
separate role regulating differentiation. Polycomb complex components have been shown 
to promote the maintenance of ES cell pluripotency by suppressing the expression of 
differentiation genes (see detailed discussion in Chapter 1). In the case of Bmi-1, it has 
been reported Bmi-1 loss causes premature lobuloalveolar differentiation in mammary 
glands (Pietersen et al., 2008). Bmi-1 is also essential for maintaining the multipotency of 
hematopoietic stem cells and multipotent hematopoietic progenitor cells by blocking 
lymphoid differentiation (Oguro et al., 2010). In neural stem cells, it has been reported 
that loss of Bmi-1 results in an increase in astroglial cells (Zencak et al., 2005), and 
differentiation-associated genes are preferentially silenced by polycomb complexes in 
neural stem/progenitor cells (Mohn et al., 2008). However, direct evidence proving Bmi-1 
maintains neural stem cell multipotency is lacking, and our analysis on the Bmi-1 
transgenic mouse has so far failed to reveal a link between Bmi-1 overexpression and 
changes in neuronal/glial differentiation in vivo (Chapter 3).  
To examine whether acute loss of Bmi-1 could lead to neural stem cell premature 
differentiation in vivo, we could cross Bmi-1 conditional knockout mice with Nestin-
CreER and LoxP-EYFP reporter mice, and analyze the cell type composition of EYFP+ 
cells in the brain of control and transgenic mice at various time points after tamoxifen 
administration to assess for changes in the timing or pattern of neural stem cell 
differentiation. Alternatively, wild type, Bmi-1-deficient or Bmi-1-overeexpressing neural 
stem cells can be cultured in vitro, and monitored for their tendency to spontaneously 
differentiate. To assess whether the effects of Bmi-1 on neural stem cell differentiation (if 
they exist) are dependent on Ink4a/Arf expression, the above mentioned experiments can 
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be repeated on an Ink4a/Arf-deficient background. Lastly, by analyzing the gene 
expression profiles and CHIP-on-chip data with Bmi-1, we could also gain insight into 
whether and how Bmi-1 may regulate neural stem cell differentiation. 
Despite the fact that Bmi-1 is overexpressed in many types of cancers and is 
essential for the maintenance of certain cancer stem cells, we have so far failed to observe 
any CNS tumorigenesis after Bmi-1 overexpression in neural stem and progenitor cells 
cells (Chapter 3). One possible explanation for the lack of tumorigenesis is that the level 
of Bmi-1 overexpression achieved in our transgenic system is not sufficient to induce de 
novo tumor formation, however, the observation that our transgene is sufficient to 
overexpress Bmi-1 to a level similar or even higher than what is observed in some human 
CNS tumors suggests against this possibility (Figure 3.1). Alternatively, since Bmi-1 is a 
member of the polycomb suppressor complex, it is also possible that other polycomb 
complex components are limiting and must also be overexpressed to achieve a gain of 
PRC1 function. However, we did observe an increase in the self-renewal potential of 
cultured neural stem cells after Bmi-1 overexpression, which indicates at least in this 
particular circumstance, the abundance of other polycomb complex components is not 
limiting. Another possibility is that since in our transgenic system, ectopic Bmi-1 
expression is driven by the human Nestin second intron enhancer, which only expresses 
in neural stem and progenitor cells but not in mature astrocytes; it is possible that the 
formation of tumors which would normally arise from differentiated astrocytes is not 
facilitated by the transgene expression. Lastly, it is possible that Bmi-1 overexpression is 
not an initiating event for CNS tumorigenesis, but rather acts as a secondary mutation to 
facilitate the progression of pre-existing neoplasms. Indeed, the fact that we also rarely 
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observe spontaneous brain tumor formation in Ink4a and Arf single or double mutant 
mice (unpublished observations) even though Ink4a and/or Arf mutations commonly 
occur in brain tumors, suggests that escaping cell cycle control by Ink4a and Arf in 
general may not be an initiating event in brain tumor development. To test whether Bmi-
1 overexpression can instead act to facilitate CNS tumorigenesis, Bmi-1 transgenic mice 
can be crossed onto genetic backgrounds which are prone to develop brain tumors, such 
as GFAP-Cre+cis-p53-/+NF1fl/+ mice or mice that expresses constitutively active EGF 
receptor, and assessed for the acceleration of tumorigenesis or changes in tumor 
spectrum. 
Although Bmi-1 overexpression does not significantly affect neural stem cell 
function or neuronal/glial differentiation in vivo, and does not induce CNS tumor 
formation, a subset of Bmi-1 transgenic mice nonetheless developed severe 
hydrocephalus and premature death. The exact cause of this phenotype is currently 
unclear. The observation that only the lateral ventricles are affected by hydrocephalus 
seems to suggest this is likely a form of non-communicating hydrocephalus where a 
physical obstruction between lateral ventricles and the third ventricle blocks the flow of 
cerebral spinal fluid (CSF). However, we have failed to detect any obstruction at any 
level of the ventricular system on histological sections. On the other hand, we did observe 
abnormal lateral ventricle ependymal cell layer morphology in some mice that developed 
hydrocephalus. Therefore, it is possible that defects in ependymal cell function may block 
the circulation of CSF between lateral ventricles and the third ventricle. To definitively 
test this possibility, it will be necessary to perform dye injection into the ventricular 
system to track CSF flow, as well as perform electron microscopy to examine the 
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ultrastructure of ependymal cells and assess their ability to direct CSF flow in vitro. 
Lastly, it is also possible that the observed hydrocephalus is not due to an intrinsic neural 
development defect, but rather a result of cranial skeletal malformation. It is known that 
Bmi-1 deficiency causes skeletal development defects (van der Lugt et al., 1996), 
therefore, it is possible that off-target transgene expression in the skeletal system may 
cause defects in the cranial skeleton that lead to hydrocephalus.  
While germ-line knockout and transgenic systems have been used extensively to 
study the in vivo function of many genes, it has argued that compensation mechanisms 
may take place under these circumstances due to long-term loss or over-expression of the 
target genes. Therefore, acute gain or loss of function studies may reveal unexpected 
phenotypes beyond what was observed from knockout or transgenic mice. In line with 
this argument, it has been reported that acute knockdown and overexpression of Bmi-1 in 
neural stem/progenitor cells during mouse embryonic development gives stronger 
phenotypes than what has been observed in our knockout and transgenic studies (Fasano 
et al., 2007; Fasano et al., 2009). However, in both of these studies, most experiments 
were performed in vitro; for in vivo knockdown or overexpression, in utero 
electroporation was used to introduce the construction. Given that Ink4a and Arf are 
induced by culture stress, and may be upregulated by tissue injury; it is unclear whether 
part of the observed enhanced phenotype could be the result of nonphysiological 
induction of these two cell cycle inhibitors by the experimental procedures. To more 
accurately assess the in vivo consequences of acute loss or gain of Bmi-1 expression, it 
would be necessary to conditionally delete Bmi-1 from fetal neural stem cells in vivo. As 
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noted above, we have recently done this and still do not observe the phenotypes that 
would be predicted by Fasano et al. 
SOX17 CONFERS FETAL LIVER HSC IDENTITY  
Sox17 is a member of the Sry-related high mobility group transcription factors, 
and is required for the formation and maintenance of definitive endoderm (Hudson et al., 
1997; Kanai-Azuma et al., 2002) and vascular endothelium (Matsui et al., 2006). We 
have previously shown that Sox17 expression is developmentally restricted to fetal and 
neonatal, but not adult, HSCs (Kim et al., 2007) and Sox17 expression is correlated with 
fetal HSC characteristics during their transition from fetal to adult HSCs in terms of both 
surface marker phenotype and cell cycle status. Germline loss of Sox17 leads to severe 
defects in definitive hematopoiesis in the fetal liver, including a complete absence of 
definitive HSCs, while conditional deletion of Sox17 leads to the loss of fetal and 
neonatal, but not adult, HSCs (Kim et al., 2007) indicating Sox17 is essential for the 
function/maintenance of fetal but not adult HSCs. 
In chapter 4, we extended our previous findings by showing that overexpression 
of Sox17 in adult hematopoietic progenitors is sufficient to confer certain fetal 
characteristics, including enhanced self-renewal potential and fetal-specific marker and 
gene expression. Furthermore, the hematopoietic reconstitution pattern of Sox17-
overexpressing adult bone marrow cells exhibited a striking resemblance to fetal liver 
hematopoiesis, including augmented myeloerythropoiesis, diminished lymphopoiesis, 
and production of platelets and myeloid cells with fetal characteristics. This was achieved 
at least partially by repressing the expression of lymphoid differentiation-associated 
genes and increasing the expression of HSC-specific genes by Sox17. Together, our data 
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have identified Sox17 as the only gene identified to date that is not only essential for fetal 
liver HSC maintenance but is also sufficient to confer fetal HSC features to adult cells. 
Our results raise many interesting questions. The observation that endogenous 
Sox17 expression in fetal liver HSCs declines with age and differentiation is intriguing. It 
suggests that cell intrinsic changes may already take place in fetal liver HSCs during late 
embryonic development before they fully transition into adult HSCs at approximately 3 
weeks after birth (Bowie et al., 2007; Bowie et al., 2006). Indeed, it has been reported 
that while HSCs isolated from fetal liver and 1 week old bone marrow can generate B 
cells that are not dependent on IL-7 signaling, bone marrow HSCs isolated from 2 week 
old mice absolutely require IL-7 signaling for B-lymphopoiesis (Kikuchi and Kondo, 
2006). This indicates fetal HSCs do undergo developmental changes with age before their 
transition into adult HSCs. Similar changes have also been observed in the pattern of fetal 
liver hematopoiesis, which is initially dominated by definitive erythropoiesis but exhibits 
a progressive increase in lymphopoiesis during late fetal development. These 
observations raise the question of whether the change in Sox17 expression in fetal liver 
HSCs during development is causally related to the changes observed in fetal HSC 
function and fetal liver hematopoiesis. One way to test this is to compare the gene 
expression profile and developmental/differentiation potential of fetal liver HSCs isolated 
at different embryonic ages to see whether consistent changes can be observed that 
correlate with Sox17 expression. Another way to test it is using the Doxycycline-
regulatable Sox17 transgene to maintain high Sox17 expression in fetal liver HSCs during 
late embryonic development to see whether sustained Sox17 expression in HSCs results 
in hematopoiesis resembling earlier stage fetal liver hematopoiesis.   
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The observation that Sox17 expression declines with fetal liver HSC 
differentiation raises the possibility that the Sox17 expression level defines the identities 
of HSCs and various progenitor cells. One way to test this is to compare the self-renewal 
and differentiation potential of each population to see whether either property correlates 
with Sox17 expression. One cell population in fetal liver, the LSK150-48-41- cells, which 
share the same surface marker phenotype as adult bone marrow multipotent progenitors, 
is particularly interesting as they seem to express the same or even higher levels of 
Sox17-GFP than fetal liver HSCs (LSK150+48-41-) at all developmental stages examined. 
It will be interesting to directly test the self-renewal and developmental potential of these 
cells in comparison to HSCs to see whether Sox17 expression indeed correlates with 
either of these properties. The next test would be to specifically knockout or over-express 
Sox17 in each cell population using mice carrying cell type-specific cre-recombinase or 
tetracycline transactivator protein to see whether modulating Sox17 expression levels 
would cause changes in the self-renewal or developmental potential of each cell 
population. In parallel, it would also be interesting to see whether Sox17+/- mice have 
lower expression of Sox17 and whether this leads to changes in population frequency or 
maturation rate of the HSCs from fetal to adult characteristics. 
Another important question would be to determine what mechanisms regulate the 
dynamic expression of Sox17 during development and differentiation. To date, no factors 
or mechanisms that regulate Sox17 expression in fetal liver HSCs have been reported, 
however, many possibilities exist. For example, Sox17 expression could be regulated by 
another yet to be identified fetal liver HSC specific transcriptional factor. We have shown 
that Sox17 overexpression is sufficient to increase the expression of some, but not all, 
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fetal liver HSC-specific genes. It is possible that one or more of the genes whose 
expression is not increased could control Sox17 expression. Alternatively, Sox17 
expression might be suppressed by certain adult HSC-specific or differentiation-
associated genes such that Sox17 expression is terminated when fetal HSCs transit into 
an adult phenotype or become differentiated. Another possibility is that Sox17 expression 
is controlled by a cell-extrinsic niche signal that is specific for the fetal liver 
environment; however, the observation that Sox17 expression persists in bone marrow 
HSCs for more than 3 weeks postnatally (Kim et al., 2007) argues against this possibility. 
Lastly, Sox17 expression in fetal liver HSCs may reflect an “endothelial memory” which 
they inherit from the hemogenic endothelial cells in the form of an epigenetic 
modification, which gets progressively lost during fetal HSC development. It is possible 
that all of the above mentioned mechanisms play a role in regulating Sox17 expression, 
and that a detailed examination of the Sox17 promoter for transcription factor binding 
sites or DNA or histone modification marks may provide some insights in answering this 
question. 
 It is also equally important to determine the direct downstream targets of Sox17. 
From our microarray comparison of Sox17-overexpressing LSK48+41- versus normal 
adult LSK48+41- cells, we have identified 376 significantly upregulated genes and 264 
significantly downregulated genes, many of which are involved in HSC maintenance or 
differentiation. The next important step would be to confirm the physiological relevance 
of these genes during normal hematopoietic system development by performing a 
microarray comparison between wild type and Sox17 deficient fetal liver HSCs, to see 
whether any of the genes that are upregulated by Sox17 overexpression are also 
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downregulated after Sox17 deletetion. After that, it would be important to perform CHIP-
on-chip or CHIP-seq analysis to identify which genes are likely to be directly regulated 
by Sox17. Since protein–partner interaction is a crucial mechanism modulating 
transcriptional activity of the Sox group-F transcription factors (Francois et al., 2010), 
which include Sox17, it may also be interesting to perform immunoprecipitation of 
Sox17 coupled with mass spectrometry in Sox17-overexpressing bone marrow cells, in 
order to identify Sox17 protein binding partners. 
Using retroviral overexpression, we have shown that Sox17 overexpression can 
bias adult hematopoiesis to partially resemble fetal liver hematopoiesis; however, it is 
unclear whether the observed phenotype is due to Sox17 overexpression in HSCs, 
progenitor cells or terminally differentiated cells. Technically, Sox17 may bias the 
lymphoid vs. myeloerythroid differentiation of HSCs or MPPs, or it might differentially 
affect the survival or proliferation of restricted progenitors or differentiated cells. To 
distinguish between these possibilities, it will be necessary to overexpress Sox17 in each 
respective cell type. Similarly, it is also unclear what level of Sox17 overexpression is 
needed to confer the above phenotypes, or whether a transient overexpression (instead of 
constitutively activated expression) is sufficient to reprogram adult hematopoietic 
progenitors to a more fetal-like phenotype. All of these questions would require more 
detailed studies using temporally and/or dosage controllable Sox17 overexpression. 
While Sox17 overexpression is sufficient to confer certain fetal characteristics to 
adult hematopoietic progenitors, this reprogramming toward fetal HSCs is clearly 
incomplete, since Sox17-overexpressing LSK48+41- cells still express distinct gene sets 
as compared to both adult and fetal liver HSCs. Therefore, it will be interesting to 
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determine what other genes are necessary to fully convert adult hematopoietic 
progenitors into fetal liver HSCs. To begin, we have identified the genes that are specific 
for fetal liver HSCs, but are not upregulated after Sox17 overexpression, and we will 
functionally test whether the overexpression of any of these genes in combination with 
Sox17 could further reprogram the adult progenitor cells. 
 
IMMORTAL STRAND SEGREGATION IS NOT A UNIVERSAL MECHANISM 
BY WHICH STEM CELLS MAINTAIN GENOMIC INTEGRITY 
Proposed by Cairns thirty year ago (Cairns, 1975) as a mechanism to protect the 
genomic integrity of stem cells, the “immortal strand” hypothesis postulates that during 
cell division, adult stem cells could selectively segregate the older DNA strands to 
daughter stem cells, and the newly synthesized DNA strands from last round of cell 
division to daughter cells fated to differentiate, therefore minimizing the accumulation of 
replication-induced DNA damage (reviewed in (Lansdorp, 2007; Rando, 2007; 
Tajbakhsh, 2008)). In support of the immortal strand hypothesis, asymmetric segregation 
of old and young DNA strands has been reported in a subset of cells in the crypt of the 
small intestine (Potten et al., 2002), in cultured neural stem cells (Karpowicz et al., 2005), 
in mammary gland epithelial cells (Smith, 2005) as well as in muscle satellite cells 
(Conboy et al., 2007; Shinin et al., 2006); however, limitations in stem cell specific 
markers in these systems introduced uncertainty about the identity of the cells that 
segregated chromosomes asymmetrically and the proportion of stem cells capable of 
doing this. Using one of the best characterized stem cell systems, the mouse 
hematopoietic stem cells, as a model, we have shown that asymmetric chromosome 
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segregation does not occur at a significant frequency in HSCs, in contrast to what would 
be predicted by the immortal strand hypothesis. This result, together with the subsequent 
finding that hair follicle stem cells also do not asymmetrically segregate their 
chromosomes during cell division (Sotiropoulou et al., 2008; Waghmare et al., 2008), 
suggests “immortal strand” segregation does not seem to be a general feature of stem 
cells, and it may not function to protect cells from accumulating mutations. However, 
given that asymmetric DNA strand segregation does appear to occur in a subset of cells, 
it will be important for future studies to determine the precise identity of the cells in 
which this phenomenon occurs and the biological consequences.  
Another important conclusion derived from our study is that BrdU label retention 
alone cannot be used as a reliable marker for identifying HSCs in situ. In chapter 5, we 
have shown that after a 10 day pulse of BrdU followed by 70 day chase without BrdU, an 
experimental strategy used by several prior studies to identify label retaining cells in the 
bone marrow (Arai et al., 2004; Zhang et al., 2003), only 4.6±0.9% of HSCs are BrdU+ 
and only 0.08% BrdU+ bone marrow cells are HSCs. Therefore, BrdU label retention 
alone is not a specific or sensitive marker for HSCs identification, and the vast majority 
of HSCs do not retain BrdU after 70 days of chase. On the other hand, we did observe 
that HSCs retain BrdU label better than whole bone marrow cells (4.6±0.9% of HSCs vs. 
0.4±0.1% of bone marrow cells were label-retaining) which is consistent with the slower 
cell cycle rate of HSCs compared with whole bone marrow cells, and does suggest HSCs 
are enriched in the label retaining bone marrow fraction. However, this enrichment (~10-
fold) is does not come close to the level of enrichment required to purify HSCs (more 
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than 10,000-fold) and is much less than what can be obtained with many cell surface 
markers.  
Nevertheless, our data did not rule out the possibility that a small subset of HSCs 
may divide even slower than the rest of the HSCs and can therefore better long-term 
retain BrdU label. In fact, using a “two-population” model which assumes that the HSCs 
include two cell populations with different cell cycle kinetics instead of the “single 
population” model which assume all HSCs are cycling at the same rate, we could better 
fit our experimental data on BrdU label dilution in HSCs with theoretical prediction 
(unpublished observations). This suggests HSCs are heterogeneous with respect to cell 
cycle status. In support of this possibility, two recent studies have reported the 
identification of a more slowly cycling, “dormant” HSC population within the phenotypic 
HSCs using more detailed analysis of BrdU label dilution kinetic as well as analysis of 
histone 2B-GFP label retention in HSCs (Foudi et al., 2008; Wilson et al., 2008). Data 
from both studies have shown that even after long term of chase, the frequencies of BrdU 
or H2B-GFP label retaining bone marrow cells (0.31% at 1.5 year in Foudi et al study, 
and 1.1% at 80 days in Wilson et al study) are still 2 orders of magnitude higher than the 
known frequency of HSCs (~0.003%) (Foudi et al., 2008; Wilson et al., 2008). Thus the 
data in these studies are consistent with our conclusion that Brdu label retention has poor 
sensitivity and poor specificity as an HSC marker. Nonetheless, these studies demonstrate 
that BrdU label retention can be used on concert with other, more powerful, HSC markers 
to identify a slowly cycling subpopulation of HSCs. Wilson et al went further and 
concluded that label retaining cells are highly enriched for HSCs, and that BrdU label 
retention can be used to identify dormant HSCs in situ together with ckit expression, an 
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assumption unsupported by experimental results. To address this issue definitively, it will 
be necessary to perform limit dilution analysis to determine the actual frequency of 
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